



Prof. Paolo Antonio Ascierto

Email: p.ascierto@istitutotumori.na.it; paolo.ascierto@gmail.com

CURRICULUM VITAE ET STUDIORUM

DATI ANAGRAFICI

Luogo e data di nascita: [REDACTED]

Stato civile: [REDACTED]

Figli: [REDACTED]

Cittadinanza: [REDACTED]

Ente di appartenenza: Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli.

Qualifica dal 28.10.1993 al 31.03.2008 Dirigente medico della U.O.C. di Immunologia dell'Istituto Nazionale dei Tumori di Napoli; dal 01.04.2008 al 15.07.2009 Direttore ad interim della U.O.C. di Oncologia Medica (ad indirizzo Cute – Muscolo Scheletrico – Testa Collo) dell'Istituto Nazionale dei Tumori di Napoli; dal 16.07.2009 al 13.07.2011 Direttore della U.O.C. di Oncologia Medica (ad indirizzo Cute – Muscolo Scheletrico – Testa Collo) dell'Istituto Nazionale dei Tumori di Napoli; dal 14.07.2011 al 15.08.2013 Dirigente medico della U.O.C. di Oncologia Medica (ad indirizzo Cute – Muscolo Scheletrico – Testa Collo) dell'Istituto Nazionale dei Tumori di Napoli; dal 16.08.2013 a tutt'oggi: Direttore della U.O.C. di Oncologia Medica Sperimentale Melanoma, Immunoterapia e Terapie Innovative dell'Istituto Nazionale dei Tumori di Napoli;

Inoltre, da aprile 2020 ad oggi Direttore del Dipartimento Dipartimento Corp-S di Ricerca e Assistenziale Cute-Melanoma, Immunologia Oncologica Sperimentale e Terapie Innovative dell'Istituto Nazionale dei Tumori di Napoli .

Iscrizione all'Ordine dei Medici Chirurghi della Provincia di Campobasso dal 28 dicembre del 1990; dal 12 settembre 1994 iscrizione, per trasferimento, all'Ordine dei Medici Chirurghi della Provincia di Benevento; dal 03 maggio 2000 iscrizione, per trasferimento, all'Ordine dei Medici Chirurghi della Provincia di Napoli.

TITOLI DI STUDIO

ANNO SCOLASTICO 1982-1983: Diploma di maturità scientifica conseguito presso il Liceo Scientifico Statale "A. Romita" di Campobasso.

NOVEMBRE 1988 – SETTEMBRE 1991: Frequenza presso la Cattedra di Oncologia Medica della II Facoltà di Medicina e Chirurgia dell'Università degli Studi di Napoli in qualità di studente interno prima e di specializzando in Oncologia dopo.

LUGLIO 1990: Laurea in Medicina e Chirurgia conseguita con voti 110 e lode/110 con menzione speciale per il curriculum presso la II Facoltà di Medicina e Chirurgia dell'Università degli Studi di Napoli (Tesi: "Determinazione quantitativa del recettore umano per gli estrogeni ed il progesterone in citosol tissutale con metodo immunoenzimatico kit Abbott ER e PgR - EIA Monoclonale").

DICEMBRE 1990: Abilitazione all'esercizio professionale conseguita presso l'Università degli Studi di Napoli nella seconda sessione del 1990 con voti 90/90.

LUGLIO 1994: Specializzazione in Oncologia con voti 70 e lode/70 presso la Facoltà di Medicina e Chirurgia dell'Università di Napoli "Fedrico II" (Tesi: "Trattamento del Melanoma Maligno in fase avanzata con anticorpi monoclonali anti-idiotipo").

LUGLIO 2017: Abilitazione Scientifica Nazionale a Professore di Seconda Fascia in: "Malattie del Sangue, Oncologia e Remautologia" (Settore: MED 06/D3). Validità Abilitazione: dal 07/07/2017 al 20/03/2027.

MARZO 2018: Abilitazione Scientifica Nazionale a Professore di Prima Fascia in: "Malattie del Sangue, Oncologia e Remautologia" (Settore: MED 06/D3). Validità Abilitazione: dal 28/03/2018 al 28/03/2024.

MAGGIO 2023: Abilitazione Scientifica Nazionale a Professore di Seconda Fascia in: "Scienze Delle Professioni Sanitarie e delle Tecnologie Mediche Applicate" (Settore: MED 06/N1). Validità Abilitazione: dal 08/02/2023 al 08/02/2034.

GIUGNO 2023: Abilitazione Scientifica Nazionale a Professore di Prima Fascia in: "Scienze Delle Professioni Sanitarie e delle Tecnologie Mediche Applicate" (Settore: MED 06/N1). Validità Abilitazione: dal 28/03/2018 al 28/03/2029

SOCIETÀ SCIENTIFICHE

Membro di: Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano di Citometria (GIC), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer, Melanoma Cooperative Group (EORTC-MCG), Intergruppo Melanoma Italiano (IMI), Network Italiano per le BioImmuno Terapie (NIBIT), Society of ImmunoTherapy of Cancer (SITC), Society of Melanoma Research (SMR).

- Dall'ottobre 2001 all'ottobre 2004 membro del Consiglio Direttivo dell'Intergruppo Melanoma Italiano (IMI)
- Dal novembre 2004 al 31 dicembre 2007 Presidente Nazionale dell'Intergruppo Melanoma Italiano (IMI). Dal 1 gennaio 2008 al dicembre 2010 Past President dell'Intergruppo Melanoma Italiano (IMI). Dal 1 gennaio 2011 a tutt'oggi Coordinatore del Comitato Tecnico Scientifico dell'Intergruppo Melanoma Italiano (IMI).
- Dal settembre 2004 al settembre 2007 Consigliere Sezione Regionale dell'Associazione Italiana di Oncologia Medica (AIOM)
- Dal febbraio 2006 componente della Commissione Nazionale "Tumori Cutanei" della Lega Italiana per la Lotta ai Tumori
- Dal giugno 2006 a tutt'oggi membro dell'International Melanoma Working Group (IMWG)
- Dal Settembre 2006 al Novembre 2012, membro del Consiglio Direttivo del Network Italiano per le Bioterapie dei Tumori (NIBIT).
- Dall'Ottobre 2007 all'Aprile 2009 componente della Commissione Oncologica Nazionale.

- Dal luglio 2010 a tutt’oggi Presidente della Fondazione Melanoma.
- Dall’ottobre 2010 al gennaio 2012 Sub Commissario della Sezione Provinciale di Benevento della Lega Italiana per la Lotta ai Tumori.
- Dal Ottobre 2021 a tutt’oggi, membro del Consiglio Direttivo del Network Italiano per le Bioterapie dei Tumori (NIBIT).
- Dal 2014 a tutt’oggi Presidente della SCITO (Società campana di immunoterapia oncologica)

CORSI SOSTENUTI

- Corso avanzato: Postgraduate course on cutaneous melanoma. Napoli 30-31 maggio 1994.
- Chemioprevenzione dei tumori. Genova 9-13 ottobre 1995.
- Corso di aggiornamento: L’immunità in patologia umana. Napoli, 19 novembre 1995 – 6 marzo 1996.
- Proliferazione e morte cellulare. Genova 10-13 giugno 1996.
- Seminari di istruzione informatica. Asti 1-5 luglio 1996.
- Corso di aggiornamento: La qualità in consulenza genetica. Napoli 28 gennaio – 28 aprile 2000.
- Corso di Formazione e Informazione ex artt. 21-22 D.Lvo 626/94: Rischio biologico da assistenza al paziente in medicina e chirurgia; rischio chimico: aggiornamenti sulla protezione da chemioterapici. Napoli 16 novembre 2000.
- Evento ECM n. 2558-63841: Assistenza domiciliare al malato terminale. N. 35 Crediti formativi ECM. Napoli 8.9.2003 – 6.10.2003.
- Evento ECM 2978-132972: 7° Corso nazionale di formazione al management e alla comunicazione efficace nel team oncologico. N. 50 Crediti Formativi ECM. Roma, 27.05.2004 – 17.07.2004.
- Evento ECM 2558-145137: Assistenza domiciliare al malato algido, cronico e terminale. N. 26 Crediti Formativi ECM. Napoli, 10.09.2004 – 02.10.2004.
- Evento ECM 2558-202472: Assistenza socio-sanitaria al malato algido, cronico e terminale. N. 42 Crediti Formativi ECM. Napoli, 17.09.2005 – 29.10.2005.
- Evento ECM 2558-215122: Organizzazione e gestione nelle Aziende Sanitarie: il ruolo del Dirigente. N. 41 Crediti Formativi ECM. Napoli, 03.11.2005 – 03.12.2005
- 23 ottobre 2012: Master Universitario di II livello in “Comunicazione in ambito sanitario” organizzato della Facoltà di Scienze Economiche e Aziendali dell’Università degli Studi del Sannio. N. 60 crediti formativi universitari.
- Dicembre 2019: Corso di Formazione Manageriale per Direttori Sanitari Aziendali e Direttori di Unità Organizzativa Complessa di Aziende ed Enti del Servizio Sanitario Regionale.

PROGETTI DI RICERCA

- Referente Scientifico dal 1999 al 2001 del **Progetto di Ricerca Corrente** “Utilizzo di marcatori molecolari del melanoma per la diagnosi delle micrometastasi nel linfonodo sentinella”
- Referente Scientifico dal 2001 al 2003 del **Progetto di Ricerca Corrente** “Individuazione di nuovi marcatori predittivi nei pazienti affetti da melanoma”.
- Referente Scientifico dal 2004 a tutt’oggi del **Progetto Strategico Ricerca Corrente M2/23**: “Approccio multidisciplinare alla diagnosi e cura del melanoma”.
- Referente Scientifico dal 2000 a tutt’oggi del Progetto di Ricerca Corrente “Vaccinoterapia mediante cellule detritiche stimulate con peptici tumore specifici o lisato tumorale nei pazienti affetti da melanoma maligno.

- Referente Scientifico del **Progetto di Ricerca Finalizzata 1999** "Basi molecolari della trasformazione e progressione neoplastica nel melanoma maligno: utilizzo di nuove metodiche di analisi citogenetica per la valutazione di specifiche alterazioni geniche correlate all'*outcome* clinico"
- Referente Scientifico per l'Isituto del **Progetto OPTIMIST** –Sistema informatico per la stesura, la validazione, la trasmissione e l'archiviazione dei documenti in forma digitale" POR Campania 2000/2006, Misura 6.2 - Azione C.
- Ricercatore associato per il **Progetto di Ricerca Finalizzata Ministero della Sanità FSN 1995** "Meccanismi molecolari di differenziazione del danno cellulare"
- Ricercatore associato per il **Progetto di Ricerca Sanitaria Finalizzata relativa agli anni 86/87 - del. 4599 Giunta Regionale della Campania** "Tumori della cute con particolare riguardo al melanoma"
- Ricercatore associato per il **Progetto di Ricerca Finalizzata Ministero della Sanità FSN 1997** "Approccio biomolecolare alla terapia del melanoma cutaneo"
- Ricercatore associato per il **Progetto di Ricerca Finalizzata Ministero della Sanità 1998** "Basi genetiche della suscettibilità al melanoma maligno: studio della predisposizione e ricorrenza familiare e definizione dei fattori di rischio e prognosi"
- Ricercatore associato per il **Progetto di ricerca della Regione Campania - contributo P.O.P. – Azione 5.4.2 - annualità 1998** "Approccio genetico molecolare nel melanoma maligno: studio dei fattori di predisposizione di vaccini antimelanoma"
- Ricercatore associato per il **Progetto di Ricerca Finalizzata Ministero della Sanità FSN 2000** "Effetti di campi elettromagnetici sulla dinamica molecolare di strutture biologiche e conseguenti implicazioni funzionali"
- Ricercatore associato per il Progetto **Fifth Framework Programme of the European Community for Research, Technological Development and Demonstration activities - Cooperative Research Craft** "GENOSENSE (Development of an innovative genotoxicity measuring device to facilitate the safety control in food products and pharmaceuticals".
- Ricercatore associato per il Progetto Anno 2000 "Formazione a distanza mediante Web-Learning. Realizzazione di un sistema prototipale di Web-Learning nel settore della Chimica, Biochimica, Matematica e Medicina" in collaborazione con la Seconda Università degli Studi di Napoli, nell'ambito dei **"Progetti Strategici" di cui al D.M. 10 maggio 2000, Legge 449/97 – Settore dell'Informazione –**
- Ricercatore associato per il **Progetto finanziato dal MIUR avviso 4391 – Progetto di Alta Formazione III.1/C Anno 2001** - "Esperto in sistemi informativi e telematica nelle attività socio sanitarie" Diagnosys: elaborazione ottimale di immagini biomediche, mediante l'utilizzo di ICT per consulenza diagnostica intelligente", progetto di Ricerca Industriale con connessa Attività di Formazione del Personale di Ricerca (MIUR).
- Ricercatore Co-Responsabile per il **Progetto di Ricerca Finalizzata FSN Anno 1999**. Finanziamento totale € 150.000. Sviluppo di nuove metodiche per la diagnostica e la valutazione del melanoma: A) Identificazione precoce di micro metastasi da melanoma, non rilevabili con metodiche tradizionali, mediante l'utilizzo del frammento variabile ricombinante a single chain (FcFb) diretto contro l'antigene melanoma associato ad alto peso molecolare (HMW-MAA). B) Sviluppo di nuove metodiche di analisi citogenetica e molecolare per la valutazione di specifiche alterazioni geniche correlate all'evoluzione e prognosi del melanoma.
- Ricercatore Responsabile per il Progetto di **Ricerca Finalizzata FSN Anno 2003** - "Studio della trasformazione e progressione neoplastica nel melanoma: nuovi bersagli molecolari ad uso diagnostico e terapeutico". Finanziamento: 88.600,00 €.
- Responsabile della **Linea Interdipartimentale Editor "Melanoma"** per l'anno 2003.

- Ricercatore Responsabile per il Progetto di **Ricerca Finalizzata FSN Anno 2005** - “Valutazione post terapia della immunosoppressione tumorale in pazienti affetti da neoplasia in fase avanzata.” Finanziamento: 200.000,00 €
- Ricercatore Responsabile di Unità Operativa per il **Progetto Integrato Oncologia - Fondi Ministero Sanità Anno 2006**. Progetto 1. Promozione della ricerca clinica nel settore delle bioterapie antitumorali e sviluppo di vaccini cellulari basati sull'uso di cellule dendritiche e di nuovi antigeni tumorali. Finanziamento totale progetto € 1.165.000,00. Finanziamento Unità Operativa € 60.000.
- Ricercatore Responsabile per il Progetto relativo ai **Fondi Alleanza Contro il Cancro – Istituto Superiore Sanità 2007**: Rete Nazionale per studi clinici e di strutture GMP per le bioterapie dei Tumori. **WORK PACKAGE 4**. Sviluppo di documenti consensus, di linee guida e documenti divulgativi degli aspetti regolatori. Informazioni sulla normativa (Help Desk). Finanziamento € 43.291,73.
- Ricercatore Responsabile del **Progetto di Ricerca Finalizzata FSN Anno 2011** “New Possible Approach for the Classification of Melanoma and Prediction of Response to Immunotherapy: Immunoscore and Immune Profiling”. Finanziamento totale € 300.000,00.
- Ricercatore Responsabile per il **Progetto Strategico di Ricerca Corrente 2008-2012** “Approccio multidisciplinare dalla ricerca alla cura del melanoma”. Finanziamento totale € 100.000.
- Ricercatore responsabile del **progetto di ricerca BMS I-O 2012** “Immunoscore in Melanoma”. Finanziamento Bristol Myers Squibb \$ 200.000.
- Ricercatore associato del **progetto di ricerca BMS I-O 2012** “Myeloid Derived Suppressor Cell quantity prior to treatment with ipilimumab as a biomarker of overall survival in patients with metastatic melanoma”. Finanziamento Bristol Myers Squibb dell'Unità Operativa \$ 10.000.
- Ricercatore Responsabile del **progetto di ricerca in collaborazione con Ventana 2012-2015**: Evaluation of a multiplex staining in lymph node from melanoma patient underwent to lymphectomy. Finanziamento Ventana dell'Unità Operativa \$ 50.000.
- Ricercatore Responsabile per il **Progetto di Ricerca Corrente 2013-2020** “Valutazione di Biomarcatori indicativi di risposta al trattamento con Immunoterapia e Farmaci Innovativi” Finanziamento totale € 360.000,00.
- Ricercatore Associato del **progetto di ricerca ERA-NET on Translational Cancer Research (TRANSCAN)**: Integrative cancer-immunology and immunoscore for cancer classification and immunotherapies. Research fund year 2013. Finanziamento totale € 242.000,00.
- Ricercatore Associato del progetto di ricerca relativo ai **Fondi Alleanza Contro il Cancro (ACC) 2017** dal titolo “ Medicina personalizzata: Allestimento di biobanche e di modelli colturali organotipici da pazienti con melanoma per l'identificazione di nuovi marcatori prognostici e la realizzazione di saggi predittivi della risposta del paziente alla terapia”. Finanziamento totale € 17.000,00.
- Ricercatore Associato per il **progetto di ricerca della Regione Campania per la realizzazione di Technology Platform nell'ambito della lotta alle patologie oncologiche- POR CAMPANIA FESR 2014/2020-** dal titolo “Dalla Genomica alla Terapia di Tumori Rari”. Finanziamento totale € 830.000,00.
- **Metastatic disease: the key unmet need in oncology - Second Edition - Fondazione AIRC 5x1000 2018**. - Id. 22757 - Progetto dal Titolo "Disease-specific universal vaccines as new combinatorial immunotherapy for metastatic melanoma, sarcoma and osteosarcoma - Acronimo UniCanVax". Finanziamento Totale unità € 156.860,00.
- Ricercatore Responsabile per il **Progetto di Ricerca Corrente 2022-2024** “Valutazione dei meccanismi di resistenza e dei biomarcatori indicativi di risposta al trattamento con Immunoterapia e/o Farmaci Innovativi” - Finanziamento totale € 95.000,00.

- Ricercatore Associato per il **Progetto di ricerca PNRR Proof of Concept** code POC 2022-12375713 “TARgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles – TACTIC. Finanziamento totale € 960.000,00.

INCARICHI DI STUDIO E SCIENTIFICI

- Anno Accademico 2002-2003: Insegnamento di “Storia della Medicina” - Diploma Universitario di Scienze Infermieristiche della Seconda Università di Napoli.
- Anno Accademico 2004-2005, 2005-2006, 2006-2007, 2007-2008, 2008-2009, 2009-2010, 2010-2011, 2011-2012, 2012-2013: Insegnamento di “Storia della Medicina” - Diploma Universitario Tecnici di Laboratorio della Seconda Università di Napoli.
- Anno Accademico 2008-2009, 2009-2010, 2010-2011, 2011-2012, 2012-2013: Insegnamento di “Oncologia Medica” - Diploma Universitario di Scienze Infermieristiche della Seconda Università di Napoli.
- Anno Accademico 2008-2009, 2009-2010, 2010-2011, 2011-2012, 2012-2013: Incarico di Professore a Contratto presso la Scuola di Specializzazione in Dermatologia e Venereologia della Facoltà di Medicina e Chirurgia della Seconda Università degli studi di Napoli.
- Dal 3 gennaio 1996 a tutt’oggi è coordinatore delle attività del Gruppo Interdipartimentale Melanoma dell’Istituto Tumori di Napoli.
- Marzo 2005 a tutt’oggi è Coordinatore Macroarea Ricerca Corrente dell’Istituto Tumori di Napoli “Strategie terapeutiche innovative nella malattia avanzata”.
- Membro del Comitato Tecnico Scientifico dell’Istituto Tumori di Napoli fino al giugno 2008.
- Dal 15 febbraio 2008 al marzo 2012 è stato il rappresentante dell’Istituto Tumori di Napoli presso l’OECI (Organization of European Cancer Institutes).
- Membro del Data Safety Management Committee per lo studio clinico sponsorizzato dalla Glaxo Smith-Kline “Phase I study NYESO1-AS15-MEL-001 (MET) (112406) An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1- positive unresectable and progressive metastatic cutaneous melanoma.”
- Co-Chair 2012 e membro del Translational Working Group dell’Immuno-Oncology Network della Bristol Myers Squibb.
- Membro del Comitato Scientifico della newsletter mensile “Melanoma newsgroup” edito da Intermedia.
- Coorganizer dell’annual meeting 2013 della Society of ImmunoTherapy of Cancer (SITC)
- Membro dello Scientific/organizing committee per il convegno ESMO 2014 in Madrid.
- Membro dello Steering Committee della World Wide Task Force per la validazione dell’Immunoscore.
- Membro dello Steering Committee dello studio Novartis “The NEMO trial (NRAS melanoma and MEK inhibitor): a randomized Phase III, open label, multicenter, two-arm study, comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS-mutation positive melanoma”.
- Membro della International Faculty del PhD program in Translational Medicine, presso la CEU Escuela Internacional de Doctorado dell’Università di Madrid.
- Coordinatore per l’aggiornamento delle Linee Guida AIOM su “Melanoma” dal 2013 a tutt’oggi.
- Membro dello Steering Committee della Society of Melanoma Research (SMR) dal 2016.
- Membro del board del Cancer Development Drug Forum (CDDF) dal 2017.
- Membro del Board of Directors of Society of Immuno Therapy of Cancer (SITC) dal 2018.
- Presidente della Fondazione Melanoma Onlus dal 2010.
- Presidente della Società Campana di Immunoterapia Oncologica dal 2013.

- Contratto insegnamento dermatologia presso la Scuola di Specializzazione in Dermatologia e Venereologia dell'Università di Napoli Federico II

STUDI CLINICI

PRINCIPAL INVESTIGATOR E COORDINATORE NAZIONALE NEI SEGUENTI STUDI CLINICI

Codice Studio	Titolo	Fase
MO25616	STUDIO MULTICENTRICO, A BRACCIO SINGOLO, IN APERTO, DI FASE II VOLTO A VALUTARE LA SICUREZZA DI VISMODEGIB (GDC-0449) IN PAZIENTI AFFETTI DA CARCINOMA BASOCELLULARE (BCC) LOCALMENTE AVANZATO O METASTATICO.	II
BRF114144	STUDIO DI ROLLOVER PER FORNIRE UNA TERAPIA CONTINUATIVA CON GSK2118436 A SOGGETTI CON TUMORI POSITIVI ALLA MUTAZIONE DI BRAF	I
GO27826	STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO DELLA TERAPIA ADIUVANTE CON VEMURAFENIB (RO5185426) IN PAZIENTI CON MELANOMA CUTANEO BRAF-MUTANTE, RESECATO CHIRURGICAMENTE, AD ALTO RISCHIO DI RECIDIVA	III
CMEK162X2111	A PHASE IB/II OPEN-LABEL, MULTI-CENTER STUDY OF THE COMBINATION OF MEK162 PLUS AMG479 (GANITUMAB) IN ADULT PATIENTS WITH SELECTED ADVANCED SOLID TUMORS	I/II
CMEK162X2110	A PHASE IB/II, MULTICENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF LGX818 IN COMBINATION WITH MEK162 IN ADULT PATIENTS WITH BRAF V600 - DEPENDENT ADVANCED SOLID TUMORS	I/II
CMEK162A2301	STUDIO RANDOMIZZATO DI FASE III, IN APERTO, MULTICENTRICO, A DUE BRACCI, DI CONFRONTO DELL' EFFICACIA DI MEK162 VERSUS DACARBAZINA IN PAZIENTI CON MELANOMA IN STADIO AVANZATO INOPERABILE O METASTATICO POSITIVO ALLA MUTAZIONE NRAS	III
CMEK162X2114	STUDIO DI FASE IB/II, MULTICENTRICO, IN APERTO, CON LEE011 IN ASSOCIAZIONE A MEK162 IN PAZIENTI ADULTI CON MELANOMA NRAS MUTATO	I/II
CMEK162B2301	STUDIO DI FASE III, MULTICENTRICO, RANDOMIZZATO, IN APERTO, A 3 BRACCI, CON LGX818 IN ASSOCIAZIONE A MEK162 E LGX818 IN MONOTERAPIA IN CONFRONTO A VEMURAFENIB IN PAZIENTI CON MELANOMA NON RESECABILE O METASTATICO CON MUTAZIONE BRAF V600	III
CD-ON-MEDI4736-1161	STUDIO IN APERTO DI FASE I SULLA SICUREZZA E SULLA TOLLERABILIT? DI MEDI4736 IN COMBINAZIONE CON DABRAFENIB E TRAMETINIB O SOLO CON TRAMETINIB IN SOGGETTI CON MELANOMA METASTATICO O NON RESECABILE	I
RETROSPECTIVE CHART REVIEWS	RETROSPECTIVE CHART REVIEWS TO CHARACTERIZE MANAGEMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA IN ONCOLOGY PRACTICE IN ITALY	NA
CA184-367	STUDIO OSSERVAZIONALE PER VALUTARE L' EFFICACIA E LA SICUREZZA DI IPILIMUMAB SOMMINISTRATO DURANTE IL PROGRAMMA EUROPEO DI ACCESSO ALLARGATO IN PAZIENTI PRECEDENTEMENTE TRATTATI AFFETTI DA MELANOMA AVANZATO (NON RESECABILE O METASTATICO)	NA

ERBB3	STUDIO OSSERVAZIONALE PROSPETTICO NO-PROFIT PER LA VALUTAZIONE DELL'ATTIVAZIONE DEL RECETTORE ERBB3 NELLE CELLULE TUMORALI CIRCOLANTI DI PAZIENTI CON MELANOMA METASTATICO TRATTATI CON TARGET THERAPY COSTITUITA DA INIBITORI DI BRAF E/O INIBITORI DI MEK	NA
CA209172	STUDIO CLINICO MULTICENTRICO, A BRACCIO SINGOLO, IN APERTO, CON NIVOLUMAB (BMS-936558) IN SOGGETTI CON MELANOMA IN STADIO III (NON RESECABILE) CONFERMATO ISTOLOGICAMENTE O IN STADIO IV IN PROGRESSIONE DOPO UN PRECEDENTE TRATTAMENTO CONTENENTE UN ANTICORPO MONOCLONALE ANTI-CTLA-4.	I/II
CLGX818X2 109	STUDIO DI FASE II, MULTICENTRICO, IN APERTO, CON ASSOCIAZIONE SEQUENZIALE DI LGX818/MEK162 SEGUITA DA UN'ASSOCIAZIONE RAZIONALE CON FARMACI TARGET DOPO PROGRESSIONE, PER CONTRASTARE LA RESISTENZA IN PAZIENTI ADULTI CON MELANOMA BRAF V600 IN STADIO LOCALMENTE AVANZATO O METASTATICO	II
ELECTRO- CHEMO- LMMUNO THERAPY	ELECTRO-CHEMO-LMMUNO THERAPY: ACTIVATING LOCAL AND SYSTEMIC IMMUNITY TO FIGHT MELANOMA AND BREAST CANCER	NA
MO29518	STUDIO IN APERTO, MULTI-COORTE, DI FASE II PER LA VALUTAZIONE DI MPDL3280A NEI TUMORI SOLIDI IN STADIO AVANZATO	II
MK3475-022	STUDIO DI FASE I/II PER VALUTARE LA SICUREZZA E L'EFFICACIA DI MK-3475 IN COMBINAZIONE CON TRAMETINIB E DABRAFENIB IN SOGGETTI CON MELANOMA AVANZATO	I/II
PILOT STUDY	ANALYSIS OF GENOMIC AND TRANSCRIPTOMIC ARRANGEMENT ON MELANOMA PATIENTS TREATED WITH TARGET AND IMMUNO THERAPY	NA
MK3475-158	STUDIO CLINICO SU PEMBROLIZUMAB (MK-3475) PER VALUTARE BIOMARCATORI PREDITTIVI IN SOGGETTI AFFETTI DA TUMORI SOLIDI AVANZATI (KN 158)	II
CA224-020	STUDIO DI FASE I DI INCREMENTO DI DOSE E DI ESPANSIONE DI COORTE PER VALUTARE LA SICUREZZA, LA TOLLERABILITÀ E L'EFFICACIA DELL'ANTICORPO MONOCLONALE ANTI-LAG-3 (BMS-986016) SOMMINISTRATO IN MONOTERAPIA E IN COMBINAZIONE CON L'ANTICORPO MONOCLONALE ANTI-PD-1 (NIVOLUMAB, BMS-936558) NEI TUMORI SOLIDI IN STADIO AVANZATO	I
BIORMARK ERS	BASELINE PERIPHERAL BLOOD BIORMARKERS ASSOCIATED WITH CLINICAL OUTCOME OF MELANOMA PATIENTS TREATED WITH IPILIMUMAB	IV
EPITOPI	STUDIO OSSERVAZIONALE RETROSPETTICO, NO PROFIT, PER L'IDENTIFICAZIONE DI NUOVI EPITOPI PRESENTATI E VALUTAZIONE DELLA RISPOSTA IMMUNITARIA NEL MELANOMA	NA
CPDR001X2 101	STUDIO IN APERTO, MULTICENTRICO, DI FASE I/II SULLA SICUREZZA D'IMPIEGO E L'EFFICACIA DI PDR001, SOMMINISTRATO IN PAZIENTI CON TUMORI IN STADIO AVANZATO	I/II
SECOMBIT	STUDIO PROSPETTICO DI FASE II RANDOMIZZATO A TRE BRACCI MIRATO A VALUTARE IL MIGLIOR APPROCCIO SEQUENZIALE CON IL TRATTAMENTO IMMUNOTERAPICO COMBINATO (IPILIMUMAB/NIVOLUMAB) E LA TERAPIA TARGET COMBINATA (LGX818/MEK162) IN PAZIENTI AFFETTI DA MELANOMA METASTATICO PORTATORI DELLA MUTAZIONE BRAF	II
35/16	ANALYSIS OF MOLECULAR PROFILING OF MELANOMA PATIENTS TREATED WITH IMMUNOTHERAPY AND TARGET THERAPY	NA
IMCGP100- 201	STUDIO MULTICENTRICO, DI FASE IB/II, IN APERTO SULLA SICUREZZA ED EFFICACIA DI IMCGP100 IN COMBINAZIONE CON	I/II

	DURVALUMAB (MEDI4736) O TREMELIMUMAB O DELLA COMBINAZIONE DI DURVALUMAB E TREMELIMUMAB RISPETTO A IMCGP100 IN MONOTERAPIA IN PAZIENTI CON MELANOMA AVANZATO	
VALIDAZIONE DI BIOMARCATORI	A RETROSPECTIVE ANALYSIS OF BIOMARKERS FOR TOXICITY AND ACTIVITY OF ANTI-CTLA-4 MAB THERAPY THROUGH THE PERIPHERAL BLOOD WHOLE GENOME AND TRANSCRIPTOME ANALYSIS IN MELANOMA PATIENTS	NA
CA209234	SCHEMA DI UTILIZZO E SICUREZZA/EFFICACIA DI NIVOLUMAB NELLA PRATICA ONCOLOGICA DI ROUTINE	NA
CO39262	STUDIO DI FASE III, IN DOPPIO CIECO, RANDOMIZZATO, CONTROLLATO CON PLACEBO PER LA VALUTAZIONE DI ATEZOLIZUMAB PIU' COBIMETINIB E VEMURAFENIB RISPETTO A PLACEBO PIU' COBIMETINIB E VEMURAFENIB IN PAZIENTI NON TRATTATI IN PRECEDENZA, AFFETTI DA MELANOMA METASTATICO O LOCALMENTE AVANZATO NON RESECABIL, POSITIVO ALLA MUTAZIONE BRAFV600	III
PV-10-MM-31	INIEZIONE INTRALESIONALE DI PV-10 VS CHEMIOTERAPIA SISTEMICA O TERAPIA VIRALE ONCOLITICA INTRALESIONALE PER IL TRATTAMENTO DEL MELANOMA CUTANEO LOCALMENTE AVANZATO	I/II
PROGETTO CROM - IMMUNOTERAPIA	ANALISI DEL PROFILO METABOLOMICO, LIPIDOMICO E CITOCINOMICO DI PAZIENTI AFFETTI DA MELANOMA STADIO IV IN TRATTAMENTO CON IMMUNOTERAPIE	NA
PROGETTO CROM - STADIO I-IV	ANALISI DEL PROFILO METABOLOMICO, LIPIDOMICO E CITOCINOMICO DI PAZIENTI AFFETTI DA MELANOMA DI STADIO I, II, III E IV	NA
IMMUNITÀ INNATA	RUOLO DELL'IMMUNITÀ INNATA NEI PAZIENTI AFFETTI DA MELANOMA METASTATICO TRATTATI CON ANTI-PD-1	NA
CPDR001F2301	STUDIO RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO VERSUS PLACEBO, DI FASE III CHE CONFRONTA L'ASSOCIAZIONE DI PDR001, DABRAFENIB E TRAMETINIB VERSUS PLACEBO, DABRAFENIB E TRAMETINIB IN PAZIENTI CON MELANOMA CON BRAF V600 MUTATO NON RESECABILE O METASTATICO NON PRECEDENTEMENTE TRATTATI	III
HEPAVAC-101	STUDIO DI FASE I/II SU IMA970A PIÙ CV8102 DOPO UNA SINGOLA INFUSIONE PRE-VACCINAZIONE DI CICLOFOSFAMIDE IN PAZIENTI CON CARCINOMA EPATOCELLULARE IN STADIO MOLTO PRECOCE, PRECOCE E INTERMEDIO DOPO QUALSIASI TRATTAMENTO STANDARD	I/II
VECODUE	UNO STUDIO CLINICO DI FASE II SULL'ASSOCIAZIONE DI VEMURAFENIB E COBIMETINIB NEI PAZIENTI GIÀ TRATTATI IN PRIMA LINEA CON IMMUNOTERAPIA SISTEMICA PER MELANOMA INOPERABILE LOCALMENTE AVANZATO O METASTATICO	II
IMCGP100-202	STUDIO DI FASE II RANDOMIZZATO, IN APERTO, MULTICENTRICO, VOLTO A VALUTARE LA SICUREZZA E L'EFFICACIA DI IMCGP100 RISPETTO ALLA TERAPIA SCELTA DALLO SPERIMENTATORE IN PAZIENTI HLA-A*0201-POSITIVI AFFETTI DA MELANOMA UVEALE IN STADIO AVANZATO E NON TRATTATO PRECEDENTEMENTE.	II
17/17 OSS	TRANSCRIPTIONAL AND PROTEOMIC PROFILING OF TUMOR AND PERIPHERAL BLOOD FROM PATIENTS WITH MELANOMA WHO RECEIVED IMMUNOTHERAPY	NA
CA013004	STUDIO DI FASE 1/2A DI BMS-986179 SOMMINISTRATO IN MONOTERAPIA E IN COMBINAZIONE CON NIVOLUMAB (BMS-936558) IN SOGGETTI CON TUMORI SOLIDI IN STADIO AVANZATO	I/II
CLXH254X2101	STUDIO DI FASE I, DI DETERMINAZIONE DELLA DOSE CON LXH254 PER VIA ORALE IN PAZIENTI ADULTI CON TUMORI SOLIDI IN	I

	STADIO AVANZATO CHE OSPITANO ALTERAZIONI DELLA VIA MAPK	
INNOP18AS C	STUDIO INTERVENTISTICO NON FARMACOLOGICO IN PAZIENTI TRATTATI CON INIBITORI DI PD1 PER CARATTERIZZARE LO STATO DI ATTIVAZIONE DI CELLULE DEL SISTEMA IMMUNITARIO DOPO IMMUNO-TERAPIA	NA
MASTER	IDENTIFICAZIONE DI NUOVI BIOMARCATORI PROGNOSTICI/PREDITTIVI DI RISPOSTA ALL'IMMUNOTERAPIA E TARGET THERAPY NEL MELANOMA METASTATICO	NA
CPDR001J2201	STUDIO RANDOMIZZATO, IN APERTO, DI FASE II, A PIATTAFORMA APERTA PER VALUTARE L'EFFICACIA E LA SICUREZZA D'IMPIEGO DELLE ASSOCIAZIONI INNOVATIVE DI SPARTALIZUMAB (PDR001) IN PAZIENTI CON MELANOMA PRECEDENTEMENTE TRATTATO NON RESECABILE O METASTATICO	II
CA030-001	STUDIO DI FASE 1/2 DI BMS-986249, SOMMINISTRATO PER LA PRIMA VOLTA NELL'UOMO, DA SOLO E IN COMBINAZIONE CON NIVOLUMAB IN TUMORI SOLIDI IN STADIO AVANZATO	I/II
CA027-002	STUDIO DI FASE 1/2A DI BMS-986253 IN COMBINAZIONE CON NIVOLUMAB IN TUMORI IN STADIO AVANZATO	I/II
CA224-048	STUDIO DI FASE 1/2 DI RELATLIMAB (ANTICORPO MONOCLONALE ANTI-LAG-3) SOMMINISTRATO IN COMBINAZIONE CON NIVOLUMAB (ANTICORPO MONOCLONALE ANTI-PD-1) E BMS-986205 (INHIBITORE DI ID01) O IN COMBINAZIONE CON NIVOLUMAB ED IPILIMUMAB (ANTICORPO MONOCLONALE ANTI-CTLA-4) IN TUMORI MALIGNI IN STADIO AVANZATO	I/II

PRINCIPAL INVESTIGATOR NEI SEGUENTI STUDI CLINICI

CODICE STUDIO	TITOLO	FASE
CA186-006	STUDIO DI FASE II RANDOMIZZATO MULTIDOSE IN APERTO CON BMS-663513 USATO IN MONOTERAPIA IN SECONDA LINEA IN PAZIENTI AFFETTI DA MELANOMA DI STADIO III NON RESECABILE O DI STADIO IV PRECEDENTEMENTE TRATTATI (EUDRACT NUMBER 2007-003993-24)	II
STUDIO AGENDA GM307	STUDIO MULTICENTRICO RANDOMIZZATO IN DOPPIO CIECO SU DACARBAZINA CON O SENZA GENASENSE IN SOGGETTI CON MELANOMA AVANZATO E LDH BASSA NON TRATTATI IN PRECEDENZA CON CHEMIOTERAPIA (EUDRACT NUMBER 2007-003340-30)	III
109752 (ONCO RD-001)	ANALISI DELL'ESPRESSIONE DI UNA SERIE SPECIFICA DI GENI E ANTIGENI TUMORALI IN PAZIENTI CON CARCINOMA POLMONARE NON A PICCOLE CELLULE E MELANOMA	NA
LX01-315-02	STUDIO CLINICO DI FASE III PER VALUTARE LA SICUREZZA E L'EFFICACIA DEL TRATTAMENTO INTRALESIONALE CON 2 MG DI ALLOVECTIN-7 RISPETTO A QUELLO CON DACARBAZINA (DTIC) O TEMOZOLOMIDE (TMZ) IN SOGGETTI CON MELANOMA METASTATICO RECIDIVANTE. (EUDRACT NUMBER 2007-004120-21)	III
CA184-029 /EORTC 18071	IMMUNOTERAPIA ADIUVANTE CON ANTICORPO MONOCLONALE ANTI-CTLA-4 (IPILIMUMAB) VS PLACEBO DOPO RESEZIONE COMPLETA DI MELANOMA AD ALTO RISCHIO IN STADIO III: STUDIO RANDOMIZZATO IN DOPPIO CIECO DI FASE III DELL'EORTC MELANOMA GROUP (EUDRACT NUMBER 2007-001974-10)	III
DERMA 111482 - MAGE A3	STUDIO DI FASE III IN DOPPIO CIECO RANDOMIZZATO CONTROLLATO VERSO PLACEBO PER VALUTARE L'EFFICACIA DI RECMAGE-A3 + AS15 COME TERAPIA ADIUVANTE IN PAZIENTI CON MELANOMA STAGE III OPERABILE MAGE-A3 POSITIVO - EUDRACT NUMBER 2008-002447-16	III

BMS CA 184068	MODALITA' DI TRATTAMENTO DEL MELANOMA ED ESITI IN PAZIENTI CON MALATTIA IN STADIO III O IV NON ASPORTABILE: INDAGINE OSSERVAZIONALE RETROSPETTIVA	NA
CINV	STUDIO PROSPETTICO SUL PESO DELLA MALATTIA IN PAZIENTI AFFETTI DA NAUSEA E VOMITO INDOTTI DALLA CHEMIOTERAPIA IN 5 PAESI EUROPEI	NA
IRST 172.01	IMMUNOTERAPIA DI MANTENIMENTO NEI PAZIENTI CON MELANOMA METASTATICO CON BENEFICIO CLINICO DOPO CHEMIOTERAPIA	II
CA184-043	STUDIO DI FASE III RANDOMIZZATO IN DOPPIO CIECO CON IPILIMUMAB VS PLACEBO DOPO RADIOTERAPIA IN PAZIENTI CON CARCINOMA PROSTATICO RESISTENTE ALLA CASTRAZIONE CHE HANNO RICEVUTO UN PRECEDENTE TRATTAMENTO CON DOCETAXEL	III
111476 MAGE-3- AS15-MEL- 001	(PREDICT) - STUDIO IN APERTO A BRACCIO SINGOLO PER VALUTARE L'EFFICACIA DI RECMAGE-A3 + AS15 IN PAZIENTI CON MELANOMA CUTANEO METASTATICO INOPERABILE MAGE-A3 POSITIVO	II
CA-033	SPERIMENTAZIONE IN APERTO MULTICENTRICA DI FASE III SU ABI-007 VS DACARBAZINA IN PAZIENTI AFFETTI DA MELANOMA MALIGNO METASTATICO NON TRATTATI IN PRECEDENZA	III
44/09	STUDIO PROSPETTICO MULTICENTRICO SULL'ELETTROCHEMIOTERAPIA NEI PAZIENTI AFFETTI DA METASTASI CUTANEE E SOTTOCUTANEE NON RESPONSIVE O NON CANDIDABILI AI TRATTAMENTI CONVENZIONALI	NA
NO25026 - BRIM 3	STUDIO DI FASE III RANDOMIZZATO IN APERTO CONTROLLATO MULTICENTRICO IN PAZIENTI NON TRATTATI IN PRECEDENZA AFFETTI DA MELANOMA NON RESECCABILE DI STADIO IIIC O IV POSITIVO ALLA MUTAZIONE V600E DEL GENE BRAF DA TRATTARE CON RO5185426 O DACARBAZINA	III
113173 PRAME- AS15-MEL- 001	STUDIO DI FASE I/II, IN APERTO, PER VALUTARE LA SICUREZZA, L'IMMUNOGENICITA' E L'ATTIVITA' CLINICA DI DOSI CRESCENTI DELL'AGENTE IMMUNOTERAPEUTICO ANTITUMORALE ANTIGENE-SPECIFICO RECPAME+AS15 SOMMINISTRATO COME TRATTAMENTO DI PRIMA LINEA IN PAZIENTI CON MELANOMA METASTATICO, PRAME POSITIVO.	I/II
E7080-702	STUDIO IN APERTO, MULTICENTRICO, RANDOMIZZATO, DI FASE IB/II SU E7080 IN ASSOCIAZIONE CON DACARBAZINA RISPETTO A DACARBAZINA IN MONOTERAPIA COME TRATTAMENTO DI PRIMA LINEA IN PAZIENTI CON MELANOMA DI STADIO IV	I/II
CAMN107B2 301 -TEAM	STUDIO MULTICENTRICO, RANDOMIZZATO, IN APERTO, A DUE BRACCI DI TRATTAMENTO, DI FASE III, PER CONFRONTARE L'EFFICACIA DI TASIGNA VERSUS DACARBAZINA (DTIC) NEL TRATTAMENTO DI PAZIENTI CON MELANOMA METASTATICO E70 INOPERABILE CHE PRESENTA MUTAZIONE C-KIT.	III
NIBIT-M1	STUDIO DI FASE II A BRACCIO UNICO DI COMBINAZIONE CON IPILIMUMAB E FOTEMUSTINA IN PAZIENTI CON MELANOMA IN STADIO III NON RESECCABILE I IV	II
BRF113710	STUDIO DI FASE II, A BRACCIO SINGOLO, IN APERTO CON GSK2118436 SU MELANOMA METASTATICO BRAF MUTATO PRECEDENTEMENTE TRATTATO	II
L19IL2/DAC ARBAZINA	STUDIO DI DEFINIZIONE DELLA DOSE E VALUTAZIONE DELL'ATTIVITA' DELLA PROTEINA DI FUSIONE TUMORE SPECIFICA CITOCHINA-ANTICORPO MONOCLONALE L19IL2 IN COMBINAZIONE CON DACARBAZINA IN PAZIENTI CON MELANOMA METASTATICO.	I/II

AB08026	STUDIO DI FASE III, PROSPETTICO, MULTICENTRICO, RANDOMIZZATO IN APERTO VERSO TRATTAMENTO ATTIVO, A DUE GRUPPI PARALLELI, PER CONFRONTARE L'EFFICACIA E LA SICUREZZA DI MASITINIB A 7,5 MG/KG/DIE RISPETTO A DACARBAZINA NEL TRATTAMENTO DI PAZIENTI CON MELANOMA NON RESECABILE O METASTATICO DI STADIO 3 O STADIO 4, CHE ABBIA UNA MUTAZIONE NEL DOMINIO IUXTA MEMBRANARIO DI C-KIT.	III
BRF113929	STUDIO DI FASE II, IN APERTO, DUE COORTI, MULTICENTRICO CON GSK2118436 COME AGENTE SINGOLO IN SOGGETTI NAIVE O PRECEDENTEMENTE TRATTATI CON MELANOMA CON METASTASI CEREBRALI POSITIVO ALLE MUTAZIONI DI BRAF	II
CNMR	REALIZZAZIONE REGISTRO CLINICO NAZIONALE SUL MELANOMA	NA
CMEK162X2 201	STUDIO IN APERTO, DI FASE II, PER VALUTARE LA SICUREZZA E L'EFFICACIA DI MEK162 SOMMINISTRATO PER VIA ORALE IN PAZIENTI ADULTI CON MELANOMA MALIGNO CUTANEO IN STADIO LOCALMENTE AVANZATO E NON OPERABILE O METASTATICO, CON LE MUTAZIONI BRAFV600E O NRAS	II
MO25515	STUDIO IN APERTO, MULTICENTRICO DI ACCESSO ALLARGATO SULL'IMPIEGO DI RO5185426 IN PAZIENTI AFFETTI DA MELANOMA METASTATICO.	IV
	STUDIO DI FASE III RANDOMIZZATO IN DOPPIO CIECO CON STA-4783 IN COMBINAZIONE CON PACLITAXEL RISPETTO AL SOLO PACLITAXEL PER IL TRATTAMENTO DI SOGGETTI NAIVE ALLA CHEMIOTERAPIA CON MELANOMA METASTATICO DI STADIO IV	III
EMR 200032- 002	STUDIO RANDOMIZZATO IN APERTO DI FASE IB TESO A CONFRONTARE EMD 640744 EMULSIONATO IN MONTANIDE ISA 51 VG VS EMD 640744 EMULSIONATO IN MONTANIDE ISA 51 VG + IMIQUIMOD VS EMD 640744 EMULSIONATO IN MONTANIDE ISA 51 VG + INTERFERONE ALFA-2B NEI SOGGETTI HLA-A2+ CON MELANOMA STADIO IIIC E IV	I
H8K-MC- JZAO	STUDIO RANDOMIZZATO DI FASE III CHE CONFRONTA TASICULAM VS PACLITAXEL IN PAZIENTI CON MELANOMA METASTATICO PRECEDENTEMENTE TRATTATO	III
CA184-095	STUDIO RANDOMIZZATO, IN DOPPIO CIECO, DI FASE III CHE COMPARA L'EFFICACIA DI IPILIMUMAB VERSO PLACEBO IN PAZIENTI ASINTOMATICI O MINIMAMENTE SINTOMATICI AFFETTI DA TUMORE METASTATICO DELLA PROSTATA RESISTENTE ALLA CASTRAZIONE (CRPC) CHE NON SONO MAI STATI SOTTOPOSTI A CHEMIOTERAPIA.	III
MEK114267	STUDIO DI FASE III RANDOMIZZATO, IN APERTO, PER CONFRONTARE GSK1120212 VERSO CHEMIOTERAPIA IN SOGGETTI CON MELANOMA AVANZATO O METASTATICO POSITIVO ALLE MUTAZIONI DI BRAFV600E/K	III
CTLA-4	ANALISI DEI POLIMORFISMI GENECI E DELL'ISOFORMA SOLUBILE DEL CTLA-4 COME FATTORI PROGNOSTICI E PREDITTIVI DEL MELANOMA	NA
CLDE225A22 01	STUDIO RANDOMIZZATO, IN DOPPIO CIECO, DI FASE II, DI VALUTAZIONE DELL'EFFICACIA E DELLA SICUREZZA D'IMPIEGO DI DUE LIVELLI DI DOSAGGIO DI LDE225 SOMMINISTRATI IN PAZIENTI CON CARCINOMA A CELLULE BASALI IN STADIO LOCALMENTE AVANZATO O METASTATICO	II
CA184-169	STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO CON IPILIMUMAB SOMMINISTRATO ALLA DOSE DI 3 MG/KG VS 10 MG/KG IN PAZIENTI CON MELANOMA NON RESECABILE O METASTATICO PRECEDENTEMENTE TRATTATO O NON TRATTATO.	III

MEK116513	STUDIO DI FASE III RANDOMIZZATO, IN APERTO, DI CONFRONTO TRA L'ASSOCIAZIONE DELL'INIBITORE DI BRAF DABRAFENIB E L'INIBITORE DI MEK TRAMETINIB VERSO L'INIBITORE DI BRAF VEMURAFENIB IN SOGGETTI AFFETTI DA MELANOMA CUTANEO METASTATICO NON RESECABILE (STADIO IIIC) O METASTATICO (STADIO IV) POSITIVO PER LA MUTAZIONE BRAF V600E/K.	III
EMR 200066-007	STUDIO DI FASE II, MULTICENTRICO, IN APERTO, RANDOMIZZATO, CON IL MEK INIBITORE PIMASERTIB O CON DACARBAZINA IN PAZIENTI AFFETTI DA MELANOMA CUTANEO MALIGNO METASTATICO O LOCALMENTE AVANZATO CON N-RAS MUTATO NON TRATTATI IN PRECEDENZA.	II
MK3475-002	STUDIO RANDOMIZZATO DI FASE II CHE CONFRONTA MK-3475 RISPETTO ALLA CHEMIOTERAPIA NEI PAZIENTI AFFETTI DA MELANOMA AVANZATO.	II
GO28141	STUDIO DI FASE III, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO DI VEMURAFENIB RISPETTO A VEMURAFENIB PLUS GDC-0973 IN PAZIENTI POSITIVI ALLA MUTAZIONE DI BRAFV600 NON TRATTATI PRECEDENTEMENTE, CON MELANOMA METASTATICO O LOCALMENTE AVANZATO NON RESECABILE	III
CA209-037	STUDIO CLINICO DI FASE III, RANDOMIZZATO, IN APERTO, DI BMS-936558 VERSUS TERAPIA A DISCREZIONE DELLO SPERIMENTATORE IN SOGGETTI AFFETTI DA MELANOMA IN STADIO AVANZATO (NON OPERABILE O METASTATICO) IN PROGRESSIONE DOPO TRATTAMENTO CON ANTI-CTLA-4	III
CD-ON-MEDI4736-1108	STUDIO DI FASE I PER VALUTARE LA SICUREZZA, TOLLERABILITA' E FARMACOCINETICA DI MEDI4736 IN SOGGETTI CON TUMORI SOLIDI	I
CA209-066	STUDIO DI FASE 3, RANDOMIZZATO, IN DOPPIO CIECO, CON LA MOLECOLA BMS-936558 VERSO DACARBAZINA, IN SOGGETTI CON MELANOMA METASTATICO O NON OPERABILE NON PRECEDENTEMENTE TRATTATI.	III
CA184-243	STUDIO MULTICENTRICO DI FASE II, RANDOMIZZATO, IN APERTO, DEL RITRATTAMENTO CON IPILIMUMAB VERSO CHEMIOTERAPIA, IN SOGGETTI CON MELANOMA AVANZATO CHE HANNO AVUTO PROGRESSIONE DI MALATTIA DOPO AVER RAGGIUNTO INIZIALMENTE IL CONTROLLO DI MALATTIA CON LA TERAPIA CON IPILIMUMAB	II
BEYPRO1	STUDIO DI FASE II A BRACCIO SINGOLO SUL TRATTAMENTO CON L'ASSOCIAZIONE VEMURAFENIB-FOTEMUSTINA DOPO RICADUTA DI MELANOMA AVANZATO IN PAZIENTI PORTATORI DELLA MUTAZIONE V600 DEL GENE BRAF IN TRATTAMENTO CON VEMURAFENIB	II
EORTC 18081	PEGINTERFERONE ALFA-2B ADIUVANTE PER 2 ANNI A CONFRONTO CON OSSERVAZIONE IN PAZIENTI AFFETTI DA MELANOMA CUTANEO PRIMITIVO ULCERATO CON T(2-4)BNOMO: UNO STUDIO RANDOMIZZATO DI FASE III DEL GRUPPO PER IL MELANOMA DELL'EORTC	III
IMI-D-001-2012	RUOLO PROGNOSTICO DEL FOLLOW UP DEL MELANOMA. UNO STUDIO PROSPETTICO RANDOMIZZATO	NA
CA209-067	STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CON NIVOLUMAB IN MONOTERAPIA O NIVOLUMAB IN COMBINAZIONE CON IPILIMUMAB VERSO IPILIMUMAB IN MONOTERAPIA IN SOGGETTI CON MELANOMA METASTATICO O NON OPERABILE NON PRECEDENTEMENTE TRATTATI	III
CLEE011X2105	STUDIO DI FASE IB/II, MULTICENTRICO, CON LEE011 IN ASSOCIAZIONE A LGX818 IN PAZIENTI ADULTI CON MELANOMA CON MUTAZIONE BRAF	I/II

VEMUPLINT	STUDIO DI FASE I-II DELLA COMBINAZIONE DEI FARMACI VEMURAFENIB + PEG-INTERFERON PER IL TRATTAMENTO DI PAZIENTI CON MELANOMA AVANZATO CON MUTAZIONE V600BRAF	I/II
CA209-032	STUDIO DI FASE 1/2, IN APERTO, CON NIVOLUMAB IN MONOTERAPIA O NIVOLUMAB IN COMBINAZIONE CON IPILIMUMAB IN SOGGETTI CON TUMORI SOLIDI IN FASE AVANZATA O METASTATICA	I/II
GP28492 - ZESS	STUDIO OSSERVAZIONALE PROSPETTICO SULLA SICUREZZA IN PAZIENTI AFFETTI DA MELANOMA METASTATICO O NON OPERABILE POSITIVO ALLA MUTAZIONE BRAFV600 TRATTATI CON VEMURAFENIB (ZELBORAF)-ZESS	NA
ML29031	SOPRAVVIVENZA GLOBALE IN PAZIENTI AFFETTI DA MELANOMA METASTATICO CON E SENZA AZIONE DI BRAF V600: STUDIO OSSERVAZIONALE DI COORTE SULL'EFFICACIA DEGLI INIBITORI DI BRAF E DELLE TERAPIE ATTUALI.	NA
CA209-141	STUDIO CLINICO DI FASE III, RANDOMIZZATO, IN APERTO, DI NIVOLUMAB VERSUS TERAPIA A DISCREZIONE DELLO SPERIMENTATORE IN SOGGETTI AFFETTI DA CARCINOMA A CELLULE SQUAMOSE DI TESTA E COLLO (HNSCC), RECIDIVO O METASTATICO REFRATTARIO AL PLATINO	III
IEO 69	RUOLO DEL GENE MELANOCORTIN-1 RECEPTOR NEL MELANOMA PEDIATRICO GIOVANILE	NA
CULPRIT STUDY	CIRCULATING MICRORNAS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS IN METASTATIC MELANOMA	NA
IEO S480-209	PHASE III, RANDOMIZED, DOUBLE BLIND TRIAL ON VITAMIN D SUPPLEMENTATION FOR RESECTED STAGE II MELANOMA PATIENTS (MELAVID)	III
MK_3475_001_GHO	PATTERN DI UTILIZZO DI IPILIMUMAB NELLA NORMALE PRATICA CLINICA, ESITI CLINICI E UTILIZZO DELLE RISORSE SANITARIE NEL TRATTAMENTO DI PAZIENTI AFFETTI DA MELANOMA CUTANEO IN STADIO AVANZATO.	NA
NIBIT-M2	STUDIO RANDOMIZZATO DI FASE III DI CONFRONTO TRA FOTEMUSTINA VERSO LA COMBINAZIONE DI FOTEMUSTINA CON IPILIMUMAB E LA COMBINAZIONE DI IPILIMUMAB E NIVOLUMAB IN PAZIENTI CON MELANOMA METASTATICO CON METASTASI CEREBRALI	III
EMR 100070-003	SPERIMENTAZIONE MULTICENTRICA, IN APERTO DI FASE II PER STUDIARE L'ATTIVITÀ CLINICA E LA SICUREZZA DI MSB0010718C IN SOGGETTI AFFETTI DA CARCINOMA A CELLULE DI MERKEL	II
35/14 OSS	EVALUATION OF THE PROGNOSTIC THE VALUE OF LMMUNOSCORE IN PATIENTS WITH COLON CANCER	NA
DACOMINT14	STUDIO SULL'EFFICACIA E LA SICUREZZA DI DACOMITINIB, INIBITORE PANTIROSINCHINASICO DEL RECETTORE DEL FATTORE DI CRESCITA EPIDERMICO (HER), NEL TRATTAMENTO DEL TUMORE SQUAMOCELLULARE DELLA PELLE LOCALMENTE AVANZATO NON RESECCABILE O METASTATICO O CON CONTROINDICAZIONE CLINICA ALLA CHIRURGIA	II
CA209-238	STUDIO DI FASE 3, RANDOMIZZATO, IN DOPPIO CIECO DI IMMUNOTERAPIA ADIUVANTE CON NIVOLUMAB VERSO IPILIMUMAB DOPO RESEZIONE COMPLETA DI MELANOMA DI STADIO IIIB/C O STADIO IV IN SOGGETTI AD ALTO RISCHIO DI RECIDIVA DI MALATTIA.	III
CA212-115	STUDIO DI FASE 1/2 DI SICUREZZA E DI EFFICACIA DI ULOCUPLUMAB IN COMBINAZIONE CON NIVOLUMAB IN SOGGETTI CON TUMORI SOLIDI IN FASE AVANZATA O METASTATICA	I/II
MK3475-054-01	IMMUNOTERAPIA ADIUVANTE CON L'ANTICORPO MONOCLONALE ANTI-PD-1 PEMBROLIZUMAB (MK-3475) RISPETTO A PLACEBO DOPO RESEZIONE COMPLETA DI MELANOMA DI III STADIO AD ALTO	III


	RISCHIO: SPERIMENTAZIONE DI FASE III RANDOMIZZATA, IN DOPPIO CIECO DEL GRUPPO MELANOMA DELL'EORTC	
C12-315-03	STUDIO DI FASE I, MULTICENTRICO, IN APERTO, A DOSI MULTIPLE, SCHEMA POSOLOGICO ASCENDENTE DI LTX-315 IN PAZIENTI AFFETTI DA TUMORI ACCESSIBILI PER VIA TRANSDERMICA	I
20120325	STUDIO CLINICO DI FASE II, MULTICENTRICO, IN APERTO, A BRACCIO SINGOLO PER LA VALUTAZIONE DELLA CORRELAZIONE TRA IL TASSO DI RISPOSTA OBIETTIVA E LA DENSITÀ DELLE CELLULE CD8+ INTRATUMORALI AL BASALE NEI SOGGETTI CON MELANOMA NON-RESECATO DI STADIO DA IIIB A IVM1C TRATTATI CON TALIMOGENE LAHERPAREPVEC.	II
CA209511	STUDIO DI FASE IIIB/IV, RANDOMIZZATO, IN DOPPIO CIECO DI NIVOLUMAB 3 MG/KG IN COMBINAZIONE CON IPILIMUMAB 1 MG/KG A CONFRONTO CON NIVOLUMAB 1 MG/KG IN COMBINAZIONE CON IPILIMUMAB 3 MG/KG IN SOGGETTI AFFETTI DA MELANOMA NON PRECEDENTEMENTE TRATTATO, NON RESECABILE O METASTATICO	IV
20110265T	20110265T - STUDIO DI FASE IB/3, MULTICENTRICO, SU TALIMOGENE LAHERPAREPVEC IN COMBINAZIONE CON PEMBROLIZUMAB (MK-3475) PER IL TRATTAMENTO DEL MELANOMA NON RESECABILE DI STADIO DA IIIB A IVM1C (MASTERKEY-265)	III
VEMUPER	VEMUPER - TERAPIA SEQUENZIALE CON VEMURAFENIB ED ELETTROCHEMIOTERAPIA NEI PAZIENTI CON MELANOMA CUTANEO E METASTASI IN TRANSITO: STUDIO PROSPETTICO MULTICENTRICO DI FASE II A SINGOLO BRACCIO DEL GRUPPO ITALIANO PER LO STUDIO DEL MELANOMA (IMI)	I
EMR 200647-001	SPERIMENTAZIONE DI FASE I, IN APERTO, A DOSI MULTIPLE CRESCENTI, VOLTA A VALUTARE LA SICUREZZA, LA TOLLERABILITA', LA FARMACOCINETICA E L'ATTIVITA' BIOLOGICA E CLINICA DI MSB0011359C IN SOGGETTI AFFETTI DA TUMORI SOLIDI METASTATICI O LOCALEMNT E AVANZATI E CON ESPANSIONE A INDICAZIONI SELEZIONATE	I
INCB24360-301/MK3475-252/KEYNO	STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO SU PEMBROLIZUMAB (MK-3475) IN ASSOCIAZIONE A EPACADOSTAT O PLACEBO IN SOGGETTI CON MELANOMA NON RESECABILE O METASTATICO (KEYNOTE-252/ECHO-301)	III
CA209401	SPERIMENTAZIONE CLINICA DI NIVOLUMAB (BMS-936558) IN COMBINAZIONE CON IPILIMUMAB SEGUITO DA NIVOLUMAB IN MONOTERAPIA COME TERAPIA DI PRIMA LINEA DI SOGGETTI AFFETTI DA MELANOMA IN STADIO III (NON RESECABILE) O IN STADIO IV CONFERMATO ISTOLOGICAMENTE	III
VEMURES	PROGNOSTIC AND FUNCTIONAL SIGNIFICANCE OF PD-L1 EXPRESSION IN METASTATIC MELANOMA	NA
ONC-2015-001/ ML29968	STUDIO MULTICENTRICO, A SINGOLO BRACCIO, FASE II, PER VALUTARE EFFICACIA E SICUREZZA DI VISMODEGIB E RADIOTERAPIA IN PAZIENTI AFFETTI DA CARCINOMA BASOCELLULARE AD ALTO RISCHIO DI RECIDIVA O LOCALMENTE AVANZATO NON SUSCETTIBILE DI CHIRURGIA RADICALE (VIRGILIO).	II
63723283LUC 1001	UNO STUDIO DI FASE 1/2, IN APERTO, FIRST-IN-HUMAN , PER VALUTARE LA SICUREZZA, LA FARMACOCINETICA, LA FARMACODINAMICA E L'ATTIVITÀ CLINICA DI JNJ-63723283, UN ANTICORPO MONOCLONALE ANTI-PD-1, NEI SOGGETTI CON CANCRO DI STADIO AVANZATO	I/II
WP29945	STUDIO DI FASE IB, IN APERTO, MULTICENTRICO, CON INCREMENTO PROGRESSIVO DELLA DOSE ED ESPANSIONE VOLTO A VALUTARE LA SICUREZZA, LA FARMACOCINETICA E L'ATTIVITA TERAPEUTICA	I

	DI RO6958688 IN ASSOCIAZIONE AD ATEZOLIZUMAB IN PAZIENTI AFFETTI DA TUMORI SOLIDI CEA-POSITIVI LOCALMENTE AVANZATI E/O METASTATICI	
BP29541	STUDIO DI FASE I, IN APERTO, MULTICENTRICO, CON INCREMENTO PROGRESSIVO DELLA DOSE, VOLTO A VALUTARE LA SICUREZZA, LA FARMACOCINETICA E L'ATTIVITA' TERAPEUTICA DI RO6958688, UN NUOVO ANTICORPO LINFOCITI T BISPECIFICO CHE AGISCE SELETTIVAMENTE SULL'ANTIGENE CARCINOEMBRIONARIO (CEA) UMANO ESPRESSO SULLE CELLULE NEOPLASTICHE E SULL'ANTIGENE CD3 PRESENTE SUI LINFOCITI T, SOMMINISTRATO PER VIA ENDOVENOSA IN PAZIENTI AFFETTI DA TUMORI SOLIDI CEA-POSITIVI LOCALMENTE AVANZATI E/O METASTATICI	I
CA209-915	STUDIO DI FASE 3, RANDOMIZZATO, DI IMMUNOTERAPIA ADIUVANTE DI NIVOLUMAB IN COMBINAZIONE CON IPILIMUMAB RISPETTO AD IPILIMUMAB O NIVOLUMAB IN MONOTERAPIA DOPO COMPLETA RESEZIONE DI MELANOMA IN STADIO IIIB/C/D O STADIO IV	III
CA209-9GW	STUDIO DI FASE 1/2 PER VALUTARE LA SICUREZZA E L'EFFICACIA PRELIMINARE DI NIVOLUMAB ASSOCIATO A DARATUMUMAB IN PAZIENTI AFFETTI DA TUMORI SOLIDI AVANZATI O METASTATICI	I/II
R2810-ONC-1620	STUDIO DI FASE 2 DI REGN2810, UN ANTICORPO MONOCLONALE INTERAMENTE UMANO VERSO LA MORTE CELLULARE PROGRAMMATA-1, IN PAZIENTI CON CARCINOMA BASOCELLULARE AVANZATO CHE HANNO MANIFESTATO PROGRESSIONE DELLA MALATTIA CON LA TERAPIA DI INIBIZIONE DELLA VIA DI SEGNALE HEDGEHOG, O ERANO INTOLLERANTI ALLA PRECEDENTE TERAPIA DI INIBIZIONE DELLA VIA DI SEGNALE HEDGEHOG	II
IEO 523	STUDIO INTERVENTISTICO, MULTICENTRICO, IN APERTO, NON RANDOMIZZATO DI FASE II CON PEMBROLIZUMAB CON ELETTROCHEMIOTERAPIA IN PAZIENTI CON MELANOMA NON OPERABILE CON METASTASI SUPERFICIALI O SUPERFICIALI E VISCERALI	II
CO39722	STUDIO DI FASE III, IN APERTO, MULTICENTRICO, A DUE BRACCI, RANDOMIZZATO PER VALUTARE L'EFFICACIA E LA SICUREZZA DI COBIMETINIB PIU' ATEZOLIZUMAB, RISPETTO A PEMBROLIZUMAB, IN PAZIENTI CON \MELANOMA BRAFV600 WILD-TYPE AVANZATO, PRECEDENTEMENTE NON TRATTATO	III
C-144-01	STUDIO MULTICENTRICO DI FASE 2 PER VALUTARE L'EFFICACIA E LA SICUREZZA DI LINFOCITI AUTOLOGHI INFILTRANTI IL TUMORE (LN-144) PER IL TRATTAMENTO DI PAZIENTI CON MELANOMA METASTATICO	II
21/17 OSS	FATTORI TUMORALI-INTRINSECI, GERMINALI E AMBIENTALI DI RISPOSTA ALL'IMMUNOTERAPIA IN PAZIENTI CON MALATTIA ONCOLOGICA AVANZATA.	NA
MFAG 2017	RUOLO DEL PATHWAY L-CISTEINA/H2S NELL'ATTIVITÀ IMMUNOSOPPRESSIVA DELLE MDSCS NEL MELANOMA	NA
CA017055	STUDIO DI FASE III RANDOMIZZATO, IN DOPPIO CIECO, DI BMS-986205 IN COMBINAZIONE CON NIVOLUMAB RISPETTO A NIVOLUMAB IN PARTECIPANTI AFFETTI DA MELANOMA METASTATICO O NON RESECABILE, NON PRECEDENTEMENTE TRATTATO.	III
CDRB436BIT 03	ANALISI RETROSPETTIVA DEI DATI DI PAZIENTI AFFETTI DA MELANOMA CON MUTAZIONE BRAF V600 IN STADIO AVANZATO O METASTATICO TRATTATI CON LA TERAPIA DI COMBINAZIONE DABRAFENIB E TRAMETINIB IN ITALIA NELL'AMBITO DEL	NA

	PROGRAMMA INDIVIDUALE DI ACCESSO AL FARMACO: STUDIO DESCRIBE ITALY	
CDRB436B2404	ESAME RETROSPETTIVO DI CARTELLE CLINICHE PER LA VALUTAZIONE DI DABRAFENIB IN MONOTERAPIA E/O DELL'ASSOCIAZIONE DABRAFENIB-TRAMETINIB IN PAZIENTI AFFETTI DA MELANOMA METASTATICO, ALLO SCOPO DI CARATTERIZZARE I PAZIENTI CON BENEFICIA A LUNGO TERMINE NEL PROGRAMMA PER SINGOLI PAZIENTI (IPP, INDIVIDUAL PATIENT PROGRAM)	NA
16-214-02	STUDIO DI FASE 1/2, IN APERTO, MULTICENTRICO SULLA COMBINAZIONE DI NKTR 214 E NIVOLUMAB O SULLA COMBINAZIONE DI NKTR 214, NIVOLUMAB E IPILIMUMAB IN PAZIENTI CON DETERMINATE NEOPLASIE MALIGNI SOLIDE LOCALMENTE AVANZATE O METASTATICHE	I/II
CA224-047	STUDIO DI FASE 2/3 RANDOMIZZATO, IN DOPPIO CIECO, DI RELATLIMAB IN COMBINAZIONE CON NIVOLUMAB RISPETTO A NIVOLUMAB IN PARTECIPANTI AFFETTI DA MELANOMA METASTATICO O NON RESECCABILE, NON PRECEDENTEMENTE TRATTATO	II/III
2125-MEL-301	CONFRONTO RANDOMIZZATO DI FASE 3 DI IMO-2125 CON IPILIMUMAB RISPETTO A IPILIMUMAB IN MONOTERAPIA IN SOGGETTI AFFETTI DA MELANOMA REFRATTARIO A TERAPIA ANTI-PD1	III
CA022-001	STUDIO DI FASE 1/2 A, PRIMA SOMMINISTRAZIONE NELL'UOMO, DELL'ANTICORPO MONOCLONALE BMS-986218 DA SOLO ED IN COMBINAZIONE CON NIVOLUMAB IN TUMORI SOLIDI IN STADIO AVANZATO.	I/II
I-TACKLE	IMMUNOTERAPIA SEGUITA DAL TRATTAMENTO CON INIBITORE EGFR IN PAZIENTI CON CARCINOMA CUTANEO SQUAMOSO LOCALMENTE AVANZATO O METASTATICO: COMBATTERE LA RESISTENZA PRIMARIA E SECONDARIA- I-TACKLE	II
E7080-J081-116	STUDIO CLINICO IN APERTO DI FASE IB CON LENVATINIB PIÙ PEMBROLIZUMAB IN PAZIENTI AFFETTI DA CARCINOMA EPATOCELLULARE	I
MK3475-587	SPERIMENTAZIONE DI ESTENSIONE DI FASE III, MULTICENTRICA, IN APERTO PER VALUTARE LA SICUREZZA E L'EFFICACIA A LUNGO TERMINE IN PAZIENTI CON TUMORI AVANZATI ATTUALMENTE IN TRATTAMENTO O IN FOLLOW-UP IN UNA SPERIMENTAZIONE CON PEMBROLIZUMAB.	III
SENSITIZE	STUDIO IN APERTO, MULTICENTRICO, DI FASE IB/II DI 4SC-202 IN COMBINAZIONE CON PEMBROLIZUMAB IN PAZIENTI CON MELANOMA CUTANEO, DI STADIO III NON RESECCABILE O IV METASTATICO, REFRATTARI PRIMARI/NON RESPONSIVI A PRECEDENTE TERAPIA CON ANTI-PD-1. STUDIO SENSITIZE.	I/II
CDRB436F2410	STUDIO IN APERTO, DI FASE IIIB CON DABRAFENIB IN COMBINAZIONE CON TRAMETINIB NEL TRATTAMENTO ADIUVANTE DEL MELANOMA IN STADIO III POSITIVO PER LA MUTAZIONE BRAF V600 DOPO RESEZIONE COMPLETA, PER VALUTARE L'IMPATTO SUGLI ESITI CORRELATI ALLA PIRESSIA DI UN ALGORITMO PER LA GESTIONE DEGLI EVENTI AVVERSI ADATTATO ALLA PIRESSIA	III
MK3475-716	TERAPIA ADIUVANTE CON PEMBROLIZUMAB VERSUS PLACEBO IN PAZIENTI CON MELANOMA DI STADIO II AD ALTO RISCHIO E RESECCATO: UNO STUDIO DI FASE III RANDOMIZZATO E IN DOPPIO CIECO (KEYNOTE 716)	III

MO39136	STUDIO DI FASE II A DUE COORTI VOLTO A VALUTARE LA SICUREZZA E L'EFFICACIA DI COBIMETINIB + ATEZOLIZUMAB NEL MELANOMA WILD-TYPE CON METASTASI A CARICO DEL SISTEMA NERVOSO CENTRALE E DI COBIMETINIB + ATEZOLIZUMAB E VEMURAFENIB NEL MELANOMA POSITIVO PER MMUTAZIONE DI BRAFV600 CON METASTASI A CARICO DEL SISTEMA NERVOSO CENTRALE	II
CA209-848	STUDIO CLINICO DI FASE II, IN APERTO, RANDOMIZZATO DI NIVOLUMAB IN COMBINAZIONE CON IPILIMUMAB O NIVOLUMAB IN MONOTERAPIA IN PAZIENTI CON TUMORI SOLIDI METASTATICI O AVANZATI CON UN ALTO CARICO MUTAZIONALE DEL TUMORE (TMB-H)	II
MK-3475-02D	STUDIO DI FASE 1/2 IN APERTO, A BRACCI MULTIPLI DI TRATTAMENTO (UMBRELLA STUDY) CON PEMBROLIZUMAB IN MONOTERAPIA O IN COMBINAZIONE CON DIVERSI AGENTI SPERIMENTALI, IN PAZIENTI AFFETTI DA MELANOMA (KEYMAKER-U02): SOTTOSTUDIO 02D	II

Numero di pazienti affetti da Melanoma arruolati negli studi clinici interventistici e osservazionali



Farmaci immunoterapici sviluppati nelle diverse patologie

CA209-032 <i>Ipilimumab</i>	CA209-032 <i>Ipilimumab</i> + <i>Nivolumab</i>	MEDI4736-1108 <i>Durvolumab</i>	CA224-020 <i>Ipilimumab</i> + <i>anti LAG 3</i>	MK3475-158 <i>Pembrolizumab</i>	WP29945 <i>Anti CEA</i> + <i>Atezolizumab</i>	MO29518 <i>Atezolizumab</i>
TNBC	TNBC	TNBC	NSCLC	NSCLC	Colon	TNBC
Gastrico	Gastrico	Melanoma Uveale	Vescica	Anale	Gastrico	Timoma
Pancreas	Pancreas	Gastroesofageo	HCC	Cervice	NSCLC	Colon
SCLC	SCLC	SCLC		Vulva	Pancreas	MSI tumori solidi
Vescica	Vescica	Vescica		Mesotelioma		Mesotelioma
		NSCLC		SCLC		Gastrico
		Nasofaringe Carcinoma		HCC		Pancreas
		Ovaio		H-MSI tumori solidi		
		Sarcoma soft tissue				

PRODUZIONE SCIENTIFICA

PERFORMANCE SCIENTIFICA by SCOPUS:

h-Index = 106

PEER-REVIEW DELLE SEGUENTI RIVISTE SCIENTIFICHE:

New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, British Journal of Dermatology, Cancer, Clinical Cancer Research, Cancer Research, Melanoma Research, Acta Dermato-Venereologica, Southern Medical Journal, Expert Review of Molecular Diagnostics, Journal of Translational Medicine, Oncology Review, Journal of the European Academy of Dermatology and Venereology.

EDITOR E MEMBRO DELL'EDITORIAL BOARD DELLE SEGUENTI RIVISTE SCIENTIFICHE:

Annals of Oncology	<i>Section Editor for Melanoma and Immuno-Oncology</i>
Journal of Translational Medicine	<i>Deputy Editor and section editor of the Combination Strategies subsection</i>
Journal of ImmunoTherapy of Cancer	<i>Associate Editor</i>
ESMO Open	<i>Associate Editor</i>

ESTENSORE O COORDINATORE DI LINEE GUIDA NAZIONALI E INTERNAZIONALI

- Alleanza Contro il Cancro. Basi scientifiche per la definizione di linee-guida in ambito clinico per il Melanoma cutaneo. Febbraio 2012. © 2012 - Alleanza Contro il Cancro – ACC. <http://www.alleanzacontroilcancro.it>
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2012: 861-95. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2013. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2014. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2015. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2016. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2017. www.aiom.it
- Linee guida dell'oncologia italiana. Melanoma. Associazione Italiana di Oncologia Medica (AIOM) 2018. www.aiom.it
- Revisore Linee guida dell'oncologia italiana. TUMORI CUTANEI NON MELANOMA. Carcinoma squamocellulare cutaneo. Associazione Italiana di Oncologia Medica (AIOM) 2019. www.aiom.it
- Revisore Linee guida dell'oncologia italiana. TUMORI CUTANEI NON MELANOMA. Carcinoma basocellulare. Associazione Italiana di Oncologia Medica (AIOM) 2020. www.aiom.it
- Revisore Linee guida dell'oncologia italiana. TUMORI CUTANEI NON MELANOMA. Carcinoma squamocellulare cutaneo. Associazione Italiana di Oncologia Medica (AIOM) 2021. www.aiom.it

- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* (2019)
- Coordinatore linee guida melanoma e non melanoma skin cancer per ESMO 2023-2024
- ASCO Melanoma guidelines panel member, 2023. (Rahul Seth et al. Systemic Therapy for Melanoma: ASCO Guideline Update. *JCO* 41, 4794-4820(2023). DOI:10.1200/JCO.23.01136)
- ASCO Melanoma guidelines panel member (Rahul Seth et al. Systemic Therapy for Melanoma: ASCO Guideline. *JCO* 38, 3947-3970(2020). DOI:10.1200/JCO.20.00198)
- SITC guidelines on Immune checkpoint toxicity adverse events panel member. Brahmer JR et al, Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435.
- Raccomandazioni per la determinazione dello stato mutazionale di BRAF nel Melanoma. Gruppo di lavoro AIOM-SIAPEC. www.aiom.it
- Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). *Ann Oncol*. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. PubMed PMID: 30295695; PubMed Central PMCID: PMC6290929.
- Michielin O, van Akkooi A, Ascierto P, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019 Sep 30. pii: mdz411. doi:10.1093/annonc/mdz411. [Epub ahead of print] PubMed PMID: 31566661.

DOCUMENTI DI RIFERIMENTO PER PAZIENTI

- Cascinelli N, **Ascierto PA**. Il Melanoma. AIMaC – Associazione Italiana Malati di Cancro, parenti e amici. La Collana del Girasole 2005.

CAPITOLI DI LIBRI IN ITALIANO

- G Castello, **PA Ascierto**, G Calmieri, R Parasole. Il melanoma maligno quale modello di studio. In *Immunità e patologie correlate*, Cap. 13; Ediz CeSII srl, Milano, 2000.
- **Ascierto P.A.** Radiazioni cosmiche. In *Progetto Ambiente e Tumori*, pagg. 176-90. Ediz. *AIOM- Associazione Italiana di Oncologia Medica, Milano, 2011*.
- **Ascierto P.A., Palla M., De Michele I., Ayala F.** Radiazioni ottiche. In *Progetto Ambiente e Tumori*, pagg. 192-203. Ediz. *AIOM- Associazione Italiana di Oncologia Medica, Milano, 2011*.
- Mandalà M., Rossi C., De Giorgi V., Massi D., Botti G., Sommariva A., **Ascierto P.A.** 2013. Melanoma Cutaneo. In: Labianca R, Cascinu S. *La Medicina Oncologica*. Milano: LSWR Srl, pp.41-75. ISBN 978-88214-3075-6.
- Mandalà M., Rossi C., De Giorgi V., Massi D., Botti G., Sommariva A., **Ascierto P.A.** 2013. Carcinomi Cutanei. In: Labianca R, Cascinu S. *La Medicina Oncologica*. Milano: LSWR Srl, pp.77-93. ISBN 978-88214-3075-6.
- Grimaldi AM, Cassidy PB, Leachmann S, **Ascierto PA**. Novel approaches in melanoma prevention and therapy. *Cancer Treat Res*. 2014;159:443-55. doi:10.1007/978-3-642-38007-5_25.
- **Ascierto PA**, Festino L. I criteri di risposta immunocorrelati. In; Pinto C ed. *Immuno-Oncologia generale: Il pensiero Scientifico editore* pp.37-48.

AUTORE DI LIBRI IN INGLESE

Marincola FM, **Ascierto PA**, Kirkwood JM. *Emerging Therapeutics for Melanoma*. Future Medicine Ltd, London, 2012.

Ascierto PA. *The treatment of melanoma Ed I*. Minerva Medica, 2019

Ascierto PA. *Principles for next generation anti - cancer immunotherapy Ed.I*. Minerva Medica, 2020.

Ascierto PA. *The treatment of melanoma Ed II*. Minerva Medica, 2021

Ascierto PA. *Principles for next generation anti - cancer immunotherapy Ed.II*. Minerva Medica, 2024

Inoltre è stato Lead Guest Editor del seguente numero special di Journal of Skin Cancer: *Melanoma: From Research to Treatment*. Guest Editors: Paolo A. Ascierto, John M. Kirkwood, Francesco M. Marincola, and Giuseppe Palmieri. *Journal of Skin Cancer 2011; Hindawi Publishing Corporation*.

CAPITOLI DI LIBRI IN INGLESE

- **Ascierto PA**, Ascierto ML, Capone M, Elaba Z, Murphy MJ, and Palmieri G. Molecular Pathogenesis of Melanoma: Established and Novel Pathways. In *Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma*. Edited by Murphy MJ. New York: Humana Press 2012: 19-37.
- Palmieri G, Rozzo C, Gentilcore G, **Ascierto PA**. *Melanoma pathophysiology and drug targets*. In *Emerging Therapeutics for Melanoma*. Edited by Marincola FM, Ascierto PA, Kirkwood JM. London, Future Medicine Ltd 2012: 7-17.
- Palmieri G, Colombino M, Sini MC, **Ascierto PA**, Lissia A and Cossu A. *Targeted Therapies in Melanoma: Successes and Pitfalls*. In *Melanoma - From Early Detection to Treatment*, Dr. Ht Duc (Ed.), ISBN: 978-953-51-0961-7, InTech, 2013: 29-58. Available from: <http://www.intechopen.com/books/melanoma-from-early-detection-to-treatment/targeted-therapies-in-melanoma-successes-and-pitfalls>.
- Staibano S., **Ascierto P.A.** 2013. Targeting tumor Angiogenesis. In: Staibano S. ed. *Prostate Cancer: Shifting from Morphology to Biology*. Heidelberg, Dordrecht, New York, London: Springer, pp.221-231. ISBN 978-94-007-7148-2.
- Simeone E., Grimaldi A.M., **Ascierto P.A.**, Merolla F., Ilardi G., Siano M. and Staibano S. 2013. Therapeutic Targeting of the Bone pre- Metastatic Niche. In: Staibano S. ed. *Prostate Cancer: Shifting from Morphology to Biology*. Heidelberg, Dordrecht, New York, London: Springer, pp.247-254. ISBN 978-94-007-7148-2.
- **Ascierto PA**, Flaherty K, Goff S. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. *Am Soc Clin Oncol Educ Book*. 2018 May 23;(38):751-758. doi: 10.1200/EDBK_199047. PubMed PMID: 30231371.
- Staibano S., **Ascierto P.A.** 2013. Targeting tumor Angiogenesis. In: Staibano S. ed. *Prostate Cancer: Shifting from Morphology to Biology*. Heidelberg, Dordrecht, New York, London: Springer, pp.221-231. ISBN 978-94-007-7148-2.
-

PUBBLICAZIONI RECENSITE CON RELATIVO IMPACT FACTOR

N.	TITOLO	I.F.
1	Balzano A, Bove A, Leonardi E, Bevilacqua N, Grande G, Ascierto PA , Castello G: The soluble interleukin-2 receptor as an indicator of clinical evolution in patients with ulcerative colitis. <i>Eur J Gastroen Hepat</i> 1997; 9: 173-7.	1.830
2	Castello G, Gallo C, Napolitano M, Ascierto PA : Immunological phenotype analysis of patients with Fanconi's Anaemia and their family members. <i>Acta Haematol</i> 1998; 100: 39-43.	1.352
3	Ascierto PA , Satriano RA, Palmieri G, et al. Epiluminescence microscopy as useful approach in the early diagnosis of cutaneous malignant melanoma. <i>Melanoma Res.</i> 1998; 8: 529-37.	2.225
4	Palmieri G, Strazzullo M, Ascierto PA , et al. PCR-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. <i>J. Clin. Oncol.</i> 1999; 17: 304-11.	15.484
5	Ascierto PA , Palmieri G, Parasole R, Daponte A, Castello G, and the Melanoma Cooperative Group. 3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma. <i>Int J Mol Med</i> 1999; 3: 303-6.	1.847
6	Ascierto PA , Palmieri G. Adjuvant therapy of cutaneous melanoma [Letter]. <i>Lancet</i> 1999; 353: 328.	28.638
7	Ascierto PA , Daponte A, Palmieri G. Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct? [Letter]. <i>Melanoma Res</i> 1999; 9: 528-9.	2.225
8	Ascierto PA , Palmieri G, Celentano E, Parasole R, Caracò C, Daponte A, Chiofalo MG, Melucci MT, Mozzillo N, Satriano RA, Castello G. and the Melanoma Cooperative Group. Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2,731 excised cutaneous pigmented lesions. <i>Br J Dermatology</i> 2000; 142: 893-8.	3.503
9	Ascierto PA , Palmieri G, Strazzullo M, Daponte A, Botti G, Satriano SMR., Motti ML, Mozzillo N, and Castello G. Low doses interferon- α in the treatment of high-risk cutaneous melanoma. <i>Ann Oncology</i> 2000; 11:487-90.	4.875
10	G Palmieri, PA Ascierto , SMR Satriano, et al. Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. [Letter]. <i>Ann Oncology</i> 2000; 11: 635-6.	4.875
11	Ascierto PA , Daponte A, Parasole R, Perrone F, Caracò C, Melucci MT, Palmieri G, Napolitano M, Mozzillo N, and Castello G. Intermediate-Dose Recombinant Interferon-Alpha as Second Line Treatment of Recurrent Cutaneous Melanoma in Patients Pre-Treated with Low-Dose Interferon. <i>Cancer</i> 2000; 89:1490-4.	4.632
12	Palmieri G, Pirastu M, Strazzullo M, Ascierto PA , Satriano SM, Motti ML, Botti G, Mozzillo N, Castello G, Cossu A, Lissia A, Tanda F. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. <i>Recent Results Cancer Res.</i> 2001; 158:200-3.	0
13	Palmieri G, Cossu A, Ascierto PA , Botti G, Strazzullo M, Lissia A, Colombino M, Casula M, Floris C, Tanda F, Pirastu M, Castello G for the Melanoma Cooperative Group. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumors and their metastases. <i>Br J Cancer</i> 2000; 83:1707-14.	4.635
14	Daponte A, Ascierto PA , Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, De Lena M, Marini G, Comella G. Cisplatin, dacarbazine, and fotemustine plus alpha interferon in advanced malignant melanoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group (SICOG). <i>Cancer</i> 2000; 89:2630-6.	4.632
15	Ascierto PA , Mozzillo N, Caracò C, Parasole R, Palmieri G, Melucci MT, Botti G, Castello G. Epithelioid cell type melanoma as a prognostic factor of poor response to immunological treatment. [Letter]. <i>Ann Oncology</i> 2000; 11:1504.	4.875
16	PA Ascierto , C Caracò, F Ionna, L Pezzullo, G Palmieri, MT Melucci, S Canzanella for the Melanoma Cooperative Group of Naples. Mobile Hospital Rooms To Fight Melanoma. [Letter]. <i>Melanoma Res</i> 2001; 11:83-4.	2.225
17	Palmieri G, Ascierto PA , Cossu, et al. Detection of occult Melanoma cells in paraffin-embedded histologically-negative sentinel lymph nodes using a reverse transcriptase-polymerase chain reaction assay. <i>J Clin Oncol</i> 2001; 19: 1437-43.	15.484
18	A Crispo, M Tamburini, MR De Marco, P Ascierto , P Silvestro, D Ronga, V Tridente, S Desicato, S Carbone, G Fabbrocini, D Spiteri, M Montella. HHV-8 prevalence, immunosuppression and Kaposi's sarcoma in South Italy. <i>Int J Mol Med</i> 2001; 7: 535-8.	1.847

19	G. Palmieri, A. Cossu, A. Lissia, L. Leoncini, S. Lazzi, P.A. Ascierto , G. Castello, and F. Tanda. Detection of tyrosinase mRNA in microdissected tumor tissues from classic Kaposi's sarcoma. <i>Ann. Oncol.</i> 2001; 12:1765-6.	4.875
20	Ascierto PA , Palmieri G, Daponte A, Melucci MT, Satriano RA, Mozzillo N, Castello G. Adjuvant therapy of melanoma: what's new? <i>Melanoma Res.</i> 2002 Jun;12(3):293-6.	2.225
21	Montella M, Crispo A, Grimaldi M, De Marco MR, Ascierto PA , Parasole R, Melucci MT, Silvestro P, Fabbrocini G. An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy. <i>Prev Med.</i> 2002 Sep;35(3):271-7.	2.314
22	Caraco C, Chiofalo MG, Niro J, Ascierto PA , Botti G, Lastoria S, Mozzillo N. Sentinel lymph node biopsy to stage patients with cutaneous melanoma at the National Cancer Institute of Naples. Results from 240 sentinel node biopsies. <i>Tumori.</i> 2002 May-Jun;88(3):S12-3.	0.597
23	Mozzillo N, Caraco C, Ascierto PA , Botti G, Chiofalo MG, Lastoria S, Nunziata CA. [Treatment of loco-regional lymph nodes in cutaneous melanoma] Suppl <i>Tumori.</i> 2002 May-Jun;1(3):S68-71.	0.597
24	Ottaiano A, Pisano C, De Chiara A, Ascierto PA , Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. CD40 activation as potential tool in malignant neoplasms. <i>Tumori.</i> 2002 Sep-Oct;88(5):361-6. Review.	0.597
25	Palmieri G, Ascierto PA , Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caraco C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. <i>J Clin Oncol.</i> 2003 Mar 1;21(5):767-73. Review. Erratum in: <i>J Clin Oncol.</i> 2003 May 15;21(10):2048.	15.484
26	Palmieri G, Ascierto PA , Cossu A, Colombino M, Casula M, Botti G, Lissia A, Tanda F, Castello G. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Res.</i> 2003 Apr;13(2):167-70.	2.225
27	Vozza A, Tolone C, Carrano EM, Di Girolamo F, Santinelli R, Ascierto PA , Toraldo R, Nacca L, Vozza G. Late onset Blueberry Muffin Syndrome following congenital rubella. <i>J Eur Acad Dermatol Venereol.</i> 2003 Mar;17(2):204-5.	1.437
28	Ascierto PA , Palmieri G, Botti G, Satriano RA, Stanganelli I, Bono R, Testori A, Bosco L, Daponte A, Caraco C, Chiofalo MG, Melucci MT, Calignano R, Tatangelo F, Cochran AJ, Castello G; Melanoma Cooperative Group. Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. <i>Int J Oncol.</i> 2003 Jun;22(6):1209-15.	2.295
29	Ottaiano A, Pisano C, De Chiara A, Barletta E, Ascierto AP , Botti G, Napolitano M, Apice G, Iaffaioli RV. Expression of CD40 has no predictive value in soft tissue sarcomas. <i>Anticancer Res.</i> 2003 Mar-Apr;23(2B):1597-604.	1.414
30	Casula M, Ascierto PA , Cossu A, Sini MC, Tore S, Colombino M, Satta MP, Manca A, Rozzo C, Satriano SMR, Castello G, Lissia A, Tanda F, Palmieri G. Mutation analysis of candidate genes in melanoma-prone families: evidences of different pathogenetic mechanisms at chromosome 9p21. <i>Melanoma Res</i> 2003 Dec;13(6):571-9.	2.225
31	Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA , Bianchi-Scarra G, Castiglia D, Budroni M, Rozzo C, Manca A, Lissia A, Carboni A, Petretto E, Satriano SM, Botti G, Mantelli M, Ghiorzo P, Stratton MR, Tanda F, Palmieri G; Italian Melanoma Intergroup Study. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. <i>J Clin Oncol.</i> 2004 Jan 15;22(2):286-92.	15.484
32	Caraco C, Celentano E, Lastoria S, Botti G, Ascierto PA , Mozzillo N. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. <i>Ann Surg Oncol.</i> 2004 Mar;11(3 Suppl):198S-202S.	3.917
33	Mozzillo N, Caraco C, Chiofalo MG, Celentano E, Lastoria S, Botti G, Ascierto PA . Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up. <i>Eur J Surg Oncol.</i> 2004 May;30(4):440-3.	2.065
34	Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F, De Rosa V, Mozzillo N, Ravo V, Morrica B, Gallo C, Pisano C, Napolitano M, Ascierto PA , Iaffaioli RV, Apice G. Prognostic value of CD40 in adult soft tissue sarcomas. <i>Clin Cancer Res.</i> 2004 Apr 15;10(8):2824-31.	6.250
35	Ottaiano A, di Palma A, Napolitano M, Pisano C, Pignata S, Tatangelo F, Botti G, Acquaviva AM, Castello G, Ascierto PA , Iaffaioli RV, Scala S. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. <i>Cancer Immunol Immunother.</i> 2004 Dec 11; [Epub ahead of print]	3.728
36	PA Ascierto , E Leonardi, A Ottaiano, M Napolitano, S Scala, G Castello. Prognostic value of serum VEGF in melanoma patients: a pilot study. <i>Anticancer Res</i> 2004; 24:4255-8.	1.414

37	Ottaiano A, Castello G, Ascierto PA . Evidence of publication bias in clinical trias of biotherapies for solid tumors. <i>Cancer</i> 2005; 103:653.	4.632
38	Ottaiano A, Mollo E, Di Lorenzo G, Pisano C, Di Maio M, Barletta E, Pensabene M, Segati R, Bullian P, Nasti G, Bryce J, Scala S, Castello G, Ascierto PA . Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunol Immunother</i> . 2005; 54:44-50.	3.728
39	Scala S, Ottaiiano A, Ascierto PA , Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G.Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. <i>Clin Cancer Res</i> . 2005; 11:1835-41.	6.250
40	Daponte A, Ascierto PA , Gravina A, Melucci M, Scala S, Ottaiiano A, Simeone E, Palmieris G, Comella G. Temozolomide and cisplatin in avdanced malignant melanoma. <i>Anticancer Res</i> . 2005; 25:1441-7.	1.414
41	Ascierto PA , Scala S, Ottaiiano A, Simeone E, de Michele I, Palmieri G, Castello G. Adjuvant treatment of malignant melanoma: Where are we? <i>Crit Rev Oncol Hematol</i> . 2005 Jun 27; [Epub ahead of print]	4.632
42	Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, Ascierto PA , Napolitano M, Cossu A, Tadolini B, Turrini F, Manca A, Sini MC, Palmieri G, Rozzo AC; Italian Melanoma Intergroup. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Res</i> . 2005 Aug;15(4):235-44.	2.225
43	Ascierto, PA , Scala S., Castello G., Daponte A., Simeone E., Ottaiiano A., Beneduce G, De Rosa V., Izzo F., Melucci MT, Ensor M., Prestayko HW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N., Feun LG, Logan, TF. Pegylated Arginine Deiminase Treatment of Subjects with Metastatic Melanoma: Results from Phase I and II Studies. <i>J Clin Oncol</i> . 2005; 23:7660-8.	15.484
44	Stanganelli I, Brucale A, Calori L, Gori R, Lovato A, Magi S, Kopf B, Bacchilega R, Rapisarda V, Testori A, Ascierto PA , Simeone E, Ferri M. Computer-aided diagnosis of melanocytic lesions. <i>Anticancer Res</i> . 2005 Nov-Dec;25(6C):4577-82.	1.414
45	Ottaiano A, Leonardi E, Simeone E, Ascierto PA , Scala S, Calemma R, Bryce J, Caraco C, Satriano RA, Gianfranco N, Franco R, Botti G, Castello G. Soluble interleukin-2 receptor in stage I-III melanoma. <i>Cytokine</i> . 2006 Feb 7;33(3):150-5. Epub 2006 Mar 6.	2.169
46	Scala S, Giuliano P, Ascierto PA , et al. Human melanoma metastases express functional CXCR4. <i>Clin Cancer Res</i> . 2006 Apr 15;12(8):2427-33.	6.250
47	Palmieri G, Satriano SM, Budroni M, Cossu A, Tanda F, Canzanella S, Caraco C, Simeone E, Daponte A, Mozzillo N, Comella G, Castello G, Ascierto PA . Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> . 2006 Nov 15;6:266.	2.709
48	Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caraco C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA , Palmieri G; Italian Melanoma Intergroup. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>Eur J Cancer</i> . 2007 Jan;43(1):137-43. Epub 2006 Oct 19.	4.454
49	Scala S, Ierano C, Ottaiiano A, Franco R, La Mura A, Liguori G, Mascolo M, Staibano S, Ascierto PA , Botti G, De Rosa G, Castello G. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. <i>Cancer Immunol Immunother</i> . 2007 Oct;56(10):1589-95.	3.728
50	Palmieri G, Casula M, Ascierto PA , Tanda F, Cossu A. Molecular classification of patients with malignant melanoma for new therapeutic strategies. <i>J Clin Oncol</i> . 2007 Jun 1;25(16):e20-1.	15.484
51	Fulciniti F, Ascierto PA , Simeone E, Bove P, Losito S, Russo S, Gallo MS, Gregg S. Nevroid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations. <i>Cytojournal</i> . 2007 Jul 3;4:14.	0.628
52	Pagnanelli G, Bono R, Pizzichetta MA, Talamini R, Ascierto PA , Testori A, Stanganelli I; Italian Melanoma Intergroup (IMI). Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity. <i>Anticancer Res</i> . 2007 Jul-Aug;27(4C):2939-44.	1.414
53	Palmieri G, Casula M, Sini MC, Ascierto PA , Cossu A. Issues affecting molecular staging in the management of patients with melanoma. <i>J Cell Mol Med</i> . 2007 Sep-Oct;11(5):1052-68. Review.	6.807
54	Sini MC, Manca A, Cossu A, Budroni M, Botti G, Ascierto PA , Cremona F, Muggiano A, D'Atri S, Casula M, Baldinu P, Palomba G, Lissia A, Tanda F, Palmieri G. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. <i>Br J Dermatol</i> . 2008 Feb;158(2):243-50. Epub 2007 Nov 19.	3.503
55	Maio M, Nicolay HJ, Ascierto P , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Anzalone L, Fonsatti E, Parmiani G. The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward. <i>J Transl Med</i> . 2008 Feb 12;6:8.	2.935
56	Eggermont AM, Suci S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group (110 collaborators	28.638

	including Ascierto P). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet</i> . 2008 Jul 12;372(9633):117-26.	
57	Ascierto PA , Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. <i>J Transl Med</i> . 2008 Oct 27;6(1):62.	2.935
58	Pisano M, Baldinu P, Sini MC, Ascierto PA , Tanda F, Palmieri G; On behalf of the Italian Melanoma Intergroup. Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Ann Oncol</i> . 2008 Oct 31.	4.875
59	Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, De Maio A, Ombra M, Gentilcore G, Capone M, Ascierto M, Satriano RA, Farina B, Faraone-Mennella M, Ascierto PA , Ialenti A. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Lett</i> . 2008 Nov 10.	3.398
60	Maio M, Nicolay HJ, Ascierto PA , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; for the NIBIT. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. <i>Cancer Immunol Immunother</i> . 2009 Mar 28.	3.804
61	Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA , Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, Leachman SA, Bianchi Scarrà G; IMI, Italian Melanoma Intergroup. Clinical genetic testing for familial melanoma in Italy: a cooperative study. <i>J Am Acad Dermatol</i> . 2009 Nov;61(5):775-82.	4.081
62	Casula M, Alaibac M, Pizzichetta MA, Bono R, Ascierto PA , Stanganelli I, Canzanella S, Palomba G, Zattra E; Italian Melanoma Intergroup (IMI), Palmieri G. Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. <i>BMC Dermatol</i> . 2009 Jul 22;9:7.	2.227
63	Casula M, Muggiano A, Cossu A, Budroni M, Caracò C, Ascierto PA , Pagani E, Stanganelli I, Canzanella S, Sini M, Palomba G; Italian Melanoma Intergroup (IMI), Palmieri G. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> . 2009 Oct 3;9:352.	3.087
64	Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA . Main roads to melanoma. <i>J Transl Med</i> . 2009 Oct 14;7:86.	2.917
65	Di Lorenzo G, Perdonà S, Damiano R, Faiella A, Cantiello F, Pignata S, Ascierto P , Simeone E, De Sio M, Autorino R. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. <i>Cancer</i> . 2010 Apr 15; 116(8):1893-900.	5.418
66	Maio M, Nicolay HJ, Ascierto PA , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009. <i>Cancer Immunol Immunother</i> . 2010 Mar 5. [Epub ahead of print].	3.791
67	Casula M, Budroni M, Cossu A, Ascierto PA , Mozzillo N, Canzanella S, Muggiano A, Palmieri G. The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. <i>Ann Oncol</i> . 2010 Jun;21(6):1379-80.	5.647
68	Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA , Curley SA, Izzo F. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. <i>J Clin Oncol</i> . 2010 May 1;28(13):2220-6.	17.793
69	Ascierto PA , Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. <i>J Transl Med</i> . 2010 Apr 20;8:38.	3.407
70	Vozza A, Di Girolamo F, Montesarchio G, Capuano A, Ascierto PA , Vozza G. Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. <i>G Ital Dermatol Venereol</i> . 2010 Apr;145(2):313-5.	0.864
71	Capasso M, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, Ascierto PA , Iolascon A. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. <i>J Hum Genet</i> . 2010 Aug;55(8):518-24.	2.547
72	Ascierto PA , Palla M, Ayala F, De Michele I, Caracò C, Daponte A, Simeone E, Mori S, Del Giudice M, Satriano RA, Vozza A, Palmieri G, Mozzillo N. The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatol</i> . 2010 Aug 13;10:5.	2.741
73	Ascierto PA , Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemme R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. <i>J Transl Med</i> . 2010 Aug 16;8(1):76.	3.407

74	Ascierto PA , Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. <i>Semin Oncol</i> . 2010 Oct;37(5):508-16.	3.143
75	Manca A, Sini MC, Izzo F, Ascierto PA , Tatangelo F, Botti G, Gentilcore G, Capone M, Mozzillo N, Rozzo C, Cossu A, Tanda F, Palmieri G. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncol Rep</i> . 2011 Jun;25(6):1495-502.	1.686
76	Ascierto PA , De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". <i>J Transl Med</i> . 2011 Mar 26;9:32.	3.508
77	Maio M, Nicolay HJ, Ascierto PA , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E; NIBIT, Parmiani G. Eighth annual meeting of the Italian network for tumor bioterapy (NIBIT), Siena, October 7-9, 2010. <i>Cancer Immunol Immunother</i> . 2011 Jun;60(6):901-7.	4.293
78	Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P , Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>N Engl J Med</i> . 2011 Jun 30;364(26):2507-16.	53.486
79	Tocchetti CG, Lombardi MC, Librera M, Ascierto PA , Maurea N. Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. <i>Eur J Echocardiogr</i> . 2011 Aug;12(8):636.	2.117
80	Ascierto PA , Marincola FM. Combination therapy: the next opportunity and challenge of medicine. <i>J Transl Med</i> . 2011 Jul 21;9:115.	3.508
81	Franco R, Scognamiglio G, Salerno V, Sebastiani A, Cennamo G, Ascierto PA , Botti G, Turco MC, Rosati A. Expression of the Anti-Apoptotic Protein BAG3 in Human Melanomas. <i>J Invest Dermatol</i> . 2012 Jan;132(1):252-4.	6.314
82	Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA , Stroncek DF, Restifo NP, Wang E, Szalay AA, Marincola FM. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. <i>BMC Cancer</i> . 2011 Oct 19;11:451.	3.153
83	Ascierto PA , Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. <i>J Transl Med</i> . 2011 Nov 13;9(1):196.	3.508
84	Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA , Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the Critical Hurdles in Cancer Immunotherapy. <i>J Transl Med</i> . 2011 Dec 14;9(1):214.	3.508
85	Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA . The immune score as a new possible approach for the classification of cancer. <i>J Transl Med</i> . 2012 Jan 3;10:1.	3.474
86	Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA . NF-κB as potential target in the treatment of melanoma. <i>J Transl Med</i> . 2012 Mar 20;10:53.	3.474
87	Simeone E, Ascierto PA . Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. <i>J Immunotoxicol</i> . 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. PubMed PMID: 22524673.	1.439
88	Montesarchio V, Grimaldi AM, Fox BA, Rea A, Marincola FM, Ascierto PA . Lean oncology: a new model for oncologists. <i>J Transl Med</i> . 2012 Apr 25;10(1):74. [Epub ahead of print].	3.474
89	Ascierto PA , Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future	3.474

	perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011". <i>J Transl Med</i> . 2012 Jul 4;10:83.	
90	Ascierto PA , Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. <i>J Transl Med</i> . 2012 Jul 9;10:85.	3.474
91	Cantile M, Scognamiglio G, Anniciello A, Farina M, Gentilcore G, Santonastaso C, Fulciniti F, Cillo C, Franco R, Ascierto PA , Botti G. Increased HOX C13 expression in metastatic melanoma progression. <i>J Transl Med</i> . 2012 May 14;10:91. doi: 10.1186/1479-5876-10-91.	3.474
92	Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, Staibano S, Montesarchio V, Palmieri G, Mozzillo N, Ascierto PA . Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. <i>J Med Case Rep</i> . 2012 May 17;6(1):131.	0.350
93	Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA , Palmieri G. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. <i>J Clin Oncol</i> . 2012 Jul 10;30(20):2522-9. Epub 2012 May 21.	18.372
94	Ascierto PA , Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. <i>J Transl Med</i> . 2012 May 28;10:107.	3.474
95	Maio M, Nicolay HJ, Ascierto PA , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Fonsatti E, Papamichail M, Parmiani G; NIBIT. Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. <i>Cancer Immunol Immunother</i> . 2012 Sep;61(9):1599-608. Epub 2012 Jun 27.	3.701
96	Lebbe C, Lorigan P, Ascierto P , Testori A, Bédane C, Middleton M, van Baardewijk M, Konto C, Dueymes A, Maio M. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). <i>Eur J Cancer</i> . 2012 Jun 26. [Epub ahead of print].	5.536
97	Mozzillo N, Caracò C, Mori S, Di Monta G, Botti G, Ascierto PA , Caracò C, Aloj L. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. <i>J Transl Med</i> . 2012 Jun 22;10:131.	3.474
98	Ascierto PA , Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. <i>Crit Rev Oncol Hematol</i> . 2012 Aug 5. [Epub ahead of print].	4.411
99	Di Giacomo AM, Ascierto PA , Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncol</i> . 2012 Sep;13(9):879-86. Epub 2012 Aug 13. PubMed PMID: 22894884.	22.589
100	Di Trollo R, Simeone E, Di Lorenzo G, Grimaldi AM, Romano A, Ayala F, Caracò C, Mozzillo N, Ascierto PA . Update on PEG-Interferon α -2b as Adjuvant Therapy in Melanoma. <i>Anticancer Res</i> . 2012 Sep;32(9):3901-9.	1.725
101	Botti G, Franco R, Cantile M, Ciliberto G, Ascierto PA . Tumor biobanks in translational medicine. <i>J Transl Med</i> . 2012 Oct 2;10(1):204. [Epub ahead of print].	3.474
102	Ascierto PA . MEK inhibition in BRAF-mutated melanoma. <i>N Engl J Med</i> . 2012 Oct 4;367(14):1364; author reply 1365. doi: 10.1056/NEJMc1209663#SA1.	53.298
103	Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA , Fox BA. Cancer classification using the Immunoscore: a worldwide task force. <i>J Transl Med</i> . 2012 Oct 3;10(1):205. [Epub ahead of print]	3.474
104	Botti G, Cerrone M, Scognamiglio G, Anniciello A, Ascierto PA , Cantile M. Microenvironment and tumor progression of melanoma: New therapeutic perspectives. <i>J Immunotoxicol</i> . 2012 Oct 5. [Epub ahead of print].	1.439
105	Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA , Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Swartzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-	22.589

	mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2012 Nov;13(11):1087-95.	
106	Maio M, Ascierto PA , Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C. The cost of unresectable stage III or stage IV melanoma in Italy. <i>J Exp Clin Cancer Res.</i> 2012 Nov 1;31(1):91.	2.150
107	Caporali S, Levati L, Graziani G, Muzi A, Atzori MG, Bonmassar E, Palmieri G, Ascierto PA , D Atri S. NF-kappaB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. <i>J Transl Med.</i> 2012 Dec 21;10(1):252.	3.474
108	Cantile M, Marra L, Franco R, Ascierto PA , Liguori G, De Chiara A, Botti G. Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors. <i>Med Oncol.</i> 2013 Mar;30(1):412. doi: 10.1007/s12032-012-0412-8. Epub 2013 Jan 18.	2.140
109	Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA . Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations. <i>BMC Cancer.</i> 2013 Jan 14;13(1):17.	3.010
110	Manca A, Lissia A, Cossu A, Rubino C, Ascierto PA , Stanganelli I, Palmieri G. Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. <i>J Invest Dermatol.</i> 2013 Jan 22. doi: 10.1038/jid.2013.27. [Epub ahead of print]	6.314
111	Mozzillo N, Caracò C, Marone U, Di Monta GL, Crispo A, Botti G, Montella M, Ascierto PA . Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. <i>World J Surg Oncol.</i> 2013 Feb 4;11(1):36. [Epub ahead of print].	1.120
112	Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA . Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma. <i>J Transl Med.</i> 2013 Feb 13;11(1):38.	3.474
113	Ascierto PA , Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zuber A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncol.</i> 2013 Feb 12. doi:pii: S1470-2045(13)70024-X.	22.589
114	Ascierto PA , Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <i>J Transl Med.</i> 2013 Mar 3;11(1):54.	3.474
115	Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA . Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. <i>Clin Cancer Res.</i> 2013 Mar 1;19(5):997-1008.	7.742
116	Ascierto PA , Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. <i>Clin Cancer Res.</i> 2013 Mar 1;19(5):1009-1020.	7.742
117	Ascierto PA , Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N. Do BRAF inhibitors select for populations with different disease progression kinetics? <i>J Transl Med.</i> 2013; 11:61.	3.474
118	Di Lorenzo G, Buonerba C, Gaudioso G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trollo R, Ascierto PA , De Placido S, Perdonà S, Franco R. EGFR mutational status in penile cancer. <i>Expert Opin Ther Targets.</i> 2013 Mar 22. [Epub ahead of print].	3.716
119	Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli P, Ascierto PA , Gentilcore G, Serra M, Marasco A, Tornari E, Dozin B, Pistillo MP. Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. <i>Cancer Invest.</i> 2013 Jun;31(5):336-45. doi:10.3109/07357907.2013.793699. Epub 2013 May 3. PubMed PMID: 23641913.	2.238
120	Ayala F, Palla M, Di Trollo R, Mozzillo N, Ascierto PA . The role of optical radiations in skin cancer. <i>ISRN Dermatol.</i> 2013 Apr 24;2013:842359. doi:10.1155/2013/842359. Print 2013. PubMed PMID: 23710365; PubMed Central PMCID: PMC3655639	0
121	Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA , Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. <i>J Transl Med.</i> 2013 May 31;11(1):135. [Epub ahead of print] PubMed PMID: 23725550.	3.460
122	Ascierto PA , Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatich S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenart P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the	3.460

	"Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 3;11(1):137. [Epub ahead of print] PubMed PMID: 23731854.	
123	Stanganelli I, Ascierto PA , Bono R, De Giorgi V, Pimpinelli N, Chiarion-Sileni V, Palmieri G, Pizzichetta MA, Testori A. Diagnostic services for melanoma in Italy. Dermatology. 2013;226 Suppl 1:3-6. doi: 10.1159/000348860. Epub 2013 May 29. PubMed PMID: 23736263	2.024
124	Stanganelli I, Ascierto PA , Bono R, De Giorgi V, Pimpinelli N, Chiarion-Sileni V, Palmieri G, Pizzichetta MA, Testori A. Management of small and intermediate congenital nevi: a nationwide survey in Italy. Dermatology. 2013;226 Suppl 1:7-12. doi: 10.1159/000348861. Epub 2013 May 29. PubMed PMID: 23736264	2.024
125	Stanganelli I, Ascierto PA , Bono R, De Giorgi V, Pimpinelli N, Chiarion-Sileni V, Palmieri G, Pizzichetta MA, Testori A. Impact of mole mapping in the Italian health system. Dermatology. 2013;226 Suppl 1:13-7. doi: 10.1159/000348863. Epub 2013 May 29. PubMed PMID: 23736265	2.024
126	De Giorgi V, Ascierto PA , Bono R, Pimpinelli N, Chiarion-Sileni V, Palmieri G, Pizzichetta MA, Testori A, Stanganelli I. Surgical management of suspicious melanocytic lesions in Italy. Dermatology. 2013;226 Suppl 1:18-21. doi:10.1159/000348864. Epub 2013 May 29. PubMed PMID: 23736266.	2.024
127	Chiarion-Sileni V, Guida M, Romanini A, Bernengo MG, Ascierto PA , Queirolo P, Mandalà M, Maio M, Ferraresi V, Stanganelli I, Testori A, Ridolfi R. Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. Dermatology. 2013;226 Suppl 1:22-7. doi: 10.1159/000348870. Epub 2013 May 29. PubMed PMID: 23736267.	2.024
128	Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA , Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013 Jun 12;11(1):145. [Epub ahead of print] PubMed PMID: 23758773.	3.460
129	Colombino M, Lissia A, Franco R, Botti G, Ascierto PA , Manca A, Sini MC, Pisano M, Paliogiannis P, Tanda F, Palmieri G, Cossu A. Unexpected Distribution of cKIT and BRAF Mutations among Southern Italian Patients with Sinonasal Melanoma. Dermatology. 2013 Jun 29. [Epub ahead of print] PubMed PMID: 23817129.	2.024
130	Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudio G, Terracciano D, Di Trollo R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA , Franco R. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. J Transl Med. 2013 Jul 2;11(1):161. [Epub ahead of print] PubMed PMID:23819610.	3.460
131	Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto PA , Ciliberto G. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med. 2013 Jul 27;11:180. doi: 10.1186/1479-5876-11-180.	3.460
132	Ascierto PA , Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol. 2013 Sep 10;31(26):3205-3211.	18.038
133	Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caracò C, Mozzillo N, Ascierto PA , Cossu A, Palmieri G. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med. 2013 Aug 29;11(1):202.	3.460
134	Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA , Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A. Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. J Clin Oncol. 2013 Sep 9.	18.038
135	Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA . Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013 Sep 25.	7.384
136	Di Monta G, Caracò C, Benedetto L, La Padula S, Marone U, Tornesello ML, Buonaguro FM, Simeone E, Ascierto PA , Mozzillo N. Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma. Eur J Surg Oncol. 2013 Sep 12.	2.614
137	Del Vecchio M, Di Guardo L, Ascierto PA , Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2013 Oct 4. pii: S0959-8049(13)00847-2.	5.061

138	Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA , Ciliberto G, Arra C. Interleukin 18: Friend or foe in cancer. <i>Biochim Biophys Acta</i> . 2013 Dec;1836(2):296-303. doi: 10.1016/j.bbcan.2013.09.001. Epub 2013 Oct 8.	3.848
139	Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA , Marincola FM, Fox BA, Pagès F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. <i>J Pathol</i> . 2014 Jan;232(2):199-209.	7.585
140	Gogas H, Abali H, Ascierto PA , Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E. Who Benefits Most From Adjuvant Interferon Treatment for Melanoma? <i>Am J Ther</i> . 2013 Oct 30. [Epub ahead of print] PubMed PMID: 24176884.	1.290
141	Ascierto PA , Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild A, Espinosa E, Robert C. Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. <i>Am J Ther</i> . 2013 Oct 31. [Epub ahead of print] PubMed PMID: 24185314.	1.290
142	Maio M, Nicolay HJ, Ascierto PA , Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Cutaia O, Fonsatti E, Parmiani G. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. <i>Cancer Immunol Immunother</i> . 2013 Dec;62(12):1851-8. doi: 10.1007/s00262-013-1496-5. Epub 2013 Nov 5. PubMed PMID: 24190546.	3.637
143	Simeone E, Grimaldi AM, Ascierto PA . Marker utility for combination therapy. <i>Methods Mol Biol</i> . 2014;1102:97-115. doi: 10.1007/978-1-62703-727-3_7. PubMed PMID: 24258976.	1.290
144	Caracò C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA . Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. <i>BMC Cancer</i> . 2013 Dec 1;13(1):564. doi: 10.1186/1471-2407-13-564. PubMed PMID: 24289268.	3.330
145	Grimaldi AM, Simeone E, Ascierto PA . The role of MEK inhibitors in the treatment of metastatic melanoma. <i>Curr Opin Oncol</i> . 2014 Mar;26(2):196-203. PMID: 24419498.	4.027
146	Altomonte M, Di Giacomo A, Queirolo P, Ascierto PA , Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>J Exp Clin Cancer Res</i> . 2013 Oct 25;32(1):82. PubMed PMID: 24423086.	3.070
147	Ascierto PA . Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. <i>Tumori</i> . 2013 Nov-Dec;99(6):302e-5e. doi: 10.1700/1390.15474. PubMed PMID: 24503809.	0.922
148	McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA , Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncol</i> . 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7. PubMed PMID: 24508103.	25.117
149	Queirolo P, Spagnolo F, Ascierto PA , Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>J Neurooncol</i> . 2014 Feb 16. [Epub ahead of print] PubMed PMID: 24532241.	3.115
150	Ascierto PA, Margolin K. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. <i>Cancer</i> . 2014 Feb 27. doi: 10.1002/cncr.28622. [Epub ahead of print] PubMed PMID: 24577788.	5.201
151	Larkin J, Del Vecchio M, Ascierto PA , Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncol</i> . 2014 Feb 26. pii:S1470-2045(14)70051-8. doi: 10.1016/S1470-2045(14)70051-8. [Epub ahead of print] PubMed PMID: 24582505.	25.117
152	Chiarion-Sileni V, Pigozzo J, Ascierto PA , Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quagliano P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>Br J Cancer</i> . 2014 Mar 11. doi: 10.1038/bjc.2014.126. [Epub ahead of print] PubMed PMID: 24619072.	5.082

153	Ascierto PA , Chiarion-Sileni V, Muggiano A, Mandalà M, Pimpinelli N, Del Vecchio M, Rinaldi G, Simeone E, Queirolo P. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>J Chemother.</i> 2013 Dec 19;1973947813Y0000000154. [Epub ahead of print] PubMed PMID: 24621162.	0.825
154	Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA . Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunol Immunother.</i> 2014 Apr 3. [Epub ahead of print] PubMed PMID: 24695951.	3.637
155	Chiarion Sileni V, Pigozzo J, Ascierto PA , Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>J Exp Clin Cancer Res.</i> 2014 Apr 4;33(1):30.	3.070
156	Banelli B, Morabito A, Laurent S, Piccioli P, Dozin B, Ghio M, Ascierto PA , Monteghirfo S, Ottaviano V, Queirolo P, Romani M, Pistillo MP. A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: Potential applications in autoimmunity and cancer. <i>Hum Immunol.</i> 2014 May 5. pii: S0198-8859(14)00130-X. doi: 10.1016/j.humimm.2014.04.019.	2.298
157	Grimaldi AM, Simeone E, Ascierto PA . The role of MEK inhibitors in the treatment of metastatic melanoma. <i>Curr Opin Oncol.</i> 2014 Mar;26(2):196-203.	4.027
158	Ascierto PA , Simeone E, Sileni VC, Vecchio MD, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Invest.</i> 2014 Apr;32(4):144-9.	2.238
159	Flaherty KT, Hennis M, Lee SJ, Ascierto PA , Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncol.</i> 2014 Mar;15(3):297-304.	25.117
160	Colombino M, Sini M, Lissia A, De Giorgi V, Stanganelli I, Ayala F, Massi D, Rubino C, Manca A, Paliogiannis P, Rossari S, Magi S, Mazzoni L, Botti G, Capone M, Palla M, Ascierto PA , Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Discrepant alterations in main candidate genes among multiple primary melanomas. <i>J Transl Med.</i> 2014 May 8;12:117. doi: 10.1186/1479-5876-12-117. PMID: 24885594; PMCID: PMC4023698.	3.930
161	Ascierto PA , Marincola FM. What have we learned from cancer immunotherapy in the last 3 years? <i>J Transl Med.</i> 2014 May 21;12:141. doi: 10.1186/1479-5876-12-141. PMID: 24886164; PMCID: PMC4038596.	3.930
162	Simeone E, Grimaldi AM, Esposito A, Curvietto M, Palla M, Paone M, Mozzillo N, Ascierto PA . Serious haematological toxicity during and after ipilimumab treatment: a case series. <i>J Med Case Rep.</i> 2014 Jul 1;8:240. doi:10.1186/1752-1947-8-240. PubMed PMID: 24986059; PubMed Central PMCID: PMC4090655.	0.400
163	Botti G, Scognamiglio G, Marra L, Collina F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R, Fulciniti F, Ascierto PA , Cantile M. SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. <i>Virchows Arch.</i> 2014 Sep;465(3):331-8. doi: 10.1007/s00428-014-1616-4. Epub 2014 Jul 4. PubMed PMID: 24993904.	2.560
164	Mozzillo N, Ascierto PA . Melanoma: the role of surgery in the era of new therapies. <i>J Transl Med.</i> 2014 Jul 11;12:195. doi: 10.1186/1479-5876-12-195. PubMed PMID: 25015684; PubMed Central PMCID: PMC4107731	3.990
165	Caputo E, Miceli R, Motti M, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero M, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA . AurA inhibitors enhance the effects of B-Raf and MEK inhibitors in melanoma treatment. <i>J Transl Med.</i> 2014 Jul 31;12(1):216. [Epub ahead of print] PubMed PMID: 25074438.	3.990
166	Testori A, Ascierto P , Chiarion Sileni V, De Lorenzo F, Pelicci P, Rossi C. Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013. <i>Ecancermedicalscience.</i> 2014 Jun 30;8:440. doi: 10.3332/ecancer.2014.440. PMID: 25075214; PMCID: PMC4096026.	0.860
167	Ascierto PA , Larkin J. Advances in immunotherapy for melanoma. <i>Melanoma Manag.</i> 2014 Aug;1(1):19-24. doi: 10.2217/mmt.14.4. Epub 2014 Sep 5. PMID: 30190806; PMCID: PMC6094603.	0

168	Ascierto PA. Combination therapies in advanced melanoma. <i>Melanoma Manag.</i> 2014 Aug;1(1):47-56. doi: 10.2217/mmt.13.1. Epub 2014 Sep 5. PMID: 30190810; PMCID: PMC6094645.	0
169	Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncoimmunology.</i> 2014 May 14;3:e28780. eCollection 2014. PubMed PMID: 25083318; PubMed Central PMCID: PMC4106166.	6.283
170	Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, Worschech A, Uccellini L, Ascierto PA, Stroncek D, Palmieri G, Chouchane L, Wang E, Marincola FM. The immune-related role of BRAF in melanoma. <i>Mol Oncol.</i> 2014 Aug 6. pii: S1574-7891(14)00169-0. doi:10.1016/j.molonc.2014.07.014. [Epub ahead of print] PubMed PMID: 25174651.	5.935
171	Ascierto PA, Grimaldi AM, Anderson A, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi F, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the 2Melanoma Bridge2, Napoli, December 5th-8th 2013. <i>J Transl Med.</i> 2014 Oct 28;12(1):277. [Epub ahead of print] PubMed PMID: 25348889; PubMed Central PMCID: PMC4232645.	3.990
172	Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. <i>Clin Cancer Res.</i> 2014 Dec 15;20(24):6258-6268. Epub 2014 Oct 23. Review. PubMed PMID: 25341541.	8.193
173	Ascierto PA, Addeo R, Carteni G, Daniele B, De Laurentis M, Ianniello G, Morabito A, Palmieri G, Pepe S, Perrone F, Pignata S, Montesarchio V. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>J Transl Med.</i> 2014 Oct 21;12(1):291. [Epub ahead of print] PubMed PMID: 25331657; PubMed Central PMCID: PMC4209076.	3.990
174	Larkin J, Ascierto PA, Dréno B, Atkinson V, Liskay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>N Engl J Med.</i> 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29. PubMed PMID:25265494.	54.420
175	Falivene S, Giugliano FM, Grimaldi AM, Di Franco R, Toledo D, Muto M, Cammarota F, Borzillo V, Ascierto PA, Muto P. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report. <i>BMC Dermatol.</i> 2014 Sep 30;14:15. doi: 10.1186/1471-5945-14-15. PMID: 25270710; PMCID: PMC4186952.	2.490
176	Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warchoła E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>N Engl J Med.</i> 2014 Nov 16. [Epub ahead of print] PubMed PMID: 25399552.	54.420
177	Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travalì S. RAN signaling in melanoma: implications for the development of alternative therapeutic strategies. <i>Cancer Lett.</i> 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20. PMID: 25444926; PMCID: PMC4277926.	5.992
178	Di Trollo R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto PA. The use of interferon in melanoma patients: a systematic review. <i>Cytokine Growth Factor Rev.</i> 2015 Apr;26(2):203-12. doi: 10.1016/j.cytogfr.2014.11.008. Epub 2014 Nov 22. PMID: 25511547.	6.571
179	Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Ann Oncol.</i> 2014 Dec 23. pii: mdu577. [Epub ahead of print] PubMed PMID: 25538176.	6.578
180	Ascierto PA. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. <i>Cancer Immunol Immunother.</i> 2015 Mar;64(3):271-4. doi: 10.1007/s00262-014-1647-3. Epub 2014 Dec 31. PubMed PMID: 25549844.	3.943
181	De Fiore L, Ascierto P. L'uso di Twitter in oncologia. Ricerca, aggiornamento e advocacy [Using Twitter in oncology. Research, continuing education, and advocacy]. <i>Recenti Prog Med.</i> 2015 Jan;106(1):40-5. Italian. doi: 10.1701/1740.18960. PMID: 25621780.	0.330

182	Grimaldi AM, Simeone E, Palla M, Festino L, Caracò C, Mozzillo N, Petrillo A, Muto P, Ascierto PA . Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. <i>Anticancer Drugs</i> . 2015 Apr;26(4):464-8. doi:10.1097/CAD.0000000000000206. PubMed PMID: 25622086.	1.891
183	Manca A, Lissia A, Capone M, Ascierto PA , Botti G, Caracò C, Stanganelli I, Colombino M, Sini M, Cossu A, Palmieri G. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>J Transl Med</i> . 2015 Jan 28;13:37. doi: 10.1186/s12967-015-0401-8. PubMed PMID: 25627962; PubMed Central PMCID: PMC4312444.	3.990
184	Ascierto PA . Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. <i>Melanoma Manag</i> . 2015 Feb;2(1):9-14. doi: 10.2217/mmt.14.35. Epub 2015 Feb 25. PMID: 30190825; PMCID: PMC6094644.	0
185	Simeone E, Grimaldi AM, Ascierto PA . Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. <i>Melanoma Manag</i> . 2015 Feb;2(1):41-50. doi: 10.2217/mmt.14.30. Epub 2015 Feb 25. PMID: 30190830; PMCID: PMC6094609.	0
186	Lorigan P, Ascierto PA , Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncol</i> . 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29. PubMed PMID: 25638540.	24.725
187	Peris K, Licitra L, Ascierto PA , Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncol</i> . 2015 Feb;11(4):703-12. doi: 10.2217/fon.14.281. PubMed PMID: 25686123.	2.611
188	Testori A, Rossi CR, Ascierto P , de Lorenzo F, Mozzillo N. Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014. <i>Ecanermedicalscience</i> . 2015 Feb 19;9:511. doi: 10.3332/ecancer.2015.511. PMID: 25729424; PMCID: PMC4335967.	1.220
189	Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA , Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol</i> . 2015 Mar 17. pii: S1470-2045(15)70076-8. doi: 10.1016/S1470-2045(15)70076-8. [Epub ahead of print] PubMed PMID: 25795410.	24.725
190	Di Trollo R, Di Lorenzo G, Fumo B, Ascierto PA . Cosmic radiation and cancer: is there a link? <i>Future Oncol</i> . 2015;11(7):1123-35. doi: 10.2217/fon.15.29. PubMed PMID: 25804126.	2.477
191	Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA , Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i> . 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. PubMed PMID: 25840693.	24.690
192	Romano S, D'Angelillo A, Staibano S, Simeone E, D'Arrigo P, Ascierto PA , Scalvenzi M, Mascolo M, Ilardi G, Merolla F, Jovarauskaite E, Romano MF. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. <i>Pigment Cell Melanoma Res</i> . 2015 Jul;28(4):442-52. doi: 10.1111/pcmr.12378. Epub 2015 May 13.	5.839
193	Caracò C, Marone U, Simeone E, Grimaldi AM, Botti G, Del Giudice M, Ascierto PA , Mozzillo N. Electrochemotherapy in melanoma patients: a single institution experience. <i>Melanoma Manag</i> . 2015 May;2(2):127-132. doi: 10.2217/mmt.15.9. Epub 2015 May 18. PMID: 30190842; PMCID: PMC6094613.	0
194	Palmieri G, Colombino M, Casula M, Budroni M, Manca A, Sini MC, Lissia A, Stanganelli I, Ascierto PA , Cossu A. Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Manag</i> . 2015 May;2(2):149-163. doi: 10.2217/mmt.15.12. Epub 2015 May 18. PMID: 30190844; PMCID: PMC6094587.	0
195	Del Vecchio M, Ascierto PA , Mandalà M, Sileni VC, Maio M, Di Guardo L, Simeone E, Queirolo P. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncol</i> . 2015 May;11(9):1355-62. doi: 10.2217/fon.15.55. PubMed PMID: 25952781.	2.477
196	Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA . Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. <i>Future Oncol</i> . 2015 May;11(9):1429-35. doi: 10.2217/fon.15.20. PubMed PMID: 25952787.	2.477

197	Basset-Seguín N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA , Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncol.</i> 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13. PubMed PMID: 25981813.	24.690
198	Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA , Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>N Engl J Med.</i> 2015 May 31. [Epub ahead of print] PubMed PMID: 26027431.	55.873
199	Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA , Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncol.</i> 2015 Jun 23. pii: S1470-2045(15)00083-2. doi: 10.1016/S1470-2045(15)00083-2. [Epub ahead of print] PubMed PMID: 26115796.	24.690
200	Ascierto PA , Marincola FM. 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. <i>EBioMedicine.</i> 2015 Jan 19;2(2):92-3. doi:10.1016/j.ebiom.2015.01.011. eCollection 2015 Feb. PubMed PMID: 26137543; PubMed Central PMCID: PMC4485477.	0
201	Ascierto PA , Marincola FM, Atkins MB. What's new in melanoma? Combination! <i>J Transl Med.</i> 2015 Jul 4;13:213. doi: 10.1186/s12967-015-0582-1. PMID: 26141621; PMCID: PMC4491255.	3.930
202	Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracò C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA . Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncoimmunology.</i> 2015 May 22;4(6):e1008842. eCollection 2015 Jun. PubMed PMID:26155423; PubMed Central PMCID: PMC4485758.	6.266
203	Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA . Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. <i>Discov Med.</i> 2015 Jun;19(107):455-61. PubMed PMID: 26175403.	3.626
204	Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA , Mancini R, Ciliberto G. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. <i>Oncotarget.</i> 2015 Jul 7. [Epub ahead of print] PubMed PMID: 26208478.	6.359
205	Ascierto ML, Melero I, Ascierto PA . Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Front Oncol.</i> 2015 Jul 13;5:152. doi:10.3389/fonc.2015.00152. eCollection 2015. Review. PubMed PMID: 26217587; PubMed Central PMCID: PMC4500097.	0
206	Grimaldi AM, Simeone E, Ascierto PA . Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. <i>Melanoma Manag.</i> 2015 Aug;2(3):209-215. doi: 10.2217/mmt.15.22. Epub 2015 Aug 10. PMID: 30190850; PMCID: PMC6094700.	0
207	Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A, Paliogiannis P, Ascierto PA , Cossu A. Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Front Oncol.</i> 2015 Aug 10;5:183. doi:10.3389/fonc.2015.00183. eCollection 2015. Review. PubMed PMID: 26322273; PubMed Central PMCID: PMC4530319.	0
208	Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbé C, Hauschild A. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? <i>Melanoma Res.</i> 2015 Dec;25(6):461-9. doi:10.1097/CMR.000000000000200. PubMed PMID: 26426764.	2.282
209	Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA . PD-L1 expression as a potential predictive biomarker. <i>Lancet Oncol.</i> 2015 Oct;16(13):1285-7. doi: 10.1016/S1470-2045(15)00307-1. PubMed PMID: 26433815.	24.690
210	Ascierto PA , Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stronck D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. <i>J Transl Med.</i> 2015 Nov 30;13:374. doi:10.1186/s12967-015-0736-1. PubMed PMID: 26619946; PubMed Central PMCID:PMC4665874.	3.930

211	Grimaldi AM, Marincola FM, Ascierto PA . Single versus combination immunotherapy drug treatment in melanoma. <i>Expert Opin Biol Ther</i> . 2016 Feb 6:1-9. [Epub ahead of print] PubMed PMID: 26642234.	3.743
212	Ugurel S, Röhm J, Ascierto PA , Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>Eur J Cancer</i> . 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17. Review. PubMed PMID: 26707829.	5.417
213	Lau PK, Ascierto PA , McArthur G. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Curr Opin Immunol</i> . 2016 Jan 5;39:30-38. doi: 10.1016/j.coi.2015.12.006. [Epub ahead of print] Review. PubMed PMID: 26765776.	7.478
214	Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto PA , Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>J Am Acad Dermatol</i> . 2016 Feb;74(2):325-32. doi:10.1016/j.jaad.2015.09.053. PubMed PMID: 26775776.	4.449
215	Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA , Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. <i>Clin Cancer Res</i> . 2016 Jan 19. pii: clincanres.2412.2015. [Epub ahead of print] PubMed PMID: 26787752.	8.722
216	Ferrucci PF, Ascierto PA , Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Ann Oncol</i> . 2016 Apr;27(4):732-8. doi: 10.1093/annonc/mdw016. Epub 2016 Jan 22. PubMed PMID:26802161.	9.269
217	Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. Antitumor Activity of BRAF Inhibitor and IFN α Combination in BRAF-Mutant Melanoma. <i>J Natl Cancer Inst</i> . 2016 Feb 5;108(7). pii: djv435. doi: 10.1093/jnci/djv435. Print 2016 Jul. PubMed PMID:26851802.	12.583
218	Ascierto PA . Editorial: Combination Strategies in the Treatment of Melanoma. <i>Front Oncol</i> . 2016 Mar 22;6:67. doi: 10.3389/fonc.2016.00067. eCollection 2016. PubMed PMID: 27047798; PubMed Central PMCID: PMC4801857.	0
219	Gandini S, Montella M, Ayala F, Benedetto L, Rossi CR, Vecchiato A, Corradin MT, DE Giorgi V, Queirolo P, Zannetti G, Giudice G, Borroni G, Forcignanò R, Peris K, Tosti G, Testori A, Trevisan G, Spagnolo F, Ascierto PA ; CLINICAL NATIONAL MELANOMA REGISTRY GROUP. Sun exposure and melanoma prognostic factors. <i>Oncol Lett</i> . 2016 Apr;11(4):2706-2714. Epub 2016 Mar 1. PubMed PMID: 27073541; PubMed Central PMCID: PMC4812599.	1.554
220	De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA , Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. <i>J Transl Med</i> . 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1. Review. PubMed PMID: 27142424; PubMed Central PMCID: PMC4855772.	3.694
221	Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA , Wolchok JD, Pawelec G, Garbe C, Weide B. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. <i>Clin Cancer Res</i> . 2016 May 11. pii: clincanres.0249.2016. [Epub ahead of print] PubMed PMID: 27169993.	8.722
222	Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA , Hossers GA, Garbe C, Wolchok JD. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. <i>Clin Cancer Res</i> . 2016 May 16. pii: clincanres.0127.2016. [Epub ahead of print] PubMed PMID: 27185375.	8.722
223	Ascierto PA , de Mello RA. Are there, or shall we discover, biomarkers to guide PD-1 inhibition? Immunotherapy. 2016 Jun;8(6):681-6. doi: 10.2217/imt-2016-5000. PubMed PMID: 27197537.	2.083

224	Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA . Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? <i>Drugs</i> . 2016 Jun;76(9):925-45. doi:10.1007/s40265-016-0588-x. Review. PubMed PMID: 27229745.	4.883
225	Casula M, Colombino M, Manca A, Caracò C, Botti G, Ascierto PA , Lissia A, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Low levels of genetic heterogeneity in matched lymph node metastases from melanoma patients. <i>J Invest Dermatol</i> . 2016 Jun 2. pii: S0022-202X(16)31332-X. doi: 10.1016/j.jid.2016.05.103.[Epub ahead of print] PubMed PMID: 27265006.	6.915
226	Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA , Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncol</i> . 2016 Jun 3. pii: S1470-2045(16)30098-5. doi:10.1016/S1470-2045(16)30098-5. [Epub ahead of print] PubMed PMID: 27269741.	26.509
227	Ascierto PA , Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. <i>Lancet Oncol</i> . 2016 Jun 17. pii:S1470-2045(16)30017-1. doi: 10.1016/S1470-2045(16)30017-1. [Epub ahead of print] PubMed PMID: 27324281.	26.509
228	Hoeller C, Michielin O, Ascierto PA , Szabo Z, Blank CU. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. <i>Cancer Immunol Immunother</i> . 2016 Jul 2. [Epub ahead of print] Review. PubMed PMID: 27372293.	4.846
229	Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA , Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>Eur J Cancer</i> . 2016 Jul 8;64:116-126. doi: 10.1016/j.ejca.2016.06.001. [Epub ahead of print] PubMed PMID: 27400322.	6.163
230	Long GV, Atkinson V, Ascierto PA , Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase 3 checkmate 066 study. <i>Ann Oncol</i> . 2016 Jul 12. pii: mdw265. [Epub ahead of print] PubMed PMID: 27405322.	9.269
231	Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorrello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA . Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. <i>Oncotarget</i> . 2016 Jul 13. doi:10.18632/oncotarget.10589. [Epub ahead of print] PubMed PMID: 27418142.	6.359
232	Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, Borgognoni L, Ascierto PA , Mozzillo N, Guida M, Bucher S, Rotunno R, Marengo F, De Salvo GL, De Paoli A, Rossi CR, Bonadies A. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. <i>Eur J Surg Oncol</i> . 2016 Jun 29. pii:S0748-7983(16)30606-0. doi: 10.1016/j.ejso.2016.06.399. [Epub ahead of print] PubMed PMID: 27424789.	2.940
233	Strizzi L, Margaryan NV, Gerami P, Haghighat Z, Harms PW, Madonna G, Botti G, Ascierto PA , Hendrix MJ. Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi. <i>Oncol Lett</i> . 2016 Aug;12(2):1349-1354.	1.800
234	Ascierto PA , McArthur GA, Dréno B, Atkinson V, Liskay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i> . 2016 Jul 29. pii: S1470-2045(16)30122-X. doi:10.1016/S1470-2045(16)30122-X.	26.509
235	Saiag P, Gutzmer R, Ascierto PA , Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Wojtek I, Peeters O, Brichard VG, Therasse P. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Ann Oncol</i> . 2016 Aug 8. pii: mdw291. [Epub ahead of print] PubMed PMID: 27502712.	9.269
236	Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA , Ciliberto G. miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proc Natl Acad Sci U S A</i> . 2016 Aug 8. pii: 201607753. [Epub ahead of print] PubMed PMID: 27503895.	9.423

237	Lacouture ME, Dréno B, Ascierto PA , Dummer R, Basset-Seguín N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> . 2016 Aug 10. pii: theoncologist.2016-0186. [Epub ahead of print] PubMed PMID: 27511905.	4.865
238	Ascierto PA , Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozzillo N. Complete response to nivolumab monotherapy in a treatment-naïve, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. <i>Cancer Immunol Immunother</i> . 2016 Sep 7. [Epub ahead of print] PubMed PMID: 27604993.	4.846
239	Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA , Capone M. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. <i>J Transl Med</i> . 2016 Sep 20;14(1):273. PubMed PMID: 27650038.	3.694
240	Gridelli C, Ascierto PA , Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opin Biol Ther</i> . 2016 Sep 21:1-11. [Epub ahead of print] PubMed PMID: 27650132.	3.438
241	Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA . Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>Br J Cancer</i> . 2016 Oct 6. doi: 10.1038/bjc.2016.321. PubMed PMID: 27711085.	5.569
242	Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA , Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>N Engl J Med</i> . 2016 Oct 7. PubMed PMID: 27717298.	59.558
243	Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA , Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clin Cancer Res</i> . 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18. PMID: 27756788.	4.929
244	Botticelli A, Zizzari I, Mazzuca F, Ascierto PA , Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> . 2016 Oct 28. doi: 10.18632/oncotarget.12985. [Epub ahead of print] Review. PubMed PMID: 27806346.	5.008
245	Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA , Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. <i>ESMO Open</i> . 2016 Aug 8;1(4):e000068. PubMed PMID:27843625; PubMed Central PMCID: PMC5070281.	0
246	Ascierto PA , Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stronck DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. <i>J Transl Med</i> . 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y. PMID: 27846884; PMCID: PMC5111349.	3.694
247	Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto PA , Rekers N, Straten PT, Awada A. Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation. <i>Ecancermedicalscience</i> . 2016 Nov 10;10:691. PubMed PMID: 27994647; PubMed Central PMCID: PMC5130327.	0
248	Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA . Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> . 2017 Feb;31(1):51-61. doi: 10.1007/s40259-016-0208-z. Review. PubMed PMID: 28058658.	2.835
249	Cantile M, Scognamiglio G, Marra L, Aquino G, Botti C, Falcone MR, Malzone MG, Liguori G, Di Bonito M, Franco R, Ascierto PA , Botti G. HOTAIR Role in Melanoma Progression and its Identification in the Blood of Patients with Advanced Disease. <i>J Cell Physiol</i> . 2017 Jan 9. doi: 10.1002/jcp.25789. [Epub ahead of print] PubMed PMID: 28067428.	4.080

250	Palmieri G, Colombino M, Cossu A, Marchetti A, Botti G, Ascierto PA . Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? J Transl Med. 2017 Jan 21;15(1):17. doi:10.1186/s12967-017-1119-6. PubMed PMID: 28109293; PubMed Central PMCID: PMC5251272.	3.786
251	Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA , Croce CM, Mancini R, Ciliberto G. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017 Jan 19. doi: 10.18632/oncotarget.14763. [Epub ahead of print] Review. PubMed PMID: 28118616.	5.168
252	Coens C, Suci S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA , Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30015-3. doi:10.1016/S1470-2045(17)30015-3. [Epub ahead of print] PubMed PMID: 28162999.	33.900
253	Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA , Wolchok JD, Blank CU, Garbe C, Pawelec G, Weide B. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur J Cancer. 2017 Feb 3;73:61-70. doi: 10.1016/j.ejca.2016.12.011. [Epub ahead of print] PubMed PMID: 28167454.	6.029
254	Itchins M, Ascierto PA , Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A. A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343. [Epub ahead of print] PubMed PMID: 28230715.	2.615
255	Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, Scala S, D'Alterio C, Trimarco C, Iano A, Cirino G, Caracò C, Colombino M, Palmieri G, Pepe S, Ascierto PA , Sabbatino F, Scognamiglio G. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med. 2017 Feb 23;15(1):46. doi: 10.1186/s12967-017-1150-7. PubMed PMID: 28231855.	3.786
256	Dummer R, Schadendorf D, Ascierto PA , Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. doi:10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. PubMed PMID: 28284557.	33.900
257	Zito Marino F, Ascierto PA , Rossi G, Staibano S, Montella M, Russo D, Alfano R, Morabito A, Botti G, Franco R. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Expert Opin Biol Ther. 2017 Jun;17(6):735-746. doi: 10.1080/14712598.2017.1309387. Epub 2017 Mar 28. PubMed PMID: 28318336.	3.684
258	Ascierto PA , Accorona R, Botti G, Farina D, Fossati P, Gatta G, Gogas H, Lombardi D, Maroldi R, Nicolai P, Ravanelli M, Vanella V. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol. 2017 Apr;112:136-152. doi:10.1016/j.critrevonc.2017.01.019. Epub 2017 Feb 13. Review. PubMed PMID:28325255.	4.971
259	Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA , Carbone E. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi:10.1080/2162402X.2016.1261242. eCollection 2017. PubMed PMID: 28344869; PubMed Central PMCID: PMC5353942.	7.719
260	Ascierto PA , Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611-622. doi:10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27. PubMed PMID: 28359784.	33.900
261	Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA . Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology. 2017 Jan	7.719

	19;6(3):e1283462. doi: 10.1080/2162402X.2017.1283462. eCollection 2017. PubMed PMID: 28405510; PubMed Central PMCID: PMC5384373.	
262	Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA , Hansson J, Masucci G. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. <i>Ann Oncol.</i> 2017 Apr 12. doi: 10.1093/annonc/mdx177. [Epub ahead of print] PubMed PMID: 28407116.	11.855
263	Romano S, Simeone E, D'Angelillo A, D'Arrigo P, Russo M, Capasso M, Lasorsa VA, Zambrano N, Ascierto PA , Romano MF. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. <i>Cancer Immunol Immunother.</i> 2017 Apr 22. doi:10.1007/s00262-017-2004-0. [Epub ahead of print] PubMed PMID: 28434031.	4.711
264	Di Monta G, Caracò C, Simeone E, Grimaldi AM, Marone U, Di Marzo M, Vanella V, Festino L, Palla M, Mori S, Mozzillo N, Ascierto PA . Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. <i>J Transl Med.</i> 2017 Apr 26;15(1):82. doi: 10.1186/s12967-017-1186-8. PubMed PMID: 28441954; PubMed Central PMCID:PMC5405498.	3.786
265	Dréno B, Ribas A, Larkin J, Ascierto PA , Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <i>Ann Oncol.</i> 2017 May 1;28(5):1137-1144. doi:10.1093/annonc/mdx040. PubMed PMID: 28444112.	11.855
266	Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA , Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quagliano P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Front Immunol.</i> 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. PubMed PMID: 28446908; PubMed Central PMCID: PMC5388686.	6.429
267	Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA , Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>Eur J Cancer.</i> 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11. PubMed PMID: 28501764.	6.029
268	McArthur GA, Mohr P, Ascierto PA , Arance A, Banos Hernaez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). <i>Oncologist.</i> 2017 May 19. pii:theoncologist.2016-0272. doi: 10.1634/theoncologist.2016-0272. [Epub ahead of print] PubMed PMID: 28526721.	4.962
269	Wongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA , Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler LC, Yan Y, Ribas A. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clin Cancer Res.</i> 2017 May 23. pii:clincanres.0172.2017. doi: 10.1158/1078-0432.CCR-17-0172. [Epub ahead of print] PubMed PMID: 28536307.	9.619
270	Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA . MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. <i>Am J Clin Dermatol.</i> 2017 May 23. doi: 10.1007/s40257-017-0292-y. [Epub ahead of print] Review. PubMed PMID: 28537004.	2.755
271	Emens LA, Ascierto PA , Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>Eur J Cancer.</i> 2017 Jun 14;81:116-129. doi:10.1016/j.ejca.2017.01.035. [Epub ahead of print] Review. PubMed PMID: 28537004.	6.029
272	de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA , Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. <i>J Transl Med.</i> 2017 Jun 24;15(1):146. doi:10.1186/s12967-017-1246-0. PubMed PMID: 28646893; PubMed Central PMCID:PMC5483259.	3.786
273	Ugurel S, Röhmel J, Ascierto PA , Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>Eur J Cancer.</i> 2017 Sep;83:247-257. doi:10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review. PubMed PMID: 28756137.	6.029

274	Ascierto PA , McArthur GA. Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future? J Transl Med. 2017 Aug 8;15(1):173. doi: 10.1186/s12967-017-1278-5. Review. PubMed PMID: 28789707; PubMed Central PMCID: PMC5549368.	3.786
275	Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA , Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhole R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. PubMed PMID:28889792; PubMed Central PMCID: PMC5706778.	72.406
276	Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA ; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. PubMed PMID: 28891423.	72.406
277	Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA , Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022. PubMed PMID: 28961465.	6.029
278	Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA , Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi:10.1093/annonc/mdx339. PubMed PMID: 28961848; PubMed Central PMCID: PMC5834156.	11.855
279	Ascierto PA , Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med. 2017 Oct 11;15(1):205. doi:10.1186/s12967-017-1309-2. PubMed PMID: 29020960; PubMed Central PMCID:PMC5637331.	3.786
280	Mohr P, Ascierto P , Arance A, McArthur G, Hernaez A, Kaskel P, Shinde R, Stevinson K. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. J Eur Acad Dermatol Venereol. 2018 Jun;32(6):962-971. doi: 10.1111/jdv.14633. Epub 2017 Nov 8. PubMed PMID: 29044660.	3.528
281	Cordaro FG, De Presbiteris AL, Camerlingo R, Mozzillo N, Pirozzi G, Cavalcanti E, Manca A, Palmieri G, Cossu A, Ciliberto G, Ascierto PA , Travali S, Patriarca EJ, Caputo E. Phenotype characterization of human melanoma cells resistant to dabrafenib. Oncol Rep. 2017 Nov;38(5):2741-2751. doi:10.3892/or.2017.5963. Epub 2017 Sep 18. PubMed PMID: 29048639; PubMed Central PMCID: PMC5780027.	2.662
282	Galon J, Lugli A, Bifulco C, Pages F, Masucci G, Marincola FM, Ascierto PA . World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016. J Transl Med. 2017 Oct 20;15(1):212. doi: 10.1186/s12967-017-1310-9. PubMed PMID: 29058595; PubMed Central PMCID:PMC5651599.	3.786
283	Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA , Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5. PubMed PMID:29073584.	6.029
284	Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA . The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2. PubMed PMID: 29100546; PubMed Central PMCID: PMC5670700.	3.786
285	Ascierto PA , Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research	3.786

	"Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2. PubMed PMID: 29145885; PubMed Central PMCID: PMC5691855.	
286	Wongchenko MJ, Ribas A, Dréno B, Ascierto PA , McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi:10.1111/pcmr.12670. Epub 2017 Dec 10. PubMed PMID: 29156488.	5.170
287	Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA . Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017 Dec 4;15(1):244. doi: 10.1186/s12967-017-1348-8. PubMed PMID: 29202855; PubMed Central PMCID: PMC5716054.	3.786
288	Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA , Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5. PubMed PMID:29208646.	8.284
289	Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA , Ciliberto G, Motti ML, Carriero MV. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x. PubMed PMID: 29216889; PubMed Central PMCID: PMC5721612.	5.189
290	Grob JJ, Schadendorf D, Lorigan P, Ascierto P , Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. PubMed PMID:29224903.	6.029
291	Marra A, Scognamiglio G, Peluso I, Botti G, Fucciello C, Filippelli A, Ascierto PA , Pepe S, Sabbatino F. Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS J. 2017 Nov 14;11:91-100. doi:10.2174/1874613601711010091. eCollection 2017. Review. PubMed PMID: 29290886; PubMed Central PMCID: PMC5730951.	0
292	Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA . PD-L1inhibitors in the pipeline: Promise and progress. Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Review. PubMed PMID: 29296516; PubMed Central PMCID: PMC5739559.	7.719
293	Tucci M, Passarelli A, Mannavola F, Stucci LS, Ascierto PA , Capone M, Madonna G, Lopalco P, Silvestris F. Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. Oncoimmunology. 2017 Nov 6;7(2):e1387706. doi:10.1080/2162402X.2017.1387706. eCollection 2018. PubMed PMID: 29308314; PubMed Central PMCID: PMC5749659.	7.719
294	Ascierto PA , Palmieri G, Gogas H. What is changing in the adjuvant treatment of melanoma? Oncotarget. 2017 Dec 6;8(67):110735-110736. doi:10.18632/oncotarget.22988. eCollection 2017 Dec 19. PubMed PMID: 29340009; PubMed Central PMCID: PMC5762277.	0
295	Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA , Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007.	7.191
296	Dréno B, Ascierto PA , Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13. PMID: 29438370; PMCID: PMC5877437.	5.416
297	Ascierto PA , Eggermont AMM. Neoadjuvant therapy in melanoma: the next step? Lancet Oncol. 2018 Feb;19(2):151-153. doi: 10.1016/S1470-2045(18)30016-0. Epub 2018 Jan 18. PubMed PMID: 29361473.	36.418
298	Weber J, Qureshi A, Ascierto PA . Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 Feb 15;378(7):680. doi: 10.1056/NEJMc1716071. PubMed PMID: 29446288.	79.258
299	Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA , Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):510-520. doi:	36.418

	10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. PubMed PMID: 29477665.	
300	Sini MC, Doneddu V, Paliogiannis P, Casula M, Colombino M, Manca A, Botti G, Ascierto PA , Lissia A, Cossu A, Palmieri G. Genetic alterations in main candidate genes during melanoma progression. Oncotarget. 2018 Jan 3;9(9):8531-8541. doi: 10.18632/oncotarget.23989. PMID: 29492214; PMCID: PMC5823576.	3.710
301	Soldati L, Di Renzo L, Jirillo E, Ascierto PA , Marincola FM, De Lorenzo A. The influence of diet on anti-cancer immune responsiveness. J Transl Med. 2018 Mar 20;16(1):75. doi: 10.1186/s12967-018-1448-0. Review. PubMed PMID: 29558948; PubMed Central PMCID: PMC5859494	4.197
302	Dummer R, Ascierto PA , Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 Mar 21. pii: S1470-2045(18)30142-6. doi: 10.1016/S1470-2045(18)30142-6. [Epub ahead of print] PubMed PMID: 29573941.	36.418
303	Capone I, Marchetti P, Ascierto PA , Malorni W, Gabriele L. Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. Front Immunol. 2018 Mar 21;9:552. doi: 10.3389/fimmu.2018.00552. eCollection 2018. PubMed PMID: 29619026; PubMed Central PMCID: PMC5871673.	5.511
304	Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suci S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018 Apr 15. doi: 10.1056/NEJMoa1802357. [Epub ahead of print] PubMed PMID: 29658430.	79.258
305	Ascierto PA , Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med. 2018 Apr 17;16(1):101. doi: 10.1186/s12967-018-1477-8. PubMed PMID:29665799.	4.197
306	Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA , Massi D, Raffaelli N, Mandalà M, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. Oncotarget. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10. PubMed PMID: 29721178; PubMed Central PMCID: PMC5922372.	0
307	Cavaliere S, Perrone F, Miceli R, Ascierto PA , Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. Eur J Cancer. 2018 May 4;97:7-15. doi: 10.1016/j.ejca.2018.04.004. [Epub ahead of print] PubMed PMID: 29734047.	7.191
308	Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA , Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018 Apr 21. pii: S1535-6108(18)30172-7. doi: 10.1016/j.ccell.2018.04.001. [Epub ahead of print] PubMed PMID: 29731394.	31.398
309	Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA , Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI). CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. Eur J Cancer. 2018 May 7. pii: S0959-8049(18)30787-1. doi:10.1016/j.ejca.2018.04.005. [Epub ahead of print] PubMed PMID: 29743138.	7.191
310	Ascierto PA , Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J. The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455. [Epub ahead of print] PubMed PMID: 29750751.	3.135
311	Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M,	53.254

	Spacek J, Petruzella L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA , Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet</i> . 2018 May 10. pii:S0140-6736(18)30789-X. doi: 10.1016/S0140-6736(18)30789-X. [Epub ahead of print] PubMed PMID: 29754777.	
312	Ascierto PA , Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). <i>J Immunother Cancer</i> . 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review. PubMed PMID: 29996914; PubMed Central PMCID: PMC6042369.	8.374
313	Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto PA , Motti ML. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. <i>Int J Oncol</i> . 2018 Sep;53(3):1149-1159. doi: 10.3892/ijo.2018.4457. Epub 2018 Jun 27. PubMed PMID:29956724; PubMed Central PMCID: PMC6065454.	3.333
314	Gridelli C, Ascierto PA , Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F. Second-line treatment of advanced non-small cell lung cancer non-oncogene addicted: new treatment algorithm in the era of novel immunotherapy. <i>Curr Clin Pharmacol</i> . 2018 Jul 11. doi: 10.2174/1574884713666180711160008. [Epub ahead of print] PubMed PMID:29992894.	0
315	Sommariva A, Forsea AM, Agius D, Ascierto PA , Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, Louwman M, Robsahm TE, Rutkowski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR. Quality assurance in melanoma care: The EU-MELACARE study. <i>Eur J Surg Oncol</i> . 2018 Jul 3. pii: S0748-7983(18)31164-8. doi: 10.1016/j.ejso.2018.06.020. [Epub ahead of print] PubMed PMID: 30001892.	3.688
316	Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA . Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. <i>J Immunother Cancer</i> . 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. PubMed PMID: 30012216; PubMed Central PMCID: PMC6048712.	8.374
317	Ascierto PA , Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). <i>J Transl Med</i> . 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6. PubMed PMID: 30031393; PubMed Central PMCID: PMC6054754.	4.197
318	Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA , Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. <i>JAMA Oncol</i> . 2018 Aug 2. doi:10.1001/jamaoncol.2018.2668. [Epub ahead of print] PubMed PMID: 30073321.	20.871
319	Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA , Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaike M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>J Clin Oncol</i> . 2018 Aug 15;JCO2017766212. doi: 10.1200/JCO.2017.76.6212. [Epub ahead of print] PubMed PMID: 30110194.	26.303
320	Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA , Libra M, Candido S. MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA. <i>Front Pharmacol</i> . 2018 Aug 14;9:856. doi: 10.3389/fphar.2018.00856. eCollection 2018. PubMed PMID: 30154717; PubMed Central PMCID: PMC6102751.	3.831
321	Festino L, Vanella V, Trojaniello C, Ascierto PA . Selecting immuno-oncology-based drug combinations - what should we be considering? <i>Expert Rev Clin Pharmacol</i> . 2018 Sep 8:1-15. doi: 10.1080/17512433.2018.1518713. [Epub ahead of print] PubMed PMID: 30169990.	2.758
322	Simeone E, Ascierto PA . Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. <i>Melanoma Manag</i> . 2017 Dec;4(4):175-178. doi: 10.2217/mmt-2017-0018. Epub 2017 Nov 21. PubMed PMID: 30190923; PubMed Central PMCID: PMC6094668.	0.130

323	Dummer R, Ascierto PA , Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncol</i> . 2018 Sep 12. pii: S1470-2045(18)30497-2. doi: 10.1016/S1470-2045(18)30497-2. [Epub ahead of print] PubMed PMID: 30219628.	36.418
324	Ascierto PA , Dummer R. Immunological effects of BRAF+MEK inhibition. <i>Oncoimmunology</i> . 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018. Review. PubMed PMID: 30228935; PubMed Central PMCID: PMC6140547.	5.503
325	Ascierto PA , Flaherty K, Goff S. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. <i>Am Soc Clin Oncol Educ Book</i> . 2018 May 23;38:751-758. doi: 10.1200/EDBK_199047. PMID: 30231371.	0
326	Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA , Mancini R, Ciliberto G. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death Differ</i> . 2018 Sep 25. doi: 10.1038/s41418-018-0205-5. [Epub ahead of print] PubMed PMID: 30254376.	8
327	Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA , Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhring K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT). <i>Ann Oncol</i> . 2018 Oct 8. doi: 10.1093/annonc/mdy423. [Epub ahead of print] PubMed PMID: 30295695.	13.926
328	Ascierto PA , Marabelle A. How do immune checkpoint targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. <i>Ann Oncol</i> . 2018 Oct 11. doi: 10.1093/annonc/mdy420. [Epub ahead of print] PubMed PMID: 30307539.	13.926
329	Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA , Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>Eur J Cancer</i> . 2018 Oct 19;104:137-144. doi: 10.1016/j.ejca.2018.09.017. [Epub ahead of print] PubMed PMID: 30347289.	7.191
330	Ascierto PA , Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocho E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncol</i> . 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. [Epub ahead of print] PubMed PMID: 30422243.	20.871
331	Fattore L, Mancini R, Ascierto PA , Ciliberto G. The potential of BRAF associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opin Ther Targets</i> . 2018 Dec 3. doi: 10.1080/14728222.2019.1554057. [Epub ahead of print] PubMed PMID: 30507327.	4.598
332	Grob JJ, Garbe C, Ascierto P , Larkin J, Dummer R, Schadendorf D. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? <i>Lancet Oncol</i> . 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review. PubMed PMID: 30507438.	36.418
333	Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA . PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncoimmunology</i> . 2018 Sep 5;7(12):e1405206. doi:10.1080/2162402X.2017.1405206. eCollection 2018. PubMed PMID: 30524879; PubMed Central PMCID: PMC6279420.	5.503
334	Pisanu ME, Maugeri-Saccà M, Fattore L, Bruschini S, De Vitis C, Tabbì E, Bellei B, Migliano E, Kovacs D, Camera E, Picardo M, Jakopin Z, Cippitelli C, Bartolazzi A, Raffa S, Torrisi MR, Fulciniti F, Ascierto PA , Ciliberto G, Mancini R. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. <i>J Exp Clin Cancer Res</i> . 2018 Dec 17;37(1):318. doi: 10.1186/s13046-018-0989-7. PubMed PMID: 30558661; PubMed Central PMCID: PMC6298024.	6.217
335	Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA , Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C. An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>Eur J Cancer</i> . 2018 Dec 20;107:175-185. doi: 10.1016/j.ejca.2018.11.018. [Epub ahead of print] PubMed PMID: 30580112.	7.191

336	Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA , Mancini R, Ciliberto G. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death Differ.</i> 2019 Jul;26(7):1267-1282. doi: 10.1038/s41418-018-0205-5. Epub 2018 Sep 25. PMID: 30254376; PMCID: PMC6748102.	10.717
337	Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA , Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI). Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunol Immunother.</i> 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11. PMID: 30311027.	5.442
338	Fattore L, Mancini R, Ascierto PA , Ciliberto G. The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opin Ther Targets.</i> 2019 Jan;23(1):53-68. doi: 10.1080/14728222.2019.1554057. Epub 2018 Dec 9. PMID: 30507327.	5.473
339	Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA , Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hossers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C. An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>Eur J Cancer.</i> 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20. PubMed PMID: 30580112.	6.680
340	Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P , Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS One.</i> 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019. PubMed PMID: 30620767; PubMed Central PMCID: PMC6324822.	2.776
341	Trojaniello C, Festino L, Vanella V, Ascierto PA . Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. <i>Expert Rev Clin Pharmacol.</i> 2019 Mar;12(3):259-266. doi: 10.1080/17512433.2019.1570847. Epub 2019 Jan 24. Review. PubMed PMID: 30652516.	2.776
342	Ottaviano M, De Placido S, Ascierto PA . Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Arch.</i> 2019 Apr;474(4):421-432. doi: 10.1007/s00428-019-02538-4. Epub 2019 Feb 12. Review. PubMed PMID: 30747264.	2.868
343	Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA , Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>Eur J Dermatol.</i> 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448. PubMed PMID: 30698147.	3.094
344	Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA , Ficorella C. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist.</i> 2019 Feb 22. pii: theoncologist.2018-0618. doi:10.1634/theoncologist.2018-0618. [Epub ahead of print] PubMed PMID: 30796151.	5.252
345	Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA , Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunol Immunother.</i> 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26. PubMed PMID: 30806748.	4.900
346	Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA , Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIb/IV CheckMate 511 Trial. <i>J Clin Oncol.</i> 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27. PubMed PMID: 30811280.	28.245

347	Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fagnoli MC, Ascierto PA , Ficarella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. <i>J Immunother Cancer</i> . 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. PubMed PMID: 30813970; PubMed Central PMCID: PMC6391761.	10.252
348	Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA , Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF (V600)-mutated Metastatic Melanoma. <i>Clin Cancer Res</i> . 2019 Mar 1. doi: 10.1158/1078-0432.CCR-18-0720. [Epub ahead of print] PubMed PMID: 30824584.	8.911
349	Heinzerling L, Ascierto PA , Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>Eur J Cancer</i> . 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. PubMed PMID:30903870.	6.680
350	Ascierto PA , Capone M, Grimaldi AM, Mallardo D, Simeone E, Madonna G, Roder H, Meyer K, Asmellash S, Oliveira C, Roder J, Grigorieva J. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. <i>J Immunother Cancer</i> . 2019 Mar 29;7(1):91. doi:10.1186/s40425-019-0569-1. PubMed PMID: 30925943; PubMed Central PMCID:PMC6440152.	10.252
351	Ascierto PA , Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. <i>Drugs Context</i> . 2019 Mar 25;8:212583. doi:10.7573/dic.212583. eCollection 2019. PubMed PMID: 30936937; PubMed Central PMCID: PMC6434981.	1.090
352	Cristiani CM, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, Mallardo D, Garofalo C, Giovannone ED, Grimaldi AM, Talerico R, Marcenaro E, Pesce S, Zotto GD, Agosti V, Costanzo FS, Gulletta E, Rizzo A, Moretta A, Karre K, Ascierto PA , Todaro M, Carbone E. Accumulation of Circulating CCR7(+) Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. <i>Cancer Immunol Res</i> . 2019 Apr 2. doi: 10.1158/2326-6066.CIR-18-0651. [Epub ahead of print] PubMed PMID: 30940644.	8.619
353	van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA , Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zuber A, Dummer R. Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. <i>Oncotarget</i> . 2019 Mar 5;10(19):1850-1859. doi:10.18632/oncotarget.26753. eCollection 2019 Mar 5. PubMed PMID: 30956763; PubMed Central PMCID: PMC6442999.	0
354	Ascierto PA , Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F. The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018. <i>J Transl Med</i> . 2019 May 10;17(1):148. doi:10.1186/s12967-019-1892-5. PubMed PMID: 31077205.	4.098
355	Harder N, Schönmeier R, Nekolla K, Meier A, Brieu N, Vanegas C, Madonna G, Capone M, Botti G, Ascierto PA , Schmidt G. Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Sci Rep</i> . 2019 May 15;9(1):7449. doi: 10.1038/s41598-019-43525-8. PubMed PMID: 31092853.	4.011
356	Pavlick AC, Fecher L, Ascierto PA , Sullivan RJ. Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer? <i>Am Soc Clin Oncol Educ Book</i> . 2019 Jan;39:564-571. doi:10.1200/EDBK_243071. Epub 2019 May 17. PubMed PMID: 31099689.	0
357	Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA , Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saki, Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>J Clin Oncol</i> . 2019 May 17;JCO1900538. doi: 10.1200/JCO.19.00538. [Epub ahead of print] PubMed PMID: 31100038.	28.245
358	Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML , Ascierto PA , Barnes JM, Barsan V, Bommarreddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.	10.252

	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. <i>J Immunother Cancer</i> . 2019 May 22;7(1):131. doi:10.1186/s40425-019-0602-4. Review. PubMed PMID: 31113486.	
359	Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA , Botti G, De Lorenzo C, Maurea N. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>Int J Cardiol</i> . 2019 May 17. pii: S0167-5273(18)37531-4. doi: 10.1016/j.ijcard.2019.05.028. [Epub ahead of print] PubMed PMID: 31160077.	3.471
360	Ascierto PA , Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghorri R, Ibrahim N, Moreno BH, Ribas A. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nat Med</i> . 2019 Jun 6. doi: 10.1038/s41591-019-0448-9. [Epub ahead of print] PubMed PMID: 31171878.	30.641
361	Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA . Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF(V600) mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. <i>Eur J Cancer</i> . 2019 Jun 4;116:45-55. doi: 10.1016/j.ejca.2019.05.002. [Epub ahead of print] PubMed PMID: 31173962.	6.680
362	Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suci S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>Eur J Cancer</i> . 2019 Jun 11;116:148-157. doi: 10.1016/j.ejca.2019.05.020. [Epub ahead of print] PubMed PMID: 31200321.	6.680
363	Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabro L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA , Reibelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH. Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. <i>J Thorac Oncol</i> . 2019 Jun 19. pii:S1556-0864(19)30475-7. doi: 10.1016/j.jtho.2019.06.010. [Epub ahead of print] PubMed PMID: 31228626.	12.460
364	Ascierto PA , Bifulco C, Palmieri G, Peters S, Sidiropoulos N. Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>J Mol Diagn</i> . 2019 Jun 25. pii: S1525-1578(19)30003-0. doi:10.1016/j.jmoldx.2019.05.004. [Epub ahead of print] Review. PubMed PMID:31251989.	4.426
365	Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA , Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncol</i> . 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review. PubMed PMID:31267972.	35.386
366	Ascierto PA , Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). <i>J Transl Med</i> . 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z. PubMed PMID: 31331337; PubMed Central PMCID: PMC6647284.	4.124
367	Vanella V, Festino L, Trojaniello C, Vitale MG, Sorrentino A, Paone M, Ascierto PA . The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Curr Oncol Rep</i> . 2019 Jul 29;21(9):76. doi:10.1007/s11912-019-0827-x. Review. PubMed PMID: 31359162.	3.949
368	Casula M, Paliogiannis P, Ayala F, De Giorgi V, Stanganelli I, Mandalà M, Colombino M, Manca A, Sini MC, Caracò C, Ascierto PA , Satta RR; Melanoma Unit of Sassari (MUS), Lissia A, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> . 2019 Aug 5;19(1):772. doi:10.1186/s12885-019-5984-7. PubMed PMID: 31382929; PubMed Central PMCID:PMC6683413.	2.933
369	Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA , Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suci S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma:	6.680

	long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>Eur J Cancer</i> . 2019 Aug 7;119:1-10. doi: 10.1016/j.ejca.2019.07.001. [Epub ahead of print] PubMed PMID: 31400634.	
370	Ascierto PA , Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quagliano P, Stanganelli I. New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>J Transl Med</i> . 2019 Aug 14;17(1):266. doi: 10.1186/s12967-019-2012-2. Review. PubMed PMID: 31412885; PubMed Central PMCID: PMC6693227.	4.124
371	Ascierto PA , Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. <i>J Immunother Cancer</i> . 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. Review. PubMed PMID: 31416487; PubMed Central PMCID: PMC6696687.	10.252
372	Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA , Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>Br J Cancer</i> . 2019 Aug 16. doi:10.1038/s41416-019-0546-y. [Epub ahead of print] PubMed PMID: 31417188.	5.416
373	Gogas HJ, Flaherty KT, Dummer R, Ascierto PA , Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>Eur J Cancer</i> . 2019 Aug 19;119:97-106. doi:10.1016/j.ejca.2019.07.016. [Epub ahead of print] PubMed PMID: 31437754.	6.680
374	Nathan P, Ascierto PA , Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>Eur J Cancer</i> . 2019 Aug 21;119:168-178. doi: 10.1016/j.ejca.2019.07.010. [Epub ahead of print] PubMed PMID: 31445199.	6.680
375	Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, Caracò C, Ascierto PA , Sini MC, Palomba G, Pisano M; Melanoma Unit of Sassari (MUS); Italian Association for Cancer Research (AIRC) Study Group, Doneddu V, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>J Transl Med</i> . 2019 Aug 28;17(1):289. doi: 10.1186/s12967-019-2039-4. PubMed PMID:31455347; PubMed Central PMCID: PMC6712827.	4.124
376	Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA , Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Res</i> . 2019 Sep 3. doi: 10.1038/s41422-019-0224-x. [Epub ahead of print] PubMed PMID: 31481761.	17.848
377	Weide B, Eigentler T, Catania C, Ascierto PA , Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C. A phase II study of the L191L2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunol Immunother</i> . 2019 Sep 3. doi:10.1007/s00262-019-02383-z. [Epub ahead of print] PubMed PMID: 31482307.	4.900
378	Ruggiero CF, Malpicci D, Fattore L, Madonna G, Vanella V, Mallardo D, Liguoro D, Salvati V, Capone M, Bedogni B, Ascierto PA , Mancini R, Ciliberto G. ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers (Basel)</i> . 2019 Sep 25;11(10). pii:E1425. doi: 10.3390/cancers11101425. PubMed PMID: 31557826.	6.162
379	Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA , Daniels GA, Long GV, Bastholt L, Rizzo JJ, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>N Engl J Med</i> . 2019 Sep 28. doi:10.1056/NEJMoa1910836. [Epub ahead of print] PubMed PMID: 31562797.	70.670
380	Michielin O, van Akkooi A, Ascierto P , Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Ann Oncol</i> . 2019 Sep 30. pii: mdz411. doi:10.1093/annonc/mdz411. [Epub ahead of print] PubMed PMID: 31566661.	14.196

381	Schadendorf D, Ascierto PA , Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Nathan P. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>Eur J Cancer</i> . 2019 Sep 30;121:144-153. doi: 10.1016/j.ejca.2019.08.014. [Epub ahead of print] PubMed PMID: 31581055.	6.680
382	Colombino M, Paliogiannis P, Cossu A, De Re V, Miolo G, Botti G, Scognamiglio G, Ascierto PA , Santeufemia DA, Fraggetta F, Manca A, Sini MC, Casula M, Palomba G, Pisano M, Doneddu V, Lissia A, Fedeli MA, Palmieri G. BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. <i>J Clin Med</i> . 2019 Oct 1;8(10). pii: E1577. doi: 10.3390/jcm8101577. PubMed PMID: 31581559.	5.688
383	Schadendorf D, Di Giacomo AM, Demidov L, Merelli B, Bondarenko I, Ascierto PA , Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Hong A, Lewis K; BRIM8 Investigators. Health-related quality of life in patients with fully resected BRAF(V600) mutation-positive melanoma receiving adjuvant vemurafenib. <i>Eur J Cancer</i> . 2019 Nov 5;123:155-161. doi:10.1016/j.ejca.2019.09.019. [Epub ahead of print] PubMed PMID: 31704549.	6.680
384	Morello S, Turiello R, Madonna G, Pinto A, Ascierto PA , Capone M. Enzyme activity of circulating CD73 in human serum. <i>Methods Enzymol</i> . 2019;629:257-267. doi: 10.1016/bs.mie.2019.05.044. Epub 2019 Jun 17. PubMed PMID: 31727244.	1.862
385	Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA . Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>J Transl Med</i> . 2019 Nov 15;17(1):376. doi:10.1186/s12967-019-02132-x. PubMed PMID: 31730009.	4.124
386	Ascierto PA , Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). <i>J Immunother Cancer</i> . 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3. Review. PubMed PMID: 31783779; PubMed Central PMCID: PMC6884742.	10.252
387	Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Palla M, Ascierto PA . Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Manag</i> . 2019 Nov 8;6(4):MMT30. doi:10.2217/mmt-2019-0005. Review. PubMed PMID: 31871619; PubMed Central PMCID:PMC6920742.	0.670
388	Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Curvietto M, Ascierto PA . Nivolumab for the treatment of small cell lung cancer. <i>Expert Rev Respir Med</i> . 2020 Jan;14(1):5-13. doi: 10.1080/17476348.2020.1681977. Epub 2019 Oct 29. PMID: 31622114.	2.725
389	Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA , Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>J Thorac Oncol</i> . 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17. PMID: 31629915.	13.357
390	Marabelle A, Le DT, Ascierto PA , Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghorri R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>J Clin Oncol</i> . 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. PMID: 31682550.	32.956
391	Strudel M, Festino L, Vanella V, Beretta M, Marincola FM, Ascierto PA . Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Curr Med Chem</i> . 2020;27(17):2792-2813. doi: 10.2174/0929867326666191205160007. PMID: 31804158.	4.184
392	Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A, Ascierto PA , Pignataro MG, Pelullo M, Rocca CD, Marchetti P, Fortunato L, Costarelli L, d'Amati G. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <i>Virchows Arch</i> . 2020 Apr;476(4):569-576. doi: 10.1007/s00428-019-02722-6. Epub 2019 Dec 18. PMID: 31853625.	2.935
393	Hauschild A, Ascierto PA , Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving	7.275

	dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033. PMID: 31864178.	
394	Luke JJ, Ascierto PA , Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. PMID: 31870188.	2.660
395	Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suci S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 2. doi:10.1001/jamaoncol.2019.5570. [Epub ahead of print] PubMed PMID: 31895407.	24.799
396	Ascierto PA , Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JWB, Loquai C, Gollerkeri A, Pickard MD, Robert C. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020 Jan 2;126:33-44. doi: 10.1016/j.ejca.2019.11.016. [Epub ahead of print] PubMed PMID: 31901705.	7.275
397	Ascierto PA , Lewis KD, Di Giacomo AM, Demidov L, Mandalà M, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib. Ann Oncol. 2020 Jan;31(1):153-159. doi: 10.1016/j.annonc.2019.10.002. PubMed PMID: 31912791.	18.274
398	Ronconi G, Piccinni C, Dondi L, Calabria S, Pedrini A, Esposito I, Ascierto PA , Naldi L, Martini N. Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database. Br J Dermatol. 2020 Jan 23. doi: 10.1111/bjd.18888. [Epub ahead of print] PubMed PMID: 31972051.	7.000
399	Luke JJ, Ascierto PA . Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020 Jan 23. doi: 10.1038/s41571-020-0328-8. [Epub ahead of print] PubMed PMID: 31974501.	53.276
400	Dummer R, Ascierto PA , Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, Hauschild A, Krattinger R, Lear JT, Malvehy J, Schadendorf D, Grob RJJ. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020 Jan 28. doi: 10.1111/jdv.16230. [Epub ahead of print] Review. PubMed PMID: 31990414.	5.248
401	Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fagnoli MC, Tiseo M, Santini D, Ascierto PA , Ficorella C. Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020. PubMed PMID: 32002308; PubMed Central PMCID: PMC6959456.	5.869
402	Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA . Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 Feb 4;128:17-26. doi: 10.1016/j.ejca.2019.12.031. [Epub ahead of print] PubMed PMID: 32109847.	7.275
403	Scognamiglio G, Capone M, Mallardo D, Botti G, Ascierto PA , Madonna G. Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods Enzymol. 2020;635:21-31. doi:10.1016/bs.mie.2019.07.045. Epub 2019 Aug 22. PubMed PMID: 32122547.	1.394
404	Capone M, Fratangelo F, Giannarelli D, Sorrentino C, Turiello R, Zannotti S, Galati D, Madonna G, Tuffanelli M, Scarpato L, Grimaldi AM, Esposito A, Azzaro R, Pinto A, Cavalcanti E, Pinto A, Morello S, Ascierto PA . Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma	4.124

	patients. J Transl Med. 2020 Mar 11;18(1):121. doi: 10.1186/s12967-020-02285-0. PubMed PMID: 32160899; PubMed Central PMCID: PMC7065327.	
405	Fattore L, Campani V, Ruggiero CF, Salvati V, Liguoro D, Scotti L, Botti G, Ascierto PA , Mancini R, De Rosa G, Ciliberto G. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 2020 Mar 12;21(6). pii: E1930. doi:10.3390/ijms21061930. PubMed PMID: 32178301.	4.556
406	Ugurel S, Röhmel J, Ascierto PA , Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020 Mar 13;130:126-138. doi:10.1016/j.ejca.2020.02.021. [Epub ahead of print] PubMed PMID: 32179447.	7.275
407	Trojaniello C, Vitale MG, Scarpato L, Esposito A, Ascierto PA . Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Rev Anticancer Ther. 2020 Apr 6:1-16. doi: 10.1080/14737140.2020.1745634. [Epub ahead of print] PubMed PMID: 32195606.	3.573
408	Ascierto PA , Garbe C. Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'. Immunotherapy. 2020 Feb;12(3):167-174. doi: 10.2217/imt-2020-0042. Epub 2020 Mar 24. PubMed PMID: 32208790.	2.964
409	Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA , Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 Mar 31;JCO2000198. doi: 10.1200/JCO.20.00198. [Epub ahead of print] PubMed PMID: 32228358.	32.956
410	Walker JW, Lebbé C, Grignani G, Nathan P, Dirix L, Fenig E, Ascierto PA , Sandhu S, Munhoz R, Benincasa E, Flasket S, Reed J, Engelsberg A, Hariharan S, Kasturi V. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020 Apr;8(1). pii: e000313. doi: 10.1136/jitc-2019-000313. PubMed PMID: 32269140.	10.252
411	Buonaguro FM, Puzanov I, Ascierto PA . Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020 Apr 14;18(1):165. doi:10.1186/s12967-020-02333-9. PubMed PMID: 32290847; PubMed Central PMCID:PMC7154570.	4.124
412	Ascierto PA , Agarwala SS, Eggermont A, Gershenwald JE, Grob JJ, Hamid O, Michielin O, Postow M, Puzanov I, Zarour HM, Caracò C, Testori A. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. J Transl Med. 2020 Apr 16;18(1):171. doi: 10.1186/s12967-020-02340-w. PubMed PMID: 32299446.	4.124
413	Ascierto PA , Fox B, Urba W, Anderson AC, Atkins MB, Borden EC, Brahmer J, Butterfield LH, Cesano A, Chen D, de Grujil T, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi F, Hwu P, Kaufman D, Kaufman H, Lotze M, McNeel DG, Margolin K, Marincola F, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 Apr;8(1). pii: e000878. doi: 10.1136/jitc-2020-000878. PubMed PMID: 32300051.	10.252
414	Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA , Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clin Cancer Res. 2020 Apr 28. pii: clincanres.3925.2019. doi: 10.1158/1078-0432.CCR-19-3925. [Epub ahead of print] PubMed PMID: 32345648.	10.107
415	Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA , Nuti M, Marchetti P. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines (Basel). 2020 Apr 28;8(2). pii: E203. doi: 10.3390/vaccines8020203. PubMed PMID: 32353934.	4.086
416	Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA , Robert C, Chaput N. Systemic short chain fatty acids limit	12.121

	antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020 May 1;11(1):2168. doi: 10.1038/s41467-020-16079-x. PubMed PMID: 32358520.	
417	Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA , Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 May 4;JCO1902727. doi: 10.1200/JCO.19.02727. [Epub ahead of print] PubMed PMID: 32364844.	32.956
418	Bossi P, Peris K, Calzavara-Pinton P, Queirolo P, Alfieri S, Palla M, Rossi MT, Spagnolo F, Tambone S, Astolfi C, Ascierto PA . Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. Future Oncol. 2020 May 6. doi: 10.2217/fon-2019-0664. [Epub ahead of print] PubMed PMID: 32374193.	2.660
419	Arnaldez FI, O'Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, Montesarchio V, Weber JS, Wei H, Wigginton JM, Ascierto PA . The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020 May;8(1). pii: e000930. doi:10.1136/jitc-2020-000930. PubMed PMID: 32385146.	10.252
420	Ascierto PA , Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, Loquai C, Mortier L, Hamid O, Bastholt L, Dreno B, Schadendorf D, Garbe C, Nyakas M, Grob JJ, Thomas L, Liszkay G, Smylie M, Hoeller C, Ferraresi V, Grange F, Gutzmer R, Pikiel J, Hosein F, Simsek B, Maio M.. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J Immunother Cancer. 2020;8(1):e000391. doi:10.1136/jitc-2019-000391	10.252
421	Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835-1844. doi:10.1016/S0140-6736(20)30934-X	60.392
422	Motti ML, Minopoli M, Di Carluccio G, Ascierto PA , Carriero MV. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. Int J Mol Sci. 2020;21(12):E4544. Published 2020 Jun 26. doi:10.3390/ijms21124544	4.556
423	Buonaguro FM, Ascierto PA , Morse GD, Buonaguro L, Puzanov I, Tornesello ML, Bréchet C, Gallo RC. Covid-19: Time for a paradigm change [published online ahead of print, 2020 Jul 3]. Rev Med Virol. 2020;e2134. doi:10.1002/rmv.2134	4.221
424	Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA , McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020 Jul;8(2):e000648. doi: 10.1136/jitc-2020-000648. PMID: 32661115; PMCID: PMC7359062.	10.252
425	Sullivan RJ, Weber J, Patel S, Dummer R, Carlino MS, Tan DSW, Lebbé C, Siena S, Elez E, Wollenberg L, Pickard MD, Sandor V, Ascierto PA . A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors [published online ahead of print, 2020 Jul 15]. Clin Cancer Res. 2020;10.1158/1078-0432.CCR-19-3550. doi:10.1158/1078-0432.CCR-19-3550	10.107
426	Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA , Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials [published online ahead of print, 2020 Jul 16]. JAMA Oncol. 2020;6(8):1-9. doi:10.1001/jamaoncol.2020.2288	24.799
427	Khushalani NI, Diab A, Ascierto PA , Larkin J, Sandhu S, Sznol M, Koon HB, Jarkowski A, Zhou M, Statkevich P, Geese WJ, Long GV. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncol. 2020 Oct;16(28):2165-2175. doi: 10.2217/fon-2020-0351. Epub 2020 Jul 29. PMID: 32723187.	2.660
428	Cascella M, Mauro I, De Blasio E, Crispo A, Del Gaudio A, Bimonte S, Cuomo A, Ascierto PA . Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. Medicina (Kaunas). 2020;56(8):E377. Published 2020 Jul 27. doi:10.3390/medicina56080377	1.500
429	Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quagliano P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA , Santinami M; Italian Melanoma Intergroup (IMI). Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A	7.275

	multicentre study of the Italian Melanoma Intergroup (IMI). Eur J Cancer. 2020;137:30-39. doi:10.1016/j.ejca.2020.07.001	
430	Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members: A Addeo, L Albiges, PA Ascierto , S Banerjee, F Barlesi, C Caldas, F Cardoso, A Cervantes, I F Chaberny, N I Cherny, T K Choueiri, M L K Chua, C Criscitiello, G Curigliano, E de Azambuja, D De Ruyscher, E de Vries, R Dent, J Y Douillard, D D'Ugo, R Dziadziuszko, C Faivre-Finn, E Felip, M Garassino, P Garrido, N Girard, R Glynne-Jones, V Golfinopoulos, J Haanen, E Hamilton, P A Jänne, K Jordan, R Kanesvaran, S B Kim, U G Liebert, F Lordick, J P Machiels, O Michielin, T S K Mok, G Morgan, R Obermannova, K Park, A Passaro, G Pentheroudakis, S Peters, M Reck, R Salazar Soler, F Scotté, S Senan, C Sessa, E Smyth, R Soo, J C Soria, J Spicer, F Strasser, J Tabernero, D S W Tan, D Trapani, E Van Cutsem, H van Halteren, P E van Schil, G Veronesi, J Yang. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693.	18.274
431	Ascierto PA , Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B.. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020;18(1):294. Published 2020 Aug 3. doi:10.1186/s12967-020-02458-x	4.124
432	Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V, Fedeli MA, Sini MC, Palomba G, Pisano M, Ascierto PA , Caracò C, Lissia A, Cossu A, Palmieri G. Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. J Clin Med. 2020;9(8):E2430. Published 2020 Jul 30. doi:10.3390/jcm9082430	3.303
433	Michielin O, van Akkooi A, Lorigan P, Ascierto PA , Dummer R, Robert C, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U.. ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee [published online ahead of print, 2020 Jul 22]. Ann Oncol. 2020;S0923-7534(20)39940-3. doi:10.1016/j.annonc.2020.07.005	18.274
434	Keilholz U, Ascierto PA , Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee [published online ahead of print, 2020 Jul 22]. Ann Oncol. 2020;S0923-7534(20)39939-7. doi:10.1016/j.annonc.2020.07.004	18.274
435	Montesarchio V, Parella R, Iommelli C, Bianco A, Manzillo E, Fraganza F, Palumbo C, Rea G, Murino P, De Rosa R, Atripaldi L, D'Abbraccio M, Curvietto M, Mallardo D, Celentano E, Grimaldi AM, Palla M, Trojaniello C, Vitale MG, Million-Weaver SL, Ascierto PA . Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089. doi:10.1136/jitc-2020-001089	10.252
436	Ascierto PA , Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer. 2020;8(2):e000921. doi:10.1136/jitc-2020-000921	10.252
437	Gebhardt C, Ascierto P , Atkinson V, Corrie P, Dummer R, Schadendorf D. The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions [published online ahead of print, 2020 Aug 26]. Eur J Cancer. 2020;138:68-76. doi:10.1016/j.ejca.2020.07.016	7.275
438	Ascierto PA , Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020;18(1):346. Published 2020 Sep 7. doi:10.1186/s12967-020-02482-x	4.124
439	Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G,	32.956

	Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Bruni D, Lanzi A, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA , Fox BA, Pagès F, Galon J. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer [published online ahead of print, 2020 Sep 8]. <i>J Clin Oncol</i> . 2020; JCO1903205. doi:10.1200/JCO.19.03205	
440	Fattore L, Malpicci D, Milite C, Castellano S, Sbardella G, Botti G, Ascierto PA , Mancini R, Ciliberto G. Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. <i>Cell Commun Signal</i> . 2020 Sep 15;18(1):150. doi: 10.1186/s12964-020-00633-7. PMID: 32933538; PMCID: PMC7493390.	4.344
441	Eggermont AMM, Blank CU, Mandalá M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>J Clin Oncol</i> . 2020 Sep 18;JCO2002110. doi: 10.1200/JCO.20.02110. Epub ahead of print. PMID: 32946353.	32.956
442	Bernardo L, Del Sesto S, Giordano L, Benincaso AR, Biondi P, Goj V, Ferrara F, Talenti A, Grisolia A, Ascierto PA . Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature. <i>Drugs Ther Perspect</i> . 2020 Sep 14:1-5. doi: 10.1007/s40267-020-00777-z. Epub ahead of print. PMID: 32952393; PMCID: PMC7487439.	0.210
443	Ascierto PA , Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i> . 2020 Sep 18:S1470-2045(20)30494-0. doi: 10.1016/S1470-2045(20)30494-0. Epub ahead of print. PMID: 32961119.	33.752
444	Dummer R, Ascierto PA , Nathan P, Robert C, Schadendorf D. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. <i>JAMA Oncol</i> . 2020 Sep 24. doi: 10.1001/jamaoncol.2020.4401. Epub ahead of print. PMID: 32970096.	24.799
445	Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Rutkowski P, Hassel JC, McNeil CM, Kalinka EA, Lebbé C, Charles J, Hernberg MM, Savage KJ, Chiarion-Sileni V, Mihalcioiu C, Mauch C, Arance A, Cognetti F, Ny L, Schmidt H, Schadendorf D, Gogas H, Zoco J, Re S, Ascierto PA , Atkinson V. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. <i>J Clin Oncol</i> . 2020 Sep 30;JCO2000995. doi: 10.1200/JCO.20.00995. Epub ahead of print. PMID: 32997575.	32.956
446	Scarpato L, Simeone E, Trojaniello C, Palla M, Ascierto P . Carcinoma squamoso cutaneo: trattamento immunoterapico della malattia localmente avanzata e metastatica [Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]. <i>Recenti Prog Med</i> . 2020 Jul-Aug;111(7):21e-27e. Italian. doi: 10.1701/3407.34316. PMID: 33006588.	0.320
447	Dummer R, Lebbé C, Atkinson V, Mandalá M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA , Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nat Med</i> . 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. PMID: 33020648.	36.130
448	Piccirillo MC, Ascierto P , Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolo N, Fraganza F, Marata A, Massari M, Montesarchio V, Mussini C, Negri EA, Parrella R, Popoli P, Botti G, Arenare L, Chiodini P, Gallo C, Salvarani C, Perrone F. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemp Clin Trials</i> . 2020 Oct 5:106165. doi: 10.1016/j.cct.2020.106165. Epub ahead of print. PMID: 33031955.	1.832
449	Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA . Evolving impact of long-term survival results on metastatic melanoma treatment. <i>J Immunother Cancer</i> . 2020 Oct;8(2):e000948. doi: 10.1136/jitc-2020-000948. PMID: 33037115.	10.252

450	Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, Guida M, Indini A, Quaglini P, Ferraresi V, Marconcini R, Tronconi MC, Rossi E, Nigro O, Ocelli M, Cortellini A, Quadri S, Palmieri G, Pigozzo J, Ascierto PA , Vitale MG, Strippoli S, Ferrucci PF, Berardi R, Randon G, Cardone P, Schinzari G, Silvestris F, Tucci M. An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Front Oncol</i> . 2020 Sep 15;10:1652. doi: 10.3389/fonc.2020.01652. PMID: 33042809; PMCID: PMC7523509.	4.250
451	Sacco A, Forgione L, Carotenuto M, Luca A, Ascierto PA , Botti G, Normanno N. Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers (Basel)</i> . 2020 Oct 10;12(10):E2914. doi: 10.3390/cancers12102914. PMID: 33050536.	5.742
452	Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantadosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA ; SCITO (Società Campana di ImmunoTerapia Oncologica). Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. <i>J Immunother Cancer</i> . 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. PMID: 33060148; PMCID: PMC7565202.	10.252
453	Perrone F, Piccirillo MC, Ascierto PA , Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. <i>J Transl Med</i> . 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. PMID: 33087150.	4.124
454	Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA , Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>Br J Cancer</i> . 2020 Oct 22. doi: 10.1038/s41416-020-01121-y. Epub ahead of print. PMID: 33087895.	5.791
455	Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA , Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. <i>J Immunother Cancer</i> . 2020 Nov;8(2):e001322. doi: 10.1136/jitc-2020-001322. PMID: 33144335.	10.252
456	Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA . Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. <i>J Immunother Cancer</i> . 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. PMID: 33154150.	10.252
457	Ascierto PA , Maricola FM, Fox BA, Galon J. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>Oncoimmunology</i> . 2020 Oct 13;9(1):1826132. doi: 10.1080/2162402X.2020.1826132. PMID: 33194317; PMCID: PMC7644246.	5.869
458	Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA , Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel	7.275

	prognostic index. Eur J Cancer. 2020 Nov 16;142:18-28. doi: 10.1016/j.ejca.2020.09.033. Epub ahead of print. PMID: 33212418.	
459	Marchetti P, Botticelli A, Ascierto AP , Curigliano G, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. J Transl Med. 2020 Nov 25;18(1):446. doi: 10.1186/s12967-020-02588-2. PMID: 33239030; PMCID: PMC7688006.	4.124
460	Faries MB, Ascierto PA , Blank C, Cochran AJ, Delman K, Gyorki D, Haanen J, Hamid O, Han D, Karakousis G, Kashani-Sabet M, Leachman S, Moncrieff M, Plasmeijer E, Enrico Testori AA, Van Akkooi A, Wong S, Zager JS. Letter Regarding Editorial by Samuel Zagarella. Am J Dermatopathol. 2020 Dec 1. doi: 10.1097/DAD.0000000000001857. Epub ahead of print. PMID: 33264129.	1.190
461	Miscio L, Olivieri A, Labonia F, De Feo G, Chiodini P, Portella G, Atripaldi L, Parrella R, Conenna R, Buonaguro FM, Cavalcanti E, Ascierto P , Botti G, Bianchi A. Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection. J Transl Med. 2020 Dec 21;18(1):488. doi: 10.1186/s12967-020-02651-y. PMID: 33349261.	4.124
462	Scarpa R, Caso F, Costa L, Passavanti S, Vitale MG, Trojaniello C, Del Puente A, Ascierto PA . May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? J Transl Med. 2020 Dec 22;18(1):489. doi: 10.1186/s12967-020-02673-6. PMID: 33353549.	4.124
463	Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, Ascierto PA ; KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020 Dec;8(2):e001806. doi: 10.1136/jitc-2020-001806. PMID: 33361337.	10.252
464	Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebbe C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, Ascierto PA . Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. J Immunother Cancer. 2020 Dec;8(2):e001689. doi: 10.1136/jitc-2020-001689. PMID: 33361405.	10.252
465	Cozzolino M, Cocco S, Piezzo M, Celia G, Costantini S, Abate V, Capone F, Barberio D, Girelli L, Cavicchiolo E, Ascierto PA , Madonna G, Budillon A, De Laurentiis M. A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. J Clin Med. 2021 Jan 3;10(1):E136. doi: 10.3390/jcm10010136. PMID: 33401546.	4.241
466	Trojaniello C, Vitale MG, Ascierto PA . Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better? Curr Opin Oncol. 2021 Jan 4; Publish Ahead of Print. doi: 10.1097/CCO.0000000000000709. Epub ahead of print. PMID: 33399314.	3.645
467	Vecchiato A, Mocellin S, Del Fiore P, Tosti G, Ascierto PA , Corradin MT, De Giorgi V, Giudice G, Queirolo P, Ferrelli C, Occelli M, Giordano M, Trevisan G, Mascheroni L, Testori A, Spina R, Buja A, Cavallin F, Caracò C, Sommariva A, Rossi CR; Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup (IMI). The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. BMC Cancer. 2021 Jan 5;21(1):8. doi: 10.1186/s12885-020-07705-4. PMID: 33402122.	4.430
468	Simeone E, Scognamiglio G, Capone M, Giannarelli D, Grimaldi AM, Mallardo D, Madonna G, Curvietto M, Esposito A, Sandomenico F, Sabbatino F, Bayless NL, Warren S, Ong S, Botti G, Flaherty KT, Ferrone S, Ascierto PA . A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. J Transl Med. 2021 Jan 6;19(1):17. doi: 10.1186/s12967-020-02680-7. PMID: 33407577.	5.531
469	Ascierto PA , Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). J Transl Med. 2021 Jan 6;19(1):13. doi: 10.1186/s12967-020-02627-y. PMID: 33407605.	5.531
470	Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA , Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer	13.751

	treated with immune checkpoint inhibition. J Immunother Cancer. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. PMID: 33468556.	
471	Guida A, Perri F, Ionna F, Ascierto PA , Grimaldi AM. New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clin Case Rep. 2020 Dec 2;9(1):61-66. doi: 10.1002/ccr3.3418. PMID: 33489133; PMCID: PMC7813008.	0
472	Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Reply to E. Hindié. J Clin Oncol. 2021 Jan 25;JCO2003463. doi: 10.1200/JCO.20.03463. Epub ahead of print. PMID: 33492998.	44.544
473	Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Quaresmini D, Gambale E, Chiarion Sileni V, Ascierto PA , Stigliano L, Strippoli S, On Behalf Of The Italian Melanoma Intergroup Imi Study. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers (Basel). 2021 Jan 26;13(3):475. doi: 10.3390/cancers13030475. PMID: 33530579.	6.639
474	Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA , Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 Feb 8. doi: 10.1038/s41591-020-01188-3. Epub ahead of print. PMID: 33558722.	53.440
475	Grignani G, Chiarion Sileni V, Pinto C, Depenni R, Fazio N, Galli L, Giuffrida D, Carnaghi C, Ciliberto D, Corsi DC, Queirolo P, Benincasa E, Venturini F, Fazzi G, Costa N, Ascierto PA . Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. J Transl Med. 2021 Feb 15;19(1):70. doi: 10.1186/s12967-021-02730-8. PMID: 33588870.	5.531
476	Mandala M, Lorigan P, De Luca M, Bianchetti A, Merelli B, Bettini AC, Bonomi L, Nahm S, Vitale MG, Negrini G, Di Croce A, Ascierto PA , Rulli E, Tondini CA. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. J Immunother Cancer. 2021 Feb;9(2):e001694. doi: 10.1136/jitc-2020-001694. PMID: 33593827.	13.751
477	Trojaniello C, Vitale MG, Ascierto PA . Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19. Ann Oncol. 2021 Feb 15;S0923-7534(21)00125-3. doi: 10.1016/j.annonc.2021.02.008. Epub ahead of print. PMID: 33600920.	32.976
478	Olofsson Bagge R, Ny L, Ascierto PA , Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, van Akkooi ACJ. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res. 2021 Feb 18. doi: 10.1097/CMR.0000000000000719. Epub ahead of print. PMID: 33625104.	3.599
479	Barbato A, Iuliano A, Volpe M, D'Alterio R, Brillante S, Massa F, De Cegli R, Carrella S, Salati M, Russo A, Russo G, Riccardo S, Cacchiarelli D, Capone M, Madonna G, Ascierto PA , Franco B, Indrieri A, Carotenuto P. Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. Int. J. Mol. Sci. 2021, 22, 1801. https://doi.org/10.3390/ijms22041801	5.923
480	Atripaldi L, Sale S, Capone M, Montesarchio V, Parrella R, Botti G, Ascierto PA , Madonna G. Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. J Transl Med. 2021 Mar 2;19(1):93. doi: 10.1186/s12967-021-02762-0. PMID: 33653336.	5.531
481	Vanella V, Festino L, Vitale MG, Alfano B, Ascierto PA . Emerging anti PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opin Emerg Drugs. 2021 Mar 9. doi: 10.1080/14728214.2021.1901884. Epub ahead of print. PMID: 33686894.	4.191
482	Goldman JD, Ascierto PA. Perspectives on COVID-19 and cancer immunotherapy: a review series. J Immunother Cancer. 2021 Mar;9(3):e002489. doi: 10.1136/jitc-2021-002489. PMID: 33688023.	13.751
483	Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Blum L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA , Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L. Outcome of melanoma patients with elevated LDH treated with first-line	9.162

	targeted therapy or PD-1-based immune checkpoint inhibition. Eur J Cancer. 2021 Mar 15;148:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub ahead of print. PMID: 33735811.	
484	Isgrò MA, Vitale MG, Celentano E, Nocerino F, Porciello G, Curvietto M, Mallardo D, Montagnese C, Russo L, Zanaletti N, Avallone A, Pensabene M, De Laurentiis M, Centonze S, Pignata S, Cannella L, Morabito A, Caponigro F, Botti G, Masucci GV, Giannarelli D, Cavalcanti E, Ascierto PA . Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. J Transl Med. 2021 Mar 31;19(1):132. doi: 10.1186/s12967-021-02798-2. PMID: 33789686.	5.531
485	Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhavé P, Reijers I, Thompson N, Vanella V, Gerard C, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA , Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan R, Long GV, Menzies AM. Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. Ann Oncol. 2021 Mar 30:S0923-7534(21)01101-7. doi: 10.1016/j.annonc.2021.03.204. PMID: 33798657.	32.976
486	Cerino P, Coppola A, Volzone P, Pizzolante A, Pierri B, Atripaldi L, Zollo M, Capasso M, Ascierto PA , Triassi M, Brambilla G, Perrella A, Bruzzese D, Buonerba C. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study. Future Sci OA. 2021 Jan 12;7(4):FSO673. doi: 10.2144/foa-2020-0203. PMID: 33815819; PMCID: PMC7802431.	0
487	Dimitriou F, Zaremba A, Allayous C, Kähler KC, Gerard CL, Festino L, Schäfer S, Toussaint F, Heinzerling L, Hassel JC, Ascierto PA , Michielin O, Hauschild A, Lebbe C, Livingstone E, Ramelyte E, Cheng PF, Dummer R, Mangana J. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer. 2021 Apr 2;149:37-48. doi: 10.1016/j.ejca.2021.02.037. Epub ahead of print. PMID: 33823361.	9.162
488	Ascierto PA , Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 Apr 7;19(1):142. doi: 10.1186/s12967-021-02808-3. PMID: 33827575.	5.531
489	Ascierto PA , Brody J, Butterfield LH, Finn OJ, Goldberg J, Perrone F, Sullivan RJ, Fox BA, Hwu P, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. J Transl Med. 2021 Apr 7;19(1):144. doi: 10.1186/s12967-021-02811-8. PMID: 33827609.	5.531
490	Ascierto PA , Fu B, Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021 Apr;9(4):e002285. doi: 10.1136/jitc-2020-002285. PMID: 33837054; PMCID: PMC8042594.	13.751
491	Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Apr 12:S1470-2045(21)00065-6. doi: 10.1016/S1470-2045(21)00065-6. Epub ahead of print. PMID: 33857412.	41.316
492	Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA , Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C, Eggermont AMM; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Apr 12:S1470-2045(21)00081-4. doi: 10.1016/S1470-2045(21)00081-4. Epub ahead of print. PMID: 33857414.	41.316
493	Borzillo V, Di Franco R, Giannarelli D, Cammarota F, Scipilliti E, D'Ippolito E, Petito A, Serra M, Falivene S, Grimaldi AM, Simeone E, Festino L, Vanella V, Trojaniello C, Vitale MG, Madonna G, Ascierto PA , Muto P. Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers (Basel). 2021 Apr 13;13(8):1857. doi: 10.3390/cancers13081857. PMID: 33924595; PMCID: PMC8068853.	6.639
494	Troiani T, De Falco V, Napolitano S, Trojaniello C, Ascierto PA . How we treat locoregional melanoma. ESMO Open. 2021 Apr 27;6(3):100136. doi: 10.1016/j.esmoop.2021.100136. Epub ahead of print. PMID: 33930656.	6.540

495	Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, Zimmer L, Kapiteijn EW, Allayous C, Johnson DB, Hepner A, Mangana J, Bhawe P, Jansen YJL, Trojaniello C, Atkinson V, Storey L, Lorigan P, Ascierto PA , Neyns B, Haydon A, Menzies AM, Long GV, Lebbe C, van der Veldt AAM, Carlino MS, Sandhu S, van Tinteren H, de Vries EGE, Blank CU, Jalving M. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>Eur J Cancer</i> . 2021 May 7;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Epub ahead of print. PMID: 33971447.	9.162
496	Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA , Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncol</i> . 2021 May 11:S1470-2045(21)00097-8. doi: 10.1016/S1470-2045(21)00097-8. Epub ahead of print. PMID: 33989557.	41.316
497	Simonetti I, Sandomenico F, Rocco MP, Fusco R, Setola SV, Granata V, Iasevoli DM, Ascierto PA , Grassi R, Petrillo A. Metastatic endo and perineural involvement of the ulnar nerve from malignant melanoma: ultrasound (US) and magnetic resonance imaging (MRI) findings. <i>Eur Rev Med Pharmacol Sci</i> . 2021 May;25(9):3478-3482. doi: 10.26355/eurev_202105_25829. PMID: 34002821.	3.507
498	Scognamiglio G, Capone M, Sabbatino F, Di Mauro A, Cantile M, Cerrone M, Madonna G, Grimaldi AM, Mallardo D, Palla M, Sarno S, Anniciello AM, Di Bonito M, Ascierto PA , Botti G. The Ratio of GrzB+ – FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> . 2021; 13(10):2325. https://doi.org/10.3390/cancers13102325	6.639
499	Atkinson VG, Quagliano P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA , Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers (Basel)</i> . 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. PMID: 34070224.	6.639
500	Ascierto PA , Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). <i>J Transl Med</i> . 2021 Jun 2;19(1):238. doi: 10.1186/s12967-021-02895-2. PMID: 34078406.	5.531
501	Gogas H, Dummer R, Ascierto PA , Arance A, Mandalà M, Liskay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, Jan de Willem G, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>Eur J Cancer</i> . 2021 Jun 3;152:116-128. doi: 10.1016/j.ejca.2021.04.028. Epub ahead of print. PMID: 34091420.	9.162
502	Ascierto PA , Dreno B, Larkin J, Ribas A, Liskay G, Maio M, Mandal M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu JJ, Jones S, Li H, McKenna E, Voulgari A, McArthur GA. 5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study. <i>Clin Cancer Res</i> . 2021 Jun 22;clinres.0809.2021. doi: 10.1158/1078-0432.CCR-21-0809. Epub ahead of print. PMID: 34158360.	12.531
503	Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Pala L, Queirolo P, Bracarda S, Macrini S, Gori S, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, Ascierto PA , Pinato DJ, Ficorella C, Porzio G, Cortellini A. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>J Transl Med</i> . 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9. PMID: 34167578.	5.531
504	Brahmer JR, Abu-Sbeih H, Ascierto PA , Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomaso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i> . 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. PMID: 34172516.	13.751
505	Trojaniello C, Luke JJ, Ascierto PA . Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Front Oncol</i> . 2021 Jun 10;11:670726. doi: 10.3389/fonc.2021.670726. PMID: 34178657; PMCID: PMC8222774.	6.244

506	Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, Cuvietto M, Khoo C, Atkinson V, Lo S, Long GV, Sandhu S, Ascierto PA , Carlino MS, Johnson DB, Larkin J, Menzies AM. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>Eur J Cancer</i> . 2021 Jun 25;153:168-178. doi: 10.1016/j.ejca.2021.04.045. Epub ahead of print. PMID: 34182268.	9.162
507	Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G, Ascierto PA . First line treatment of BRAF mutated advanced melanoma: Does one size fit all? <i>Cancer Treat Rev</i> . 2021 Jun 18;99:102253. doi: 10.1016/j.ctrv.2021.102253. Epub ahead of print. PMID: 34186441.	12.111
508	Ascierto PA , Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). <i>J Transl Med</i> . 2021 Jun 30;19(1):278. doi: 10.1186/s12967-021-02951-x. PMID: 34193182.	5.531
509	Crispo A, Corradin MT, Giulioni E, Vecchiato A, Del Fiore P, Queirolo P, Spagnolo F, Vanella V, Caracò C, Tosti G, Pennacchioli E, Giudice G, Nacchiero E, Quagliano P, Ribero S, Giordano M, Marussi D, Barruscotti S, Guida M, De Giorgi V, Occelli M, Grosso F, Cairo G, Gatti A, Massa D, Atzori L, Calvani N, Fabrizio T, Mastrangelo G, Toffolutti F, Celentano E, Budroni M, Gandini S, Rossi CR, Testori A, Palmieri G, Ascierto PA ; Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup. Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Front Oncol</i> . 2021 Jul 8;11:672797. doi: 10.3389/fonc.2021.672797. PMID: 34307142; PMCID: PMC8298066.	6.244
510	Palmieri G, Puzanov I, Massi D, Ascierto PA . Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma. <i>Front Oncol</i> . 2021 Jul 9;11:728113. doi: 10.3389/fonc.2021.728113. PMID: 34307183; PMCID: PMC8299098.	6.244
511	Ascierto PA , Orlova K, Grignani G, Dudzisz-Śledź M, Fenig E, Chiarion Sileni V, Fazio N, Samimi M, Mortier L, Gebhardt C, Kramkimel N, Steven N, Bechter O, Arance A, Benincasa E, Kostkova L, Costa N, Lorigan P. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>Int J Cancer</i> . 2021 Jul 26. doi: 10.1002/ijc.33746. Epub ahead of print. PMID: 34310716.	7.396
512	da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA , Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. <i>Lancet Oncol</i> . 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8. PMID: 34339647.	41.316
513	Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA . TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma. <i>Cancer Immunol Res</i> . 2021 Aug 13;canimm.0983.2020. doi: 10.1158/2326-6066.CIR-20-0983. Epub ahead of print. PMID: 34389558.	11.151
514	Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA , Long GV, Schadendorf D, Zimmer L. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>Eur J Cancer</i> . 2021 Aug 12;155:268-280. doi: 10.1016/j.ejca.2021.07.002. Epub ahead of print. PMID: 34392069.	9.162
515	Madonna G, Masucci GV, Capone M, Mallardo D, Grimaldi AM, Simeone E, Vanella V, Festino L, Palla M, Scarpato L, Tuffanelli M, D'angelo G, Villabona L, Krakowski I, Eriksson H, Simao F, Lewensohn R, Ascierto PA . Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. <i>Cancers (Basel)</i> . 2021 Aug 19;13(16):4164. doi: 10.3390/cancers13164164. PMID: 34439318.	6.639
516	Madonna G, Sale S, Capone M, De Falco C, Santocchio V, Di Matola T, Fiorentino G, Pirozzi C, D'Antonio A, Sabatino R, Atripaldi L, Atripaldi U, Raffone M, Curvietto M, Grimaldi AM, Vanella V, Festino L, Scarpato L, Palla M, Spatarella M, Perna F, Cerino P, Botti G, Parrella R, Montesarchio V, Ascierto PA , Atripaldi L. Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF- α Expression. <i>Biology (Basel)</i> . 2021 Aug 1;10(8):735. doi: 10.3390/biology10080735. PMID: 34439967.	5.079
517	Giunta EF, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, Diana A, Giordano P, Petrillo A, Federico P, Fabozzi T, Parola S, Riccio V, Mucci B, Vanella V, Festino L, Daniele B, Ascierto PA , Ottaviano M, On Behalf Of Scito Youth. Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> . 2021 Aug 11;10(8):2048. doi: 10.3390/cells10082048. PMID: 34440824.	6.600

518	Vannucchi AM, Mortara A, D'Alessio A, Morelli M, Tedeschi A, Festuccia MB, Monforte AD, Capochiani E, Selleri C, Simonetti F, Saracino A, Rapezzi D, Badagliacca MR, Falasca K, Molteni A, Palazzolo R, Schettino G, Bocchia M, Turrini M, Ascierto PA , Zuurman M, Paley C, Coco P, Saglio G. JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. <i>J Clin Med</i> . 2021 Aug 23;10(16):3752. doi: 10.3390/jcm10163752. PMID: 34442045.	4.241
519	Mandala M, Larkin J, Ascierto PA , Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. <i>J Immunother Cancer</i> . 2021 Aug;9(8):e003188. doi: 10.1136/jitc-2021-003188. PMID: 34452930.	13.751
520	Baggi A, Quagliano P, Rubatto M, Depenni R, Guida M, Ascierto PA , Trojaniello C, Queirolo P, Saponara M, Peris K, Spagnolo F, Bianchi L, De Galitiis F, Potenza MC, Proietti I, Marconcini R, Botticelli A, Barbieri V, Licitra L, Alfieri S, Ficorella C, Cortellini A, Fagnoli MC, Troiani T, Tondulli L, Bossi P. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>Eur J Cancer</i> . 2021 Sep 15;157:250-258. doi: 10.1016/j.ejca.2021.08.018. Epub ahead of print. PMID: 34536948.	9.162
521	Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators: Anthony Joshua, Michael Brown, Damien Kee, Jean-Francois Baurain, Marcus Butler, John Walker, Lauris Gastaud, Sophie Piperno-Neumann, Christoffer Gebhardt, Jessica Hassel, Cornelia Mauch, Friedegund Meier, Sebastian Ochsenreither, Max Schlaak, Jens Siveke, Jeffery Evans, Paul Nathan, Joseph Sacco, Paolo Antonio Ascierto , Michele Del Vecchio, Ellen Kapiteijn, Piotr Rutkowski, Lev Demidov, Svetlana Protsenko, Alfonso Berrocal, Luis De la Cruz Merino, Enrique Espinosa, Josep Maria Piulats, Carmela Rodriguez-Lopez, Reinhard Dummer, Igor Bondarenko, Valeriy Evgenovych Cheshuk, Yevhen Hotko, Eric Bernicker, Richard Carvajal, Sunandana Chandra, Bartosz Chmielowski, Brendan Curti, Jason Luke, Omid Hamid, Leonel Hernandez-Aya, Alexandra Ikeguchi, Kari Kendra, Kevin Kim, John Kirkwood, Jose Lutzky, Mohammed Milhem, Marlana Orloff, Igor Puzanov, Sunil Reddy, Matthew Rieth, April Salama, Alexander Shoushtari, Ryan Sullivan, Melinda Yushak. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>N Engl J Med</i> . 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. PMID: 34551229.	91.245
522	Scarpato L, Festino L, Vanella V, Madonna G, Mastroianni M, Palla M, Ascierto PA . Dermatologic adverse events associated with targeted therapies for melanoma. <i>Expert Opin Drug Saf</i> . 2021 Oct 1. doi: 10.1080/14740338.2022.1986000. Epub ahead of print. PMID: 34595993.	4.250
523	Weber JS, Ascierto PA , Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>Eur J Cancer</i> . 2021 Oct 15:S0959-8049(21)00555-4. doi: 10.1016/j.ejca.2021.08.028. Epub ahead of print. PMID: 34663559.	9.162
524	Ziogas DC, Mandellos D, Theocharopoulos C, Lialios PP, Bouros S, Ascierto PA , Gogas H. Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. <i>Front Oncol</i> . 2021 Oct 15;11:727010. doi: 10.3389/fonc.2021.727010. PMID: 34722270; PMCID: PMC8554100.	6.244
525	Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutillo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA , Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. <i>JAMA Oncol</i> . 2021 Nov 4. doi: 10.1001/jamaoncol.2021.4960. Epub ahead of print. PMID: 34734989.	31.777
526	Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto P , Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Target Oncol</i> . 2021 Nov 10. doi: 10.1007/s11523-021-00850-1. Epub ahead of print. PMID: 34755244.	4.493
527	Maraolo AE, Crispo A, Piezzo M, Di Gennaro P, Vitale MG, Mallardo D, Ametrano L, Celentano E, Cuomo A, Ascierto PA , Cascella M. The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. <i>J Clin Med</i> . 2021 Oct 25;10(21):4935. doi: 10.3390/jcm10214935. PMID: 34768455; PMCID: PMC8584705.	4.241

528	Maio M, Carlino MS, Joshua AM, McWhirter E, Ribas A, Ascierto PA , Miller WH Jr, Butler MO, Ferrucci PF, Zielinski RR, Del Vecchio M, Gasal E, Ghorri R, Diede SJ, Croydon E, Hamid O. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Eur J Cancer. 2021 Nov 17:S0959-8049(21)00621-3. doi: 10.1016/j.ejca.2021.09.024. Epub ahead of print. PMID: 34801354.	9.162
529	Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, BAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA , Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021 Nov 24;JCO2102229. doi: 10.1200/JCO.21.02229. Epub ahead of print. PMID: 34818112.	44.544
5230	Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA , Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoun N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2021 Dec 21;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub ahead of print. PMID: 34952480.	9.162
531	Coppola A, Buonerba C, Cardinale D, Lo Conte G, Sansone D, Rofrano G, De Vita S, Morgante M, Triassi M, Atripaldi L, Brambilla G, Sabatino R, Pierri A, Pacella D, Pizzolante A, Pierri B, Ferrucci V, Zollo M, Capasso M, Stringhini S, Ascierto PA , Roperto S, Cerino P. Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up. Front Public Health. 2021 Dec 17;9:801609. doi: 10.3389/fpubh.2021.801609. PMID: 34976939; PMCID: PMC8718636.	3.018
532	Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA , Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285.	91.245
533	Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA , Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 Jan 14;JCO2101601. doi: 10.1200/JCO.21.01601. Epub ahead of print. PMID: 35030011.	44.544
534	Weber J, Mandala M, Ascierto PA , Larkin J. Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al. J Immunother Cancer. 2022 Jan;10(1):e004347. doi: 10.1136/jitc-2021-004347. PMID: 35042825.	13.751
535	Ottaviano M, Giunta EF, Marandino L, Tortora M, Attademo L, Bosso D, Cardalesi C, Fabbrocini A, Rosanova M, Silvestri A, Montella L, Tammaro P, Marra E, Trojaniello C, Vitale MG, Simeone E, Troiani T, Daniele B, Ascierto PA . Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicine. 2022 Jan 11;10(1):150. doi: 10.3390/biomedicine10010150. PMID: 35052829.	6.081
536	Stanganelli I, Spagnolo F, Argenziano G, Ascierto PA , Bassetto F, Bossi P, Donato V, Massi D, Massone C, Patuzzo R, Pellacani G, Quaglino P, Queirolo P, Zalaudek I, Palmieri G, On Behalf Of Italian Melanoma Intergroup Imi. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers (Basel). 2022 Jan 13;14(2):377. doi: 10.3390/cancers14020377. PMID: 35053539.	6.639
537	Eggermont AM, Ascierto PA , Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. PIVOT-12: a Phase III study of adjuvant bimepegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022 Jan 25. doi: 10.2217/fon-2021-1286. Epub ahead of print. PMID: 35073733.	3.404
538	Mallardo D, Cortellini A, Capone M, Madonna G, Pinato DJ, Warren S, Simeone E, Ascierto PA . Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of Lag-3: a transcriptomic analysis on retrospective cohort. Ann Oncol. 2022 Jan 24:S0923-7534(22)00016-3. doi: 10.1016/j.annonc.2022.01.007. Epub ahead of print. PMID: 35085735.	32.976

539	van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA , Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Ann Surg Oncol</i> . 2022 Jan 28. doi: 10.1245/s10434-021-11236-y. Epub ahead of print. PMID: 35089452.	5.344
540	Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA , Santoro A, Shah M, Asselah J, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. <i>Lancet Gastroenterol Hepatol</i> . 2022 Jan 31:S2468-1253(21)00382-4. doi: 10.1016/S2468-1253(21)00382-4. Epub ahead of print. PMID: 35114169.	18.486
541	Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA . Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. <i>Ann Oncol</i> . 2022 Feb 4:S0923-7534(22)00103-X. doi: 10.1016/j.annonc.2022.01.076. Epub ahead of print. PMID: 35131452.	32.976
542	Costa Svedman F, Jalsenius M, Höiom V, Grozman V, Bergqvist M, Söderdahl F, Eriksson H, Rotstein S, Ny L, Ascierto PA , Brage SE, Helgadottir H. Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers (Basel)</i> . 2022 Jan 29;14(3):702. doi: 10.3390/cancers14030702. PMID: 35158970.	6.639
543	Cristiani CM, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP, Viglietto G, Ascierto PA , Spits H, Carbone E. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. <i>Front Immunol</i> . 2022 Jan 31;13:811131. doi: 10.3389/fimmu.2022.811131. PMID: 35173725; PMCID: PMC8841353.	6.429
544	Troisi J, Tafuro M, Lombardi M, Scala G, Richards SM, Symes SJK, Ascierto PA , Delrio P, Tatangelo F, Buonerba C, Pierri B, Cerino P. A Metabolomics-Based Screening Proposal for Colorectal Cancer. <i>Metabolites</i> . 2022 Jan 25;12(2):110. doi: 10.3390/metabo12020110. PMID: 35208185; PMCID: PMC8878838.	4.932
545	Conte P, Ascierto PA , Patelli G, Danesi R, Vanzulli A, Sandomenico F, Tarsia P, Cattelan A, Comes A, De Laurentiis M, Falcone A, Regge D, Richeldi L, Siena S. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. <i>ESMO Open</i> . 2022 Feb 23;7(2):100404. doi: 10.1016/j.esmoop.2022.100404. Epub ahead of print. PMID: 35219244; PMCID: PMC8881716.	5.329
546	Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>Eur J Cancer</i> . 2022 Feb 24;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Epub ahead of print. PMID: 35220182.	9.162
547	Schuler M, Zimmer L, Kim KB, Sosman JA, Ascierto PA , Postow MA, De Vos F, van Herpen CML, Carlino MS, Johnson DB, Berking C, Reddy MB, Harney AS, Berlin JD, Amaria RN. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-Mutant Melanoma. <i>Clin Cancer Res</i> . 2022 Mar 16:clincanres.3872.2021. doi: 10.1158/1078-0432.CCR-21-3872. Epub ahead of print. PMID: 35294522.	12.531
548	Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA , Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemother Pharmacol</i> . 2022 Mar 17. doi: 10.1007/s00280-022-04414-6. Epub ahead of print. PMID: 35298698.	3.333
549	Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, McKean M, Santos ES, Brill K, Polli A, Pietro AD, Ascierto PA . STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. <i>Future Oncol</i> . 2022 Mar 11. doi: 10.2217/fon-2021-1486. Epub ahead of print. PMID: 35272485.	3.404

550	Turiello R, Capone M, Morretta E, Monti MC, Madonna G, Azzaro R, Del Gaudio P, Simeone E, Sorrentino A, Ascierto PA , Morello S. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. <i>J Immunother Cancer</i> . 2022 Mar;10(3):e004043. doi: 10.1136/jitc-2021-004043. PMID: 35273100.	13.751
551	Carbone ML, Madonna G, Capone A, Bove M, Mastroeni S, Levati L, Capone M, Ascierto PA , De Galitiis F, D'Atri S, Fortes C, Volpe E, Failla CM. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. <i>Sci Rep</i> . 2022 Mar 31;12(1):5448. doi: 10.1038/s41598-022-09373-9. PMID: 35361879; PMCID: PMC8971439.	4.380
552	Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA , Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> . 2022 Mar 31:S0140-6736(22)00562-1. doi: 10.1016/S0140-6736(22)00562-1. Epub ahead of print. PMID: 35367007.	79.321
553	Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA , Stigliano L, Strippoli S. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>J Transl Med</i> . 2022 Apr 5;20(1):159. doi: 10.1186/s12967-022-03359-x. PMID: 35382857.	8.440
554	Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto P, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh H, Rammensee HG, Buonaguro L. Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. <i>Clin Cancer Res</i> . 2022 Apr 14:clincanres.4424.2021. doi: 10.1158/1078-0432.CCR-21-4424. Epub ahead of print. PMID: 35421231.	12.531
555	Ascierto PA , Butterfield LH, Finn OJ, Futreal A, Hamid O, LaVallee T, Postow MA, Puzanov I, Sosman J, Fox BA, Hwu P. The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. <i>J Transl Med</i> . 2022 Apr 21;20(1):179. doi: 10.1186/s12967-022-03384-w. PMID: 35449104; PMCID: PMC9022317.	8.440
556	Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA , Long GV. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. <i>N Engl J Med</i> . 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768. PMID: 35476655.	91.245
557	Ascierto PA , Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. <i>J Transl Med</i> . 2022 May 10;20(1):200. doi: 10.1186/s12967-022-03406-7. PMID: 35538491; PMCID: PMC9087170.	8.440
558	Homicsko K, Dummer R, Hoeller C, Wolchok JD, Hodi FS, Larkin J, Ascierto PA , Atkinson V, Robert C, Postow MA, Re S, Paulucci D, Dobler D, Michielin O. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers (Basel)</i> . 2022 May 5;14(9):2300. doi: 10.3390/cancers14092300. PMID: 35565428; PMCID: PMC9103038.	6.639
559	Maio M, Amonkar MM, Norquist JM, Ascierto PA , Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Wang R, Norwood K, Marabelle A. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. <i>Eur J Cancer</i> . 2022 May 16;169:188-197. doi: 10.1016/j.ejca.2022.03.040. Epub ahead of print. PMID: 35588692.	9.162
560	Spada F, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quaglino P, Queirolo P, Ascierto PA ; DELPHI Panel Members. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. <i>J Immunother Cancer</i> . 2022 Jun;10(6):e004742. doi: 10.1136/jitc-2022-004742. PMID: 35701070.	13.751
561	Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA . Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. <i>J Transl Med</i> . 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x. PMID: 35706041.	8.440

562	Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA , Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>J Clin Oncol</i> . 2022 Jun 16;JCO2200202. doi: 10.1200/JCO.22.00202. Epub ahead of print. PMID: 35709414.	44.544
563	Palla M, Scarpato L, Di Trollo R, Ascierto PA . Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research. <i>J Immunother Cancer</i> . 2022 Jun;10(6):e004397. doi: 10.1136/jitc-2021-004397. PMID: 35710292.	13.751
564	Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhavé P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA , Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Ann Oncol</i> . 2022 Jun 15:S0923-7534(22)01731-8. doi: 10.1016/j.annonc.2022.06.004. Epub ahead of print. PMID: 35716907.	32.976
565	Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA . Spaltalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). <i>J Immunother Cancer</i> . 2022 Jun;10(6):e004226. doi: 10.1136/jitc-2021-004226. PMID: 35728875.	13.751
566	Bhavé P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, Blank CU, Ramelyte E, Kähler KC, Roy S, Ascierto PA , Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. <i>J Immunother Cancer</i> . 2022 Jul;10(7):e004668. doi: 10.1136/jitc-2022-004668. PMID: 35793872.	13.751
567	Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA , Johnson DB, Carlino M, Menzies A, Long G. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. <i>J Immunother Cancer</i> . 2022 Jul;10(7):e004610. doi: 10.1136/jitc-2022-004610. PMID: 35798536.	13.751
568	Granata V, Simonetti I, Fusco R, Setola SV, Izzo F, Scarpato L, Vanella V, Festino L, Simeone E, Ascierto PA , Petrillo A. Management of cutaneous melanoma: radiologists challenging and risk assessment. <i>Radiol Med</i> . 2022 Jul 14. doi: 10.1007/s11547-022-01522-4. Epub ahead of print. PMID: 35834109.	6.313
569	Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liskay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, di Pietro A, Cantey-Kiser J, Edwards M, Ascierto PA . COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. <i>J Clin Oncol</i> . 2022 Jul 21;JCO2102659. doi: 10.1200/JCO.21.02659. Epub ahead of print. PMID: 35862871.	44.544
570	Simonetti I, Trovato P, Granata V, Picone C, Fusco R, Setola SV, Mattace Raso M, Caracò C, Ascierto PA , Sandomenico F, Petrillo A. Imaging Assessment of Interval Metastasis from Melanoma. <i>J Pers Med</i> . 2022 Jun 24;12(7):1033. doi: 10.3390/jpm12071033. PMID: 35887530; PMCID: PMC9315548.	3.370
571	Dummer R, Queirolo P, Abajo Guijarro AM, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA , Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liskay G, de la Cruz Merino L, Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncol</i> . 2022 Aug 5:S1470-2045(22)00452-1. doi: 10.1016/S1470-2045(22)00452-1. Epub ahead of print. PMID: 35940183.	54.433
572	Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelsen M, Ascierto PA , Mandalá M. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. <i>Eur J Cancer</i> . 2022 Aug 11;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub ahead of print. PMID: 35964471.	9.162
573	Cristinziano L, Modestino L, Capone M, Madonna G, Mallardo D, Giannarelli D, D'Angelo G, Ferrara AL, Loffredo S, Varricchi G, Vanella V, Festino L, Ascierto PA , Galdiero MR. PD-L1+ neutrophils as novel	6.429

	biomarkers for stage IV melanoma patients treated with nivolumab. <i>Front Immunol.</i> 2022 Aug 9;13:962669. doi: 10.3389/fimmu.2022.962669. PMID: 36016960; PMCID: PMC9398490.	
574	Ascierto PA , Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. <i>J Clin Oncol.</i> 2022 Sep 1;JCO2102961. doi: 10.1200/JCO.21.02961. Epub ahead of print. PMID: 36049147.	44.544
575	Ascierto PA , Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). <i>J Transl Med.</i> 2022 Sep 4;20(1):391. doi: 10.1186/s12967-022-03592-4. PMID: 36058945.	8.440
576	Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhashi T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Yoshino T, Taniguchi H, Bifulco C, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Marincola FM, Ascierto PA , Fox BA, Pagès F, Kawakami Y, Galon J. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. <i>Cancers (Basel).</i> 2022 Sep 6;14(18):4346. doi: 10.3390/cancers14184346. PMID: 36139506; PMCID: PMC9497086.	6.575
577	Horgan D, Baird AM, Middleton M, Mihaylova Z, Van Meerbeeck JP, Vogel-Claussen J, Van Schil PE, Malvey J, Ascierto PA , Dube F, Zaiac M, Lal JA, Kamińska-Winciorek G, Donia M, André T, Kozaric M, Osterlund P, Dumitrascu DL, Bertolaccini L. How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? <i>Healthcare (Basel).</i> 2022 Aug 25;10(9):1618. doi: 10.3390/healthcare10091618. PMID: 36141230; PMCID: PMC9498919.	6.575
578	Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA , Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). <i>J Clin Oncol.</i> 2022 Sep 26;JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.	44.544
579	Atkins MB, Abu-Sbeih H, Ascierto PA , Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). <i>J Immunother Cancer.</i> 2022 Sep;10(9):e005413. doi: 10.1136/jitc-2022-005413. PMID: 36175037; PMCID: PMC9528604.	13.751
580	Mallardo D, Simeone E, Vanella V, Vitale MG, Palla M, Scarpato L, Paone M, De Cristofaro T, Borzillo V, Cortellini A, Sparano F, Pignata S, Fiore F, Caracò C, Maiolino P, Petrillo A, Cavalcanti E, Lastoria S, Muto P, Budillon A, Warren S, Ascierto PA . Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization. <i>J Transl Med.</i> 2022 Sep 30;20(1):436. doi: 10.1186/s12967-022-03643-w. PMID: 36180872; PMCID: PMC9523893.	8.440
581	Khattak MA, Luke JJ, Long GV, Ascierto PA , Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. <i>Eur J Cancer.</i> 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. PMID: 36202690.	10.002
582	Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto	54.433

	PA ; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. PMID: 36265502.	
583	Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, Ferrante L, Tammaro R, Morleo M, De Cegli R, Iuliano A, Testa M, Andreone F, Ciliberto G, Clery E, Troncone G, Palma G, Arra C, Barbieri A, Capone M, Madonna G, Ascierto PA , Lanfranccone L, Indrieri A, Franco B. Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. <i>Cell Rep.</i> 2022 Nov 8;41(6):111601. doi: 10.1016/j.celrep.2022.111601. PMID: 36351409.	9.995
584	Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, Ascierto PA , Mancini R, Ciliberto G. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. <i>Theranostics</i> 2022; 12(17):7420-7430. doi:10.7150/thno.77761.	11.600
585	Ascierto PA , Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. <i>J Immunother Cancer.</i> 2022 Dec;10(12):e005082. doi: 10.1136/jitc-2022-005082. PMID: 36455990; PMCID: PMC9716987.	13.751
586	Ascierto PA , Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. <i>Lancet Oncol.</i> 2023 Jan;24(1):33-44. doi: 10.1016/S1470-2045(22)00687-8. Epub 2022 Nov 29. PMID: 36460017.	54.433
587	Lee J, Ahmed T, Maurichi A, Di Guardo L, Stagno AM, Warburton L, Taylor AM, Livingstone E, Rehman S, Khattak A, Kahler KC, Vanella V, Atkinson V, Millward M, Schadendorf D, Johnson DB, Ascierto PA , Hauschild A, Lo SN, Long GV, Menzies AM, Carlino MS. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. <i>Eur J Cancer.</i> 2023 Jan;179:87-97. doi: 10.1016/j.ejca.2022.11.009. Epub 2022 Nov 12. PMID: 36509002.	9.433
588	Auricchio L, Brambilla N, Cazzaniga ME, Bonfanti P, Milleri S, Ascierto PA , Capici S, Vitalini C, Girolami F, Giacobelli G, Caselli G, Visintin M, Fanti F, Ghirri M, Conforti A, Compagnone M, Lione L, Salvatori E, Pinto E, Muzi A, Marra E, Palombo F, Roscilli G, Manenti A, Montomoli E, Cadossi M, Rovati LC. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19. <i>Mol Ther.</i> 2022 Dec 27:S1525-0016(22)00753-5. doi: 10.1016/j.ymthe.2022.12.017. Epub ahead of print. PMID: 36575794; PMCID: PMC9792419.	12.910
589	Long GV, Luke JJ, Fukunaga-Kalabis M, Ascierto PA . Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply. <i>Lancet Oncol.</i> 2023 Jan;24(1):e8. doi: 10.1016/S1470-2045(22)00753-7. PMID: 36603931.	54.433
590	Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, Vliet SVL, Knijn N, Muşină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Patel P, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA , Fox BA, Pagès F, Galon J. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. <i>Cancers (Basel).</i> 2023 Jan 8;15(2):418. doi: 10.3390/cancers15020418. PMID: 36672367; PMCID: PMC9856473.	6.639
591	Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, Ascierto PA , Petrillo A. Immunotherapy Assessment: A New Paradigm for Radiologists. <i>Diagnostics (Basel).</i> 2023 Jan 13;13(2):302. doi: 10.3390/diagnostics13020302. PMID: 36673112; PMCID: PMC9857844.	3.992
592	Núñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmayr S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA , Dummer R, Jäger E, Driessen	17.000

	C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. <i>Med (N Y)</i> . 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. PMID: 36693381.	
593	Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wiltshagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA , van Akkooi ACJ, van de Poll-Franse LV. Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. <i>Crit Rev Oncol Hematol</i> . 2023 Feb 1;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub ahead of print. PMID: 36736511.	6.312
594	Di Cosola M, Spirito F, Saracino P, Caponio VC, Diaz-Flores Garcia V, Madonna G, Ascierto P , Lo Muzio L. Oral immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study. <i>Minerva Dent Oral Sci</i> . 2022 Dec;71(6):318-323. doi: 10.23736/S2724-6329.22.04768-4. PMID: 36760201.	0
595	Ascierto PA , Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. <i>J Clin Oncol</i> . 2023 Feb 13;JCO2202072. doi: 10.1200/JCO.22.02072. Epub ahead of print. PMID: 36780608.	50.717
596	Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C, Vitale MG, Ottaviano M, Capone M, Madonna G, Sparano F, Cioli E, Scarpato L, Palla M, Di Trollo R, Meinardi P, Caracò C, Ferrara G, Muto P, Cavalcanti E, Ascierto PA . IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. <i>J Transl Med</i> . 2023 Feb 23;21(1):140. doi: 10.1186/s12967-023-03971-5. PMID: 36823670; PMCID: PMC9948392.	8.440
597	Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, Ascierto PA , Lebbe C, Sandhu S. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. <i>Eur J Cancer</i> . 2023 Jan 30;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Epub ahead of print. PMID: 36842413.	10.002
598	Ascierto PA , Cioli E, Chiarion-Sileni V, Quagliano P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A, Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. <i>Front Oncol</i> . 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. PMID: 36845751; PMCID: PMC9949553.	6.244
599	Costantini S, Madonna G, Di Gennaro E, Capone F, Bagnara P, Capone M, Sale S, Nicastro C, Atripaldi L, Fiorentino G, Parrella R, Montesarchio V, Atripaldi L, Ascierto PA , Budillon A. New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. <i>Int J Mol Sci</i> . 2023 Mar 3;24(5):4922. doi: 10.3390/ijms24054922. PMID: 36902351; PMCID: PMC10003544.	6.208
600	Monfrecola G, Fornaro L, Ascierto PA , Scarpato L, Anniciello AM, Fabbrocini G, Marasca C. Could wide tattoo delay the early diagnosis of cutaneous melanoma? <i>J Eur Acad Dermatol Venereol</i> . 2023 Mar 13. doi: 10.1111/jdv.19037. Epub ahead of print. PMID: 36912734.	9.228
601	Atkins MB, Ascierto PA , Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. <i>J Immunother Cancer</i> . 2023 Mar;11(3):e005923. doi: 10.1136/jitc-2022-005923. PMID: 36918225; PMCID: PMC10016252.	12.458
602	de Braud F, Doms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA , Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. <i>J Clin Oncol</i> . 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. PMID: 36947734.	50.717
603	Trojaniello C, Sparano F, Cioli E, Ascierto PA . Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. <i>Curr Oncol Rep</i> . 2023 Jun;25(6):623-634. doi: 10.1007/s11912-023-01402-8. Epub 2023 Mar 30. PMID: 36995534; PMCID: PMC10164000.	4.700
604	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Vecchia A, Di Giacomo AM, Festino L,	10.300

	Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA , Aerts JGJV, Berardi R. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. PMID: 37042716; PMCID: PMC10323889.	
605	Larkin J, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA , Weber J. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clin Cancer Res. 2023 Apr 14;CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145. Epub ahead of print. PMID: 37058595.	11.500
606	Ascierto PA , Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med. 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. PMID: 37072748; PMCID: PMC10114457.	8.440
607	Ascierto PA , Brentjens R, Khleif SN, Odunsi K, Rezvani K, Ruella M, Sullivan RJ, Fox BA, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. J Transl Med. 2023 Apr 22;21(1):275. doi: 10.1186/s12967-023-04117-3. PMID: 37087493; PMCID: PMC10122806.	8.440
608	Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA , Ficorella C, Pinato DJ. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023 May 1;CCR-22-3116. doi: 10.1158/1078-0432.CCR-22-3116. Epub ahead of print. PMID: 37125965.	11.500
609	Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalho S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglino P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P , Sersa G, Valpione S; Melanoma Delphi Working Group. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. Br J Surg. 2023 Jun 12;110(7):818-830. doi: 10.1093/bjs/znad105. PMID: 37131298.	9.600
610	Galati D, Zanotta S, Capone M, Madonna G, Mallardo D, Romanelli M, Simeone E, Festino L, Sparano F, Azzaro R, De Filippi R, Pinto A, Paulos CM, Ascierto PA . Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. J Transl Med. 2023 May 11;21(1):318. doi: 10.1186/s12967-023-04184-6. PMID: 37170241; PMCID: PMC10176780.	8.440
611	Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA , Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1. PMID: 37193799.	87.244
612	Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khatkhat A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2023 Apr 29;S0959-8049(23)00217-4. doi: 10.1016/j.ejca.2023.04.016. Epub ahead of print. PMID: 37277264.	8.400
613	Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA , Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma:	12.458

	a phase 1 study. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. PMID: 37286303; PMCID: PMC10254987.	
614	Clifton GT, Rothenberg M, Ascierto PA , Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023 Jun;11(6):e006773. doi: 10.1136/jitc-2023-006773. PMID: 37290925; PMCID: PMC10254706.	12.458
615	Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P , Weber J, Kirchhoff T. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 May 18;112923. doi: 10.1016/j.ejca.2023.05.011. Epub ahead of print. PMID: 37301715.	8.400
616	Monfrecola G, Fornaro L, Ascierto PA , Scarpato L, Costa C, Martora F, Marasca C. Comment on the relationship between wide tattoos and delayed melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023 Jun 12. doi: 10.1111/jdv.19247. Epub ahead of print. PMID: 37306218.	9.228
617	Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA , Maio M. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol. 2023 Jun 12;JCO2202199. doi: 10.1200/JCO.22.02199. Epub ahead of print. PMID: 37307514.	50.717
618	Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pietro AD, Cantey-Kiser J, Edwards M, Ascierto PA . COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. Future Oncol. 2023 May;19(16):1091-1098. doi: 10.2217/fon-2022-1258. Epub 2023 Jun 13. PMID: 37309702.	3.674
619	Mannino M, Piccerillo A, Fabbrocini G, Quaglini P, Argenziano G, Dika E, Ascierto PA , Pellacani G, Longo C, Fagnoli MC, Bianchi L, Calzavara-Pinton P, Zalaudek I, Fava P, Scalvenzi M, Bocchino E, Di Stefani A, Peris K. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of HHI safety and effectiveness. Dermatology. 2023 Jun 13. doi: 10.1159/000531280. Epub ahead of print. PMID: 37311439.	5.197
620	de Braud F, Doms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA , Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. PMID: 36947734.	50.717
621	Trojaniello C, Sparano F, Cioli E, Ascierto PA . Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. Curr Oncol Rep. 2023 Jun;25(6):623-634. doi: 10.1007/s11912-023-01402-8. Epub 2023 Mar 30. PMID: 36995534; PMCID: PMC10164000.	4.700
622	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Vecchia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA , Aerts JGJV, Berardi R. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. PMID: 37042716; PMCID: PMC10323889.	10.300
623	Larkin J, Del Vecchio M, Mandalà M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA , Weber J. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clin Cancer Res. 2023 Apr 14;CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145. Epub ahead of print. PMID: 37058595.	11.500
624	Ascierto PA , Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. The "Great Debate" at	8.440

	Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med. 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. PMID: 37072748; PMCID: PMC10114457.	
625	Ascierto PA , Brentjens R, Khleif SN, Odunsi K, Rezvani K, Ruella M, Sullivan RJ, Fox BA, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. J Transl Med. 2023 Apr 22;21(1):275. doi: 10.1186/s12967-023-04117-3. PMID: 37087493; PMCID: PMC10122806.	8.440
626	Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA , Ficorella C, Pinato DJ. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023 May 1;CCR-22-3116. doi: 10.1158/1078-0432.CCR-22-3116. Epub ahead of print. PMID: 37125965.	11.500
627	Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalhal S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglini P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P , Sersa G, Valpione S; Melanoma Delphi Working Group. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. Br J Surg. 2023 Jun 12;110(7):818-830. doi: 10.1093/bjs/znad105. PMID: 37131298.	9.600
628	Galati D, Zanotta S, Capone M, Madonna G, Mallardo D, Romanelli M, Simeone E, Festino L, Sparano F, Azzaro R, De Filippi R, Pinto A, Paulos CM, Ascierto PA . Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. J Transl Med. 2023 May 11;21(1):318. doi: 10.1186/s12967-023-04184-6. PMID: 37170241; PMCID: PMC10176780.	8.440
629	Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA , Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1. PMID: 37193799.	87.244
630	Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2023 Apr 29;S0959-8049(23)00217-4. doi: 10.1016/j.ejca.2023.04.016. Epub ahead of print. PMID: 37277264.	8.400
631	Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA , Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. PMID: 37286303; PMCID: PMC10254987.	12.458
632	Clifton GT, Rothenberg M, Ascierto PA , Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023 Jun;11(6):e006773. doi: 10.1136/jitc-2023-006773. PMID: 37290925; PMCID: PMC10254706.	12.458
633	Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P , Weber J, Kirchhoff T. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 May 18;112923. doi: 10.1016/j.ejca.2023.05.011. Epub ahead of print. PMID: 37301715.	8.400
634	Monfrecola G, Fornaro L, Ascierto PA , Scarpato L, Costa C, Martora F, Marasca C. Comment on the relationship between wide tattoos and delayed melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023 Jun 12. doi: 10.1111/jdv.19247. Epub ahead of print. PMID: 37306218.	9.228

635	Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA , Maio M. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. <i>J Clin Oncol</i> . 2023 Jun 12;JCO2202199. doi: 10.1200/JCO.22.02199. Epub ahead of print. PMID: 37307514.	50.717
636	Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pietro AD, Cantey-Kiser J, Edwards M, Ascierto PA . COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. <i>Future Oncol</i> . 2023 May;19(16):1091-1098. doi: 10.2217/fon-2022-1258. Epub 2023 Jun 13. PMID: 37309702.	3.674
637	Mannino M, Piccerillo A, Fabbrocini G, Quagliano P, Argenziano G, Dika E, Ascierto PA , Pellacani G, Longo C, Fargnoli MC, Bianchi L, Calzavara-Pinton P, Zalaudek I, Fava P, Scalvenzi M, Bocchino E, Di Stefani A, Peris K. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of HHI safety and effectiveness. <i>Dermatology</i> . 2023 Jun 13. doi: 10.1159/000531280. Epub ahead of print. PMID: 37311439.	5.197
638	de Braud F, Doms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA , Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. <i>J Clin Oncol</i> . 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. PMID: 36947734.	50.717
639	Trojaniello C, Sparano F, Cioli E, Ascierto PA . Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. <i>Curr Oncol Rep</i> . 2023 Jun;25(6):623-634. doi: 10.1007/s11912-023-01402-8. Epub 2023 Mar 30. PMID: 36995534; PMCID: PMC10164000.	4.700
640	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Vecchia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA , Aerts JGJV, Berardi R. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. <i>J Natl Cancer Inst</i> . 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. PMID: 37042716; PMCID: PMC10323889.	10.300
641	Larkin J, Del Vecchio M, Mandalà M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA , Weber J. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. <i>Clin Cancer Res</i> . 2023 Apr 14;CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145. Epub ahead of print. PMID: 37058595.	11.500
642	Ascierto PA , Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. <i>J Transl Med</i> . 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. PMID: 37072748; PMCID: PMC10114457.	8.440
643	Ascierto PA , Brentjens R, Khleif SN, Odunsi K, Rezvani K, Ruella M, Sullivan RJ, Fox BA, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. <i>J Transl Med</i> . 2023 Apr 22;21(1):275. doi: 10.1186/s12967-023-04117-3. PMID: 37087493; PMCID: PMC10122806.	8.440
644	Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA , Ficorella C, Pinato DJ. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. <i>Clin Cancer Res</i> . 2023 May 1;CCR-22-3116. doi: 10.1158/1078-0432.CCR-22-3116. Epub ahead of print. PMID: 37125965.	11.500

645	Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalhal S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglino P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P , Sersa G, Valpione S; Melanoma Delphi Working Group. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. Br J Surg. 2023 Jun 12;110(7):818-830. doi: 10.1093/bjs/znad105. PMID: 37131298.	9.600
646	Galati D, Zanotta S, Capone M, Madonna G, Mallardo D, Romanelli M, Simeone E, Festino L, Sparano F, Azzaro R, De Filippi R, Pinto A, Paulos CM, Ascierto PA . Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. J Transl Med. 2023 May 11;21(1):318. doi: 10.1186/s12967-023-04184-6. PMID: 37170241; PMCID: PMC10176780.	8.440
647	Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA , Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1. PMID: 37193799.	87.244
648	Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2023 Apr 29:S0959-8049(23)00217-4. doi: 10.1016/j.ejca.2023.04.016. Epub ahead of print. PMID: 37277264.	8.400
649	Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA , Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. PMID: 37286303; PMCID: PMC10254987.	12.458
650	Clifton GT, Rothenberg M, Ascierto PA , Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023 Jun;11(6):e006773. doi: 10.1136/jitc-2023-006773. PMID: 37290925; PMCID: PMC10254706.	12.458
651	Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P , Weber J, Kirchhoff T. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 May 18:112923. doi: 10.1016/j.ejca.2023.05.011. Epub ahead of print. PMID: 37301715.	8.400
652	Monfrecola G, Fornaro L, Ascierto PA , Scarpato L, Costa C, Martora F, Marasca C. Comment on the relationship between wide tattoos and delayed melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023 Jun 12. doi: 10.1111/jdv.19247. Epub ahead of print. PMID: 37306218.	9.228
653	Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbe C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA , Maio M. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol. 2023 Jun 12;JCO2202199. doi: 10.1200/JCO.22.02199. Epub ahead of print. PMID: 37307514.	50.717
654	Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pietro AD, Cantey-Kiser J, Edwards M, Ascierto PA . COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. Future Oncol. 2023 May;19(16):1091-1098. doi: 10.2217/fon-2022-1258. Epub 2023 Jun 13. PMID: 37309702.	3.674
655	Mannino M, Piccerillo A, Fabbrocini G, Quaglino P, Argenziano G, Dika E, Ascierto PA , Pellacani G, Longo C, Fargnoli MC, Bianchi L, Calzavara-Pinton P, Zalaudek I, Fava P, Scalvenzi M, Bocchino E, Di Stefani A, Peris K. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation	5.197

	of HHI safety and effectiveness. <i>Dermatology</i> . 2023 Jun 13. doi: 10.1159/000531280. Epub ahead of print. PMID: 37311439.	
656	Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto PA , Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib. <i>Tumori</i> . 2023 Jul 7:3008916231179251. doi: 10.1177/03008916231179251. Epub ahead of print. PMID: 37417313.	2.438
657	Bossi P, Ascierto PA , Basset-Seguín N, Dreno B, Dummer R, Hauschild A, Mohr P, Kaufmann R, Pellacani G, Puig S, Moreno-Ramírez D, Robert C, Stratigos A, Gutzmer R, Queirolo P, Quaglino P, Peris K. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. <i>Crit Rev Oncol Hematol</i> . 2023 Sep;189:104066. doi: 10.1016/j.critrevonc.2023.104066. Epub 2023 Jul 11. PMID: 37442495.	6.625
658	Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA , Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liskay G, de la Cruz Merino L, Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncol</i> . 2023 Jul 14:S1470-2045(23)00334-0. doi: 10.1016/S1470-2045(23)00334-0. Epub ahead of print. PMID: 37459873.	54.433
659	Ascierto PA , Avallone A, Bifulco C, Bracarda S, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, Kirchhoff T, Klebanoff CA, Lesinski GB, Monette A, Neyns B, Odunsi K, Paulos CM, Powell DJ Jr, Rezvani K, Segal BH, Singh N, Sullivan RJ, Fox BA, Puzanov I. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). <i>J Transl Med</i> . 2023 Jul 20;21(1):488. doi: 10.1186/s12967-023-04329-7. PMID: 37475035; PMCID: PMC10360352.	8.440
660	Ascierto PA , Dummer R, Gogas HJ, Arance A, Mandala M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Robert C, Flaherty KT. Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. <i>J Clin Oncol</i> . 2023 Oct 10;41(29):4621-4631. doi: 10.1200/JCO.22.02322. Epub 2023 Jul 28. PMID: 37506329.	50.717
661	Ascierto PA , Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). <i>J Transl Med</i> . 2023 Jul 28;21(1):508. doi: 10.1186/s12967-023-04325-x. PMID: 37507765; PMCID: PMC10375730.	8.440
662	Modestino L, Cristinziano L, Trocchia M, Ventrì A, Capone M, Madonna G, Loffredo S, Ferrara AL, Romanelli M, Simeone E, Varricchi G, Rossi FW, de Paulis A, Marone G, Ascierto PA , Galdiero MR. Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps. <i>Cancer Immunol Immunother</i> . 2023 Oct;72(10):3363-3376. doi: 10.1007/s00262-023-03493-5. Epub 2023 Jul 31. PMID: 37525065; PMCID: PMC10491523.	5.800
663	Ascierto PA , Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile. <i>Eur J Cancer</i> . 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. PMID: 37549531.	8.400
664	Martora F, Ascierto P , Palla M, Costa C, D'Andrea M, Di Trollo R, Scarpato L, Marasca C. Tirbanibulin: An alternative topical approach to manage superficial Basal Cell Carcinoma. <i>Clin Exp Dermatol</i> . 2023 Aug 11:llad271. doi: 10.1093/ced/llad271. Epub ahead of print. PMID: 37566741.	4.481
665	Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA , Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Systemic Therapy for Melanoma: ASCO Guideline Update. <i>J Clin Oncol</i> . 2023 Aug 14:JCO2301136. doi: 10.1200/JCO.23.01136. Epub ahead of print. PMID: 37579248.	50.717
666	Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA , Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. <i>J Clin Oncol</i> . 2023 Aug 31:JCO2300172. doi: 10.1200/JCO.23.00172. Epub ahead of print. PMID: 37651676.	50.717

667	Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M, Facchini AB, Ong S, Maiolino P, Caracò C, Church S, Cavalcanti E, Warren S, Budillon A, Cesano A, Simeone E, Chiodini P, Ascierto PA . CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. <i>J Transl Med</i> . 2023 Sep 8;21(1):610. doi: 10.1186/s12967-023-04419-6. PMID: 37684649; PMCID: PMC10492378.	8.440
668	Martora F, Ascierto PA , Scalvenzi M, Palla M, Costa C, D'Andrea M, Di Trollo R, Scarpato L, Marasca C. Tirbanibulin ointment to manage recurrence of superficial Basal Cell Carcinoma of the face: report of a case. <i>Clin Exp Dermatol</i> . 2023 Sep 27;llad334. doi: 10.1093/ced/llad334. Epub ahead of print. PMID: 37758501.	4.481
669	Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojaniello C, Ascierto PA , Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. <i>Eur J Cancer</i> . 2023 Nov;194:113354. doi: 10.1016/j.ejca.2023.113354. Epub 2023 Sep 22. PMID: 37827067.	8.400
670	Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA , Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. <i>Nat Med</i> . 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Erratum in: <i>Nat Med</i> . 2023 Nov 3;: Erratum in: <i>Nat Med</i> . 2024 Jan 4;: PMID: 37845511; PMCID: PMC10667090.	87.244
671	Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Ramelyte E, Dimitriou F, Wicky A, Wallace R, Mallardo M, Cortellini A, Budillon A, Atkinson V, Sandhu S, Olivier M, Dummer R, Lorigan P, Schadendorf D, Long GV, Simeone E, Ascierto PA . The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. <i>J Transl Med</i> . 2023 Oct 25;21(1):753. doi: 10.1186/s12967-023-04607-4. PMID: 37880788; PMCID: PMC10601323.	8.440
672	Choucrair K, Nebhan C, Cortellini A, Hentzen S, Wang Y, Liu C, Giusti R, Filetti M, Ascierto PA , Vanella V, Galetta D, Catino A, Al-Bzour N, Saeed A, Cavalcante L, Pizzutillo P, Genova C, Bersanelli M, Buti S, Johnson DB, Fulgenzi CAM, Pinato DJ, Radford M, Kim C, Naqash AR, Saeed A. Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival. <i>Cancers (Basel)</i> . 2023 Oct 19;15(20):5052. doi: 10.3390/cancers15205052. PMID: 37894419; PMCID: PMC10605297.	5.200
673	Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA , Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglini P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. <i>EClinicalMedicine</i> . 2023 Oct 31;65:102290. doi: 10.1016/j.eclinm.2023.102290. PMID: 37965433; PMCID: PMC10641479.	15.100
674	Faria SS, Giannarelli D, Cordeiro de Lima VC, Anwar SL, Casadei C, De Giorgi U, Madonna G, Ascierto PA , Mendoza López RV, Chammass R, Capone M. Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics. <i>Oncologist</i> . 2023 Nov 16;oyad303. doi: 10.1093/oncolo/oyad303. Epub ahead of print. PMID: 37971409.	5.837
675	Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJ, Bhav P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA , McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, Blank CU, Lo SN, Long GV, Menzies AM. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. <i>Eur J Cancer</i> . 2024 Jan;196:113441. doi: 10.1016/j.ejca.2023.113441. Epub 2023 Nov 20. PMID: 37988842.	8.400
676	Soon JA, To YH, Alexander M, Trapani K, Ascierto PA , Athan S, Brown MP, Burge M, Haydon A, Hughes B, Itchins M, John T, Kao S, Koopman M, Li BT, Long GV, Loree JM, Markman B, Meniawy TM, Menzies AM, Nott L, Pavlakis N, Petrella TM, Popat S, Tie J, Xu W, Yip D, Zalcberg J, Solomon BJ, Gibbs P, McArthur GA, Franchini F, IJerman M. A tailored approach to horizon scanning for cancer medicines. <i>J Cancer Policy</i> . 2023 Dec;38:100441. doi: 10.1016/j.jcipo.2023.100441. Epub 2023 Nov 20. PMID: 38008488.	1.180
677	Castaldo V, Minopoli M, Di Modugno F, Sacconi A, Liguoro D, Frigerio R, Ortolano A, Di Martile M, Gesualdi L, Madonna G, Capone M, Cirombella R, Catizone A, Del Bufalo D, Vecchione A, Carriero MV, Ascierto PA , Mancini R, Fattore L, Ciliberto G. Upregulated expression of miR-4443 and miR-4488 in drug resistant	12.658

	melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin. J Exp Clin Cancer Res. 2023 Nov 27;42(1):317. doi: 10.1186/s13046-023-02878-9. PMID: 38008717; PMCID: PMC10680267.	
678	Quagliano P, Ascierto PA , Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M. Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program. Cancer Manag Res. 2023 Nov 11;15:1271-1281. doi: 10.2147/CMAR.S423970. PMID: 38027240; PMCID: PMC10649847.	3.602
679	Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA , Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. PMID: 38039779.	8.400
680	Alfieri S, Romanò R, Marcegaglia S, De Giorgi V, Peris K, Sollena P, Piccerillo A, Moro R, Gualdi G, Ascierto PA , Palla M, Paone M, Eibenschutz L, Spagnolo F, Queirolo P, Filippini DM, Cavalieri S, Resteghini C, Bergamini C, Manocchio A, Licitra L, Bossi P. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? Oncologist. 2023 Dec 21:oyad319. doi: 10.1093/oncolo/oyad319. Epub ahead of print. PMID: 38127280.	5.837
681	Ascierto PA , Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024 Jan 2;15(1):146. doi: 10.1038/s41467-023-44475-6. PMID: 38167503; PMCID: PMC10761671.	17.694
682	Pallocca M, Molineris I, Berrino E, Marcozzi B, Betti M, Levati L, D'Atri S, Menin C, Madonna G, Ghiorzo P, Bulgarelli J, Ferraresi V, Venesio T, Rodolfo M, Rivoltini L, Lanfrancone L, Ascierto PA , Mazzarella L, Pelicci PG, De Maria R, Ciliberto G, Medico E, Russo G. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres. J Transl Med. 2024 Jan 6;22(1):29. doi: 10.1186/s12967-023-04776-2. PMID: 38184610; PMCID: PMC10770968.	8.440
683	Quarto G, Benassai G, Colao A, Cittadini A, Ascierto PA , Pivonello R, Elefante A, Bocchino M, Marra AM, Gentile I, Benassai G, Miletti A, Calemma F, Furino E; members of FACTA study group. Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection. J Transl Med. 2024 Jan 17;22(1):70. doi: 10.1186/s12967-024-04857-w. PMID: 38233934; PMCID: PMC10795284.	8.440
684	Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA , Dummer R, Gogas H, Lebbe C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. PMID: 38262306.	8.400
685	Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quagliano P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA . Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Eur J Cancer. 2024 Mar;199:113542. doi: 10.1016/j.ejca.2024.113542. Epub 2024 Jan 19. PMID: 38266540.	8.400
686	Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA , Bhawe P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur J Cancer. 2024 Mar;199:113563. doi: 10.1016/j.ejca.2024.113563. Epub 2024 Jan 22. PMID: 38278007.	8.400
687	Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh HL, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbe C, Dummer R, Ascierto PA , Lo S, Long GV, Carlino MS, Menzies AM. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local	8.400

	therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy. Eur J Cancer. 2024 Mar;199:113561. doi: 10.1016/j.ejca.2024.113561. Epub 2024 Jan 20. PMID: 38278009.	
688	Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA , Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobieski AM, Dolfi S, Tawbi HA. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22. Erratum in: NEJM Evid. 2023 May;2(5):EVIDx2300104. PMID: 38320023.	0.000
689	Quagliariello V, Passariello M, Bisceglia I, Paccone A, Inno A, Maurea C, Rapuano Lembo R, Manna L, Iovine M, Canale ML, Scherillo M, Ascierto PA , Gabrielli D, De Lorenzo C, Maurea N. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1 β and interleukin-6: biochemical implications in cardio-immuno-oncology. Front Cardiovasc Med. 2024 Jan 23;11:1232269. doi: 10.3389/fcvm.2024.1232269. PMID: 38322766; PMCID: PMC10844473.	3.600
690	Maul LV, Jamiolkowski D, Lapidés RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA , Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi ÁJ, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roeder E. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open. 2024 Feb 5;7(2):e2356479. doi: 10.1001/jamanetworkopen.2023.56479. PMID: 38363565; PMCID: PMC10873772.	13.800
691	Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA , Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery. Future Oncol. 2024 May;20(15):959-968. doi: 10.2217/fon-2023-0977. Epub 2024 Feb 23. PMID: 38390818.	3.300
692	Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA , Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhner E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. PMID: 38402687.	8.400
693	Luke JJ, Ascierto PA , Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 Mar 7;JCO2302355. doi: 10.1200/JCO.23.02355. Epub ahead of print. PMID: 38452313.	45.300
694	Liguoro D, Frigerio R, Ortolano A, Sacconi A, Acunzo M, Romano G, Nigita G, Bellei B, Madonna G, Capone M, Ascierto PA , Mancini R, Ciliberto G, Fattore L. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Cell Death Dis. 2024 Mar 12;15(3):208. doi: 10.1038/s41419-024-06580-2. PMID: 38472212; PMCID: PMC10933445.	9.000
695	Schadendorf D, Luke JJ, Ascierto PA , Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. PMID: 38485189; PMCID: PMC10941196.	12.458
696	Gattuso G, Lavoro A, Caltabiano R, Madonna G, Capone M, Ascierto PA , Falzone L, Libra M, Candido S. Methylation-sensitive restriction enzyme-droplet digital PCR assay for the one-step highly sensitive analysis of DNA methylation hotspots. Int J Mol Med. 2024 May;53(5):42. doi: 10.3892/ijmm.2024.5366. Epub 2024 Mar 15. PMID: 38488030; PMCID: PMC10998716.	5.400
697	Greco V, Fornaro L, Ascierto PA , Palla M, Martora F, Marasca C. Basal cell carcinoma of the palm: an uncommon anatomical area involvement. Ital J Dermatol Venerol. 2024 Apr 12. doi: 10.23736/S2784-8671.24.07660-6. Epub ahead of print. PMID: 38619199.	2.000
698	Gunenc D, Ozluk AA, Yildirim UM, Ascierto PA , Karaca B. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report. Front Oncol. 2024 Apr 10;14:1355971. doi: 10.3389/fonc.2024.1355971. PMID: 38660135; PMCID: PMC11040682.	4.700

	TOTALE	7941.636
--	---------------	-----------------

PUBBLICAZIONI NON RECENSITE

- Russo G, Cuomo A, Del Giudice M, Viscidi PL, Acampora G, **Ascierto PA**, Leonardi E, Napolitano M, Castello G. Livelli circolanti dei recettori solubili per l'interleuchina-2 in pazienti sottoposti a terapia analgesica per il trattamento del dolore da cancro. Pandora – Giornale di Ricerca Clinica e Diagnostica Anno 9, n. 2 maggio-agosto 1997.
- Daponte A, Gravina A, **Ascierto P**, Palmieri G. Prevenzione primaria e secondaria del melanoma. In Medicina e Terapia Vol. 4 n. 3, 1998. Ed EDIMES 1998.
- Mozzillo N, Caracò C, Chiofalo MG, Pezzullo L, Ascierto PA, Comella G. cosa c'è di nuovo: il melanoma. Estratto da archivio ed atti della Società Italiana di Chirurgia 1999 - Vol. I. Catania 10-13 ottobre 1999.
- **Ascierto PA**, Simeone E, Palmieri G, Castello G. Vaccini: quale futuro? Supplemento International Journal of Clinical Investigation. Supplemento n. 2/2007.
- **Ascierto PA**, Simeone E, Napolitano M, Mozzillo N, Caracò C, Rocco G, De Michele I, Di Martino S, Melucci MT, Palmieri G, Castello G. Possibile ruolo delle alte dosi di interferone (HDI) nella riduzione dei linfociti T regolatori (Treg) circolanti. In I Casi Clinici nel trattamento del Melanoma. Ed. Springer 2007.
- **P.A. Ascierto**. La Chemioterapia del Melanoma Avanzato – Update. In L'Immunoterapia del Melanoma Avanzato – in “Indicazioni e Nuove Prospettive” a cura di Ruggero Ridolfi. Accademia Nazionale di Medicina 2008.
- **Ascierto P.A.** The future of melanoma therapy is the combination approach. *J Mol Biomark Diagn*. 2011; 2:3.
- **Ascierto PA**, Kirkwood JM, Marincola FM, Palmieri G. Melanoma: From Research to Treatment. *J Skin Cancer* 2011; Volume 2011, Article ID 710697, doi:10.1155/2011/710697.
- Palmieri G, Rozzo C, Cossu A, **Ascierto PA**. *J Mol Biomark Diagn* 2012; 3:5. <http://dx.doi.org/10.4172/2155-9929.1000e110>
- **Paolo A. Ascierto**, Vanna Chiarion-Sileni, Antonio Muggiano, Mario Mandalà, Nicola Pimpinelli, Michele Del Vecchio, Tania Rinaldi, Paola Queirolo. INTERFERONE ALFA NEL TRATTAMENTO ADIUVANTE DEL MELANOMA. Rivisitazione della letteratura internazionale e raccomandazioni pratiche sull'uso dell'interferone. Tumori 2012 (OSSERVATORIO Report congressuali e notizie dalla ricerca aziendale)
- Antonio Muggiano, Vanna Chiarion-Sileni, **Paolo A. Ascierto**, Mario Mandalà, Nicola Pimpinelli, Michele Del Vecchio, Tania Rinaldi, Paola Queirolo. INTERFERONE ALFA IN ADIUVANTE NEL MELANOMA. Tollerabilità e gestione degli effetti collaterali. Tumori 2012 (OSSERVATORIO Report congressuali e notizie dalla ricerca aziendale).
- **Paolo Ascierto**, Davide Bernardi, Rita Rielli, Elisa Rossi, Nello Martini per il gruppo di lavoro ARNO. I percorsi assistenziali della popolazione con melanoma. ARNO Journal 2013.
- **Ascierto PA**. Is there still a role for tremelimumab in the treatment of cancer? *Transl Cancer Res* 2013;2(1):48-50

PIANO ONCOLOGICO NAZIONALE 2008-2010

In qualità di componente della Commissione Oncologica Nazionale, ha collaborato alla stesura del Piano Oncologico Nazionale 2008-2010.

COMUNICAZIONI A CONGRESSI NAZIONALI ED INTERNAZIONALI

1. Palmieri G., **Ascierto P.A.**, Lauria R., Montesarchio V., Tagliaferri P., Merola C., Gravina A., Leo L., Bianco A.R.: 5-Fluorouracile (5-FU) e α -Interferone (α -IFN) nei tumori del tratto gastrointestinale in fase avanzata. IX Riunione Nazionale di Oncologia Sperimentale e Clinica, Napoli 20-23 ottobre 1991. *Tumori*, 1991; 77 (suppl. 3): 61 (abs. 143).

2. Lauria R., Palmieri G., Montesarchio V., Libetta C., Memoli B., Tagliaferri P., Leo L., **Ascierto P.A.**, Morabito A., Bianco A.R.: Prospective effect of dopamine infusion in acute renal failure induced by intravenous infusion of interleukin-2 (rIL-2). *Eur J Cancer* 1991 (suppl. 2) : 225 (abs. 1376).
3. Comella P, Comella G, Castello G, Daponte A, Casaretti R, **Ascierto P**, Napolitano M, Manzo T: Low-dose subcutaneous r-IL2 given intermittently during r-IFN α -2a administration in metastatic malignant melanoma. XVIIth Congress ESMO, Lyon 7-10 novembre 1992. *Ann. Oncol* 1992; 3 (suppl.5):160 (abs. 616),.
4. Casaretti R., Comella P., Daponte A., Parziale A., **Ascierto P.A.**, Sarnataro A., Comella G.: Profilassi con G-CSF durante un intensivo trattamento radio-chimioterapico per NSCLC. X Riunione Nazionale di Oncologia Sperimentale e Clinica, Pordenone 4-7 novembre 1992. *Tumori* 1992; 78 (suppl.3): 88 (abs. 208).
5. Comella P, Casaretti R, Parziale AP, **Ascierto PA**, Daponte A, Sarnataro A, Comella G: Recombinant human granulocyte colon-stimulating factor (G-CSF) during an alternated combined approach for locally advanced non small cell lung carcinoma (NSCLC). *IV Congres International sur la Chimiotherapie anti-cancereuse*, Paris, France, 2-5 febbraio 1993.
6. Comella P., Castello G., Daponte A., Casaretti R., **Ascierto P.**, Napolitano M., Manzo T., Comella G.: Subcutaneous r-IL2 combined intermittently with r-IFN alpha 2a in metastatic malignant melanoma. *IV Congres International sur la Chimiotherapie anti-cancereuse*, Paris, France, 2-5 febbraio 1993.
7. Comella P., Casaretti R., Daponte A., Cannada Bartoli G., Parziale A.P., Palmieri G., **Ascierto P.**, Comella G.: Combination of vinorelbine, cisplatin and etoposide in advanced non small cell lung carcinoma (NSCLC): a pilot study. *Congress on Chemotherapy of non small cell lung cancer: five years later*, Perugia, 18-19 giugno 1993.
8. Comella P., Casaretti R., Daponte A., Parziale A.P., **Ascierto P.**, Sarnataro A., Comella G.: Prophylactic administration of rhG-CSF can prevent occurrence and severity of neutropenia induced by a chemoradiotherapeutic approach in advanced NSCLC. *18th International Congress of Chemotherapy*. Stockholm, Sweden 27 giugno-2 luglio 1993, (abs. 308).
9. Comella P., Castello G., Daponte A., Casaretti R., **Ascierto P.**, Napolitano M., Manzo T., Comella G.: Low dose subcutaneous r-IL2 given intermittently during r-IFN alpha 2a administration for metastatic malignant melanoma. *18th International Congress of Chemotherapy*, Stockholm, Sweden 27 giugno-2 luglio 1993, (abs. 688).
10. Cuomo A, Acampora A, **Ascierto PA**, Castello G, del Giudice M, Leonardi E, Napolitano M, Russo G, Viscidi PL: Soluble interleukin-2 receptor levels in cancer patients undergoing analgesic therapy. *European Federation of IASP Chapters: "Pain in Europe"*, Verona, 18-21 maggio 1995.
11. Russo G., **Ascierto P.A.**, Cuomo A., del Giudice M., Leonardi E., Napolitano M., Viscidi P.L., Castello G., Acampora A.: Variazioni delle concentrazioni ematiche dei recettori solubili dell'Interleuchina-2 in corso di terapia analgesica per il trattamento del dolore da cancro. *Minerva Anestesiologica* 1995; 61 (suppl.2): 355.
12. **Ascierto PA**, Bosco L, Satriano RA, Botti G, Mozzillo N, Comella G, and Castello G: The epiluminescent microscopy in the diagnosis of pigmented cutaneous lesions: the experience of National Cancer Institute of Naples, Italy. *Pig Cell Res* 1996; suppl. 5: 39 (abs 86).
13. **Ascierto PA**, Parasole R., Botti G., Daponte A., Ionna F., Palmieri G., Satriano R. and Castello G.: Early diagnosis of the cutaneous malignant melanoma by epiluminescent microscopy: one year experience from the melanoma group of the national cancer institute of Naples. *2° International Congress "Prevention of Human Cancer"*. Venezia, 6-8 giugno 1997.

14. **Ascierto PA**, Parasole R, Bosco L, Botti G, Daponte A, Ionna F, Satriano R and Castello G: Epiluminescent microscopy: an innovative analytical methods in the early diagnosis of cutaneous melanoma. *Pigmentary disorders: from a global perspective*. Bali, Indonesia, 22-24 giugno 1997.
15. **Ascierto PA**, Satriano RA, Botti G, Bosco L, Daponte A, Ionna F, Parasole R, Castello G: The early diagnosis of cutaneous malignant melanoma: the role of the epilunimescence microscopy. *Eur J Cancer* 1997; 33 (suppl. 8): S255, (abs. 1154).
16. **Ascierto PA**, Satriano R., Bosco L., Botti G., Daponte A., Ionna F., Parasole R., Picone A., Castello G.: The role of the epilunimescent microscopy in the early diagnosis of cutaneous melanoma. *Skin Research and Technology* 1997; 3: 186 (abs. 4).
17. Palmieri G., **Ascierto PA**, Romano G., Strazzullo M., Napolitano M., Leonardi E., Daponte A., Ionna F., Mozzillo N., Comella G., Castello G.: Multiple-Marker RT-PCR as a new approach in monitoring melanoma patients. *Tumori*, 1997; 83 (suppl. 1): 63 (abs. 146).
18. **Ascierto PA**, Palmieri G, Parasole R, Napolitano M, Leonardi E, Castello G: Adjuvant treatment of high risk melanoma with Interferon α . *Tumori* 1997; 83 (suppl. 1): 63, (abs. 147).
19. **Ascierto PA**, Satriano R., Botti G., Daponte A., Ionna F., Palmieri G., Parasole R., Castello G.: Epilunimescent microscopy: an innovative analytical approach for early diagnosis of cutaneous melanoma. *Tumori* 1997; 83 (suppl. 1): 64 (abs. 150).
20. **Ascierto PA**, Satriano R., Bosco L., Botti G., Daponte A., Ionna F., Palmieri G., Parasole R., Castello G.: Is the epiluminescent microscopy useful for the early diagnosis of cutaneous melanoma?. *Pig Cell Res* 1997; 10: 343 (abs. P1).
21. Marfella A, Polese C, Comella P, Daponte A, Beneduce G, **Ascierto PA**, Creazzola S, Satriano RA, Perna M, Castello G: Neopterin, kynurenine and clinical response in advanced melanoma patients treated with interferon alpha and IL-2. *Pig Cell Res* 1997; 10: 344 (P8).
22. Palmieri G, **Ascierto PA**, Romano G, Strazzullo M, Napolitano M, Leonardi E, Daponte A, Ionna F, Mozzillo N, Comella G, Castello G: Detection of circulating tumor cells in melanoma patients by RT-PCR. *Pig Cell Res* 1997; 10: 347 (abs. P18).
23. Bosco L, **Ascierto PA**, Satriano RA, Castello G, Ruocco V. La microscopia in epiluminescenza: una nuova metodica per la diagnosi precoce del melanoma cutaneo. Esperienza di un anno del gruppo melanoma di Napoli. *72° Congresso Nazionale della Società Italiana di Dermatologia e Venereologia*, Firenze 15-18 ottobre 1997.
24. **Ascierto PA**, Satriano RA, Parasole R, et al. Effectiveness of epiluminescence microscopy in the early diagnosis of cutaneous melanoma. *XIII Congress of the Italian Society for Dermatologic Surgery and Oncology*. Rome –Italy, April 22-25, 1998.
25. **Ascierto PA**, Satriano RA, Parasole R, et al. Two years experience in using epiluminescence microscopy in the early diagnosis of cutaneous melanoma. *17th International Cancer Congress – UICC*. Rio de Janeiro – Brasil, August 23-28, 1998.
26. **Ascierto PA**, Satriano RA, Palmieri G, Parasole R, Caracò C, Venditti C, Facchini G, Castello G. Effectiveness of epiluminescence microscopy in the early diagnosis of cutaneous melanoma: Two years experience of the National Cancer Institute of Naples. *Ann Oncol* 1998; 9 (suppl. 4): 116.
27. Palmieri G, Strazzullo M, **Ascierto PA**, Satriano SMR, Daponte A, Castello G and Melanoma Cooperative Group. Assessment of new molecular markers in malignant melanoma. *Tumori* 1998; 84 (suppl. 1): 78.
28. **Ascierto PA**, Satriano RA, Parasole R, Caracò C, Palmieri G, Castello G and Melanoma Cooperative Group of National Tumor Institute of Naples. Final results of health campaign for early diagnosis of cutaneous melanoma by using epiluminescence microscopy. *Tumori* 1998; 84 (suppl. 1): 111.

29. **Ascierto PA**, Palmieri G, Parasole R, Caracò C, Castello G and Melanoma Cooperative Group of National Tumor Institute of Naples. Preliminary results of a phase II study about adjuvant treatment of cutaneous malignant melanoma with low dose interferon therapy. *Tumori* 1998; 84 (suppl. 1): 113.
30. Daponte A, Comella P, Cellerino R, De Lena M, Brandi M, Marini G, Failla G, De Vita F, Rivellini F, Gravina A, **Ascierto PA**, Mozzillo N, Caracò C, Comella G. Combined immuno-chemotherapy with cisplatin, dacarbazine, fotemustine, and interferon α 2b in advanced melanoma. A phase II study of italian melanoma study group (IMSG). *Ninth International Congress on anti-cancer treatment*. Paris, France, 2-5 February 1999.
31. Strazzullo M, Palmieri G, **Ascierto PA**, Satriano SMR, Daponte A, Comella G, Mozzillo N, Castello G and the Melanoma Cooperative Group. Detection of circulating mRNAs in melanoma patients using RT-PCR Assays: an effective tumor progression marker. *IV Meeting of Molecular Oncology*, Positano 12-15 maggio 1999.
32. Palmieri G, Strazzullo M, **Ascierto PA**, Satriano SMR, Pisano M, Daponte A, Caracò C, Mozzillo N, Castello G and the Melanoma Cooperative Group. PCR-Positive mRNAs in peripheral blood of patients with malignant melanoma as an effective tumor progression marker. *Proc Am Soc Clin Oncol* 1999; 18: 538a.
33. **Ascierto PA**, Satriano RA, Palmieri G, Parasole R, Caracò C, Daponte A, Mozzillo N, Castello G and the Melanoma Cooperative Group. Epiluminescence microscopy is helpful for early diagnosis of cutaneous melanoma: results of a two-year study. *Proc Am Soc Clin Oncol* 1999; 18: 549a.
34. **Ascierto PA**, Parasole R, Caracò C, Chiofalo M G, Mazzeo M, Daponte A, Palmieri G, Satriano R A, Mozzillo N and Castello G. ELM is helpful for early detection of cutaneous melanoma, including the in situ stage. *Skin Research and Technology* 1999; 5: 125 (abs 3).
35. Palmieri G, Strazzullo M, **Ascierto PA**, Satriano SMR, Motti ML, Botti G, Cossu A, Lissia A, Daponte A, Castello G. Definition of new tumor progression markers in malignant melanoma (MM). *Eur J Cancer* 1999; 35 (suppl. 4): S374 (abs 1504).
36. Daponte A, Rivellini F, Gravina A, **Ascierto PA**, D'Aniello R, Mozzillo N, Caracò C, Comella P and Castello G. Cisplatin (CDDP), decarbazine (DTIC), interferon (IFN) and amifostine (AMI) in advanced melanoma. *Eur J Cancer* 1999; 35 (suppl. 4): S373 (abs 1520).
37. **Ascierto PA**, Daponte A, Parasole R, Palmieri G, Mozzillo N and Castello G. Adjuvant treatment with interferon- α in melanoma stage II-III: Experience of Melanoma Cooperative Group. *Eur J Cancer* 1999; 35 (suppl. 4): S370 (abs 1525).
38. Palmieri G, Strazzullo M, **Ascierto PA**, Satriano SMR, Motti ML, Botti G, Cossu A, Lissia A, Tanda F, Mozzillo N and Castello G. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma (MM) patients. Minimal residual disease in Melanoma - International Symposium on biology, detection, and clinical relevance of micrometastases. Homburg/Saar, Germany, 17-18 September 1999. Pag. 4, abs. O4.
39. **Ascierto PA**, Daponte A, Rivellini F, Gravina A, Mozzillo N, Ionna F, Caracò C, Comella P, Comella G. Cisplatin (CDDP), dacarbazine (DTIC), interferon (IFN) and amifostine (AMI) in advanced melanoma. A phase I study. *I Congresso nazionale di Oncologia Medica*, Roma 24-28 ottobre 1999. Pag. 35 Abs 105.
40. **Ascierto PA**, Daponte A, Parasole R, Caracò C, Chiofalo MG, Melucci MT, Palmieri G, Comella G, Mozzillo N, Castello G, Low dose interferon-alpha + tamoxifen as second line adjuvant treatment for melanoma patients recurred after adjuvant therapy. *Proc Am Soc Clin Oncol* 2000; 19: 2264.
41. Palmieri G, **Ascierto PA**, Satriano SMR, Motti ML, Botti G, Cossu A, Tanda F, Mozzillo N, Castello G. PCR-based analysis of patients with malignant melanoma (mm): assessment

- of genetic alterations and detection of occult metastases as tumor progression markers. *Proc Am Soc Clin Oncol* 2000; 19: 2233.
42. **Ascierto PA**, Caracò C, Daponte A, Parasole R, Chiofalo MG, Melucci MT, Palmieri G, Comella G, Mozzillo N, Castello G on behalf of the Melanoma Cooperative Group. Low dose interferon-alpha + tamoxifen as second line adjuvant treatment of cutaneous melanoma. Experience of Melanoma Cooperative Group of Naples. Melanoma 2000. *The research view point: II Melanoma research meeting for specialists in dermatology, surgery and medical oncology*. Milano 23-24 June 2000: 33.
 43. G Palmieri, **PA Ascierto**, SMR Satriano, N Mozzillo, G Botti, C Caracò, R Parasole, A Daponte, MG Chiofalo, MT Melucci, A Cossu, A Lissia, F Tanda, and G Castello. The role of RT-PCR markers in peripheral blood and regional nodes in the management of Melanoma (MM) patients. *IV Conferenza Internazionale sul Melanoma: Dalla Biologia alla Clinica*. Forlì, 26-28 settembre 2000: 29.
 44. Daponte, **PA Ascierto**, F. Perrone, on behalf of the Melanoma Cooperative Group of Naples. Advanced Melanoma in the elderly. *IV Conferenza Internazionale sul Melanoma: Dalla Biologia alla Clinica*. Forlì, 26-28 settembre 2000: 39.
 45. **Ascierto PA**, Daponte A, Parasole R, Caracò C, Melucci MT, Palmieri G, Comella G, Mozzillo N, Castello G on behalf of the Melanoma Cooperative Group. Low dose interferon- α + tamoxifen in the treatment of recurred melanoma patients. *Ann Oncology* 2000; 11 (suppl. 2): 57.
 46. **Ascierto PA**, Daponte A, Parasole R, Caracò C, Melucci MT, Palmieri G, Comella G, Mozzillo N, Castello G. Low dose interferon- α + tamoxifen in the treatment of recurred melanoma patients after adjuvant therapy: The experience of Melanoma Cooperative Group of Naples. *Ann Oncology* 2000; 11 (suppl. 4): 129-30.
 47. G Palmieri, A Cossu, **PA Ascierto**, M Strazzullo, G Botti, A Lissia, M Colombino, M Casula, C Floris, F Tanda, M Pirastu, G Castello for the Melanoma Cooperative Group. Genetic alterations at chromosome 9p21 in primary tumors and metastases from patients with sporadic melanoma: definition of their clinical significance. *Ann Oncology* 2000; 11 (suppl. 2): 60.
 48. G Palmieri, **PA Ascierto**, G Botti, N Mozzillo, C Caracò, SMR Satriano, R Parasole, A Daponte, MG Chiofalo, MT Melucci, A Cossu, A Lissia, F Tanda, and G Castello. The RT-PCR markers in the management of Melanoma (MM) patients: the experience of Melanoma Cooperative Group of Naples. *Sentinel Node 2000*; Santa Monica, CA, USA, December 1-4, 2000; Pag. 38: abs 12.
 49. A Daponte, **PA Ascierto**, A Gravina, MT Melucci, G Palmieri, P Com'ella, R Celerino, M De Lena, G Marini, G Comella. Cisplatin, dacarbazine, and fotemustine plus alpha interferon in advanced malignant melanoma. A multicenter phase II study of the Southern Italy Cooperative Group (SICOG). *Melanoma Res* 2001; 11 (suppl 1): S133-4.
 50. **PA Ascierto**, A Daponte, G Palmieri, G Botti, N Mozzillo, G Castello. Melanoma from research to treatment. The experience of Melanoma Cooperative Group of Naples. *Melanoma Res* 2001; 11 (suppl 1): S135-6.
 51. Montella M, Carbone S, Fusco M, **Ascierto P**, Silvestro P, Serraino D, Rezza G, Palombino R, Desicato S, De Marco MR, Tamburini M. Prevalenza del HHV-8 in un'area ad alta incidenza di Sarcoma di Kaposi. *A.I.R.T. V Riunione Scientifica Annuale, Alghero (SS) 29-30 Marzo 2001*.
 52. **PA Ascierto**, G Palmieri, A Daponte, G Botti, C Caracò, R Parasole, MT Melucci, N Mozzillo, G Castello. From research to treatment in cutaneous melanoma: The point of view from a Melanoma Cooperative Group. *Proc Am Soc Clin Oncol* 2001; 20: 284b (abs 2888).
 53. **PA Ascierto**, G Palmieri, N Mozzillo, C Caracò, G Botti, Satriano SMR, A Daponte, MG Chiofalo, MT Melucci, M Napoletano, E Leonardi, A Cossu, A liscia, F Tanda and G

- Castello. The experience of Melanoma Cooperative Group of Naples in the utilizing of RT-PCR markers for the management of melanoma patients. *J Surg Oncol* 2001; 78: 148 (abstr 338).
54. G Palmieri, **PA Ascierto**, A Cossu, M Casula, P Cannada Batoli, G Botti, A Daponte, A Lissia, F Tanda, G Castello. Genetic analysis of sporadic and familial malignant melanoma (MM): assessment of the role of 9p21 region and p16/CDKN2A gene in MM tumorigenesis and its clinicopathological correlation. *Eur J Cancer* 2001; 37 (suppl. 6) : S81 (abs 288).
 55. **P.A. Ascierto**, G. Palmieri, F. Perrone, S.M.R. Satriano, A. Ottaiano, A. Daponte, E. Leonardi, M. Napolitano, M. Melucci, N. Mozzillo, C. Gallo, A. Cossu, F. Tanda, G. Castello. Circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction: evaluation of prognostic role after a long-time follow-up. *Proc Am Soc Clin Oncol* 21: 340a, 2002 (abstr. 1357).
 56. G. Palmieri, A. Cossu, M. Casula, A. Manca, S. Tore, C. Sini, C. Loddo, **P.A. Ascierto**, G. Botti, A. Daponte, G. Castello, A. Lissia, F. Tanda. From genetics to physiopathology of malignant melanoma (MM): assessment of the role of known genes (p16, CDK4, Id-1) and identification of a new candidate locus on chromosome 9p21 through combined genomic and functional approaches. *Proc Am Soc Clin Oncol* 21: 345a, 2002 (abstr. 1379).
 57. A. Ottaiano, A. De Chiara, G. Botti, V. Boccia, C. Pisano, R. De Vivo, F. Fazioli, **P. A. Ascierto**, S. Mori, M. Napolitano, E. Barletta, V. R. Iaffaioli, G. Apice. CD40 expression on spindle soft tissue sarcomas is not associated with response to ifosfamide and epirubicin first line chemotherapy: a retrospective study. *Proc Am Soc Clin Oncol* 21: 278b, 2002 (abstr. 2932).
 58. M. Casula, **P.A. Ascierto**, A. Cossu, A. Manca, C. Rozzo, M. Colombino, C. Loddo, S.M.R. Satriano, G. Castello, A. Lissia, F. Tanda, and G. Palmieri. Mutational analysis of candidate genes in families with malignant melanoma (MM): assessment of the role of the CDKN2A gene in MM predisposition. 4th National Congress of Medical Oncology, Turin, Italy, n. G42. *Ann. Oncol.* 13, Suppl. 3: 100, 2002.
 59. G. Palmieri, A. Cossu, A. Manca, M. Casula, C. Rozzo, G. Botti, G. Castello, A. Lissia, F. Tanda, and **P.A. Ascierto**. Low prevalence of microsatellite instability in malignant melanoma. 27th ESMO Congress, Nice, France, n. 583P. *Ann. Oncol.* 13, Suppl. 5: 158-159, 2002.
 60. T. Logan, L. Feun, J.S. Bomalaski, M.A. Clark, G. Castello, G. Benedice, S. Scala, F. Izzo, **P.A. Ascierto**. Phase I/II testing of pegylated arginine deiminase in metastatic melanoma. *Proc Am Soc Clin Oncol* 22: 710, 2003 (abstr 2855).
 61. **Ascierto PA**, Cossu A, Lissia A, Tanda F, Satriano SMR, Nardelli M, Colombino M, Manca A, Rozzo C, Palmieri G. Assessment of microsatellite instability in benign nevi, dysplastic nevi, and primary melanomas along with their metastases Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology, Chicago, U.S.A. *Proc Am Soc Clin Oncol* 22: 722, 2003 (abstr 2905).
 62. A Ottaiano, S Scala, A di Palma, M Napolitano, M Di Bonito, **PA Ascierto**, AM Acquaviva, G Botti, G Castello, G Santelli, B Daniele, S Pignata, VR Iaffaioli. Expression of Functional CXCR4 on colorectal human cancer. *AACR 94th Annual Meeting, Washington, D.C., USA*; July 11-14, 2003. (abstr. LB-132).
 63. A Ottaiano, S Scala, A di Palma, M Napolitano, M Di Bonito, **PA Ascierto**, F Tatangelo, S Pignata, AM Acquaviva, C Pisano, E Barletta, G Botti, G Castello, RV Iaffaioli. Expression of functional CXCR4 on colorectal human cancer. 5th National Congress of Medical Oncology, Roma. *Ann. Oncol.* 14, Suppl. 4: iv75, 2003, n. G4.
 64. C Pisano, A Ottaiano, F Perrone, A De Chiara, G Botti, F Fazioli, V De Rosa, V Ravo, C Gallo, E Barletta, M Napolitano, **PA Ascierto**, RV Iaffaioli. Prognostic value of CD40 in

- adult non-round cell soft tissue sarcomas. 5th National Congress of Medical Oncology, Roma. *Ann. Oncol.* 14, Suppl. 4: iv76, 2003, n. G5.
65. G. Palmieri, M. Casula, M. Colombino, M.P. Satta, C. Rozzo, **P.A. Ascierto**, G. Castello, G. Bianchi-Scarrà, A. Cossu, F. Tanda. BRAF gene contributes to melanoma pathogenesis but not to melanoma susceptibility. *Proc Am Soc Clin Oncol* 23: 852, 2004 (abstr 9584).
 66. G Palmieri, F Carta, F Turrini, PP Demuro, A Manca, MC Sini, **PA Ascierto**, S D'Atri, A Cossu, C Rozzo. Proteomics and expression analysis for identifications of new candidate genes in melanoma progression. 29th ESMO Congress, Vienna, Austria. *Ann. Oncol.* 15, Suppl. 3: iii197, 2004, n. 746O.
 67. Casula M, Colombino M, Satta MP, Cossu A, **Ascierto PA**, Bianchi Scarrà G, Mantelli M, Ghiorzo P, Castiglia D, D'Atri S, Budroni M, Rozzo C, Manca A, Lissia A, Tanda F, Botti G, Castello G, Palmieri G. Role on the BRAF gene in malignant melanoma. *Annual Meeting IMI 2004*, Napoli, 2004.
 68. Palomba G, Pisano M, Budroni M, Cossu A, Manca A, Balduin P, Sini MC, Rozzo C, **Ascierto PA**, Palmieri G. *BRCA1* and *BRCA2* mutation analysis through an evaluation clinic program among Sardinian breast cancer patients. ESMO Scientific and Educational Conference (ESEC), Budapest, n. 35P. *Ann. Oncol.* 16, Suppl. 2: 279-280, 2005.
 69. Ottaiano A, Scala S, **Ascierto PA**, Simeone E, Napolitano M, Pisano C, Castello G. Contents and quality of prospective trials of biotherapies in solid tumors: a five-year survey. 7th National Congress of Medical Oncology, Naples, Italy, n. C3 *Ann. Oncol.* 16, Suppl.7: vii30, 2005.
 70. S. Scala, M. Napolitano, F. Fulciniti, P. Giuliano, F. Mauro, C. Ieranò, E. Simeone, A. Ottaiano, G. Botti, **P. Ascierto**, G. Castello. CXCR4 in melanoma: A prognostic biomarker and a target of therapy. *Proc Am Soc Clin Oncol* 24: 465s, 2006 (abstr 8051).
 71. G. Comella, L. Maiorino, G. Filippelli, B. Massidda, N. Mozzillo, C. Caracò, **P. A. Ascierto**, M. G. Chiofalo, E. Simeone, A. Daponte. fotemustine (FM) and dacarbazine (DTIC) versus DTIC +/- interferon α in advanced malignant melanoma: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG). *Proc Am Soc Clin Oncol* 24: 686s, 2006 (abstr LBA 18000).
 72. **P.A. Ascierto**, M. Budroni, A. Cossu, S. Scala, E. Simeone, P. Giuliano, S. M. Satriano, C. Caracò, M. Casula, G. Palmieri. Serial RT-PCR detection of circulating tumour cells as a marker of disease progression in patients with malignant melanoma. *Proc Am Soc Clin Oncol* 24, 686s, 2006 (abstr 18009).
 73. Casula M, Colombino M, Satta MP, Cossu A, Budroni M, Lissia A, Simeone E, Caracò C, Daponte A, Comella G, Mozzillo N, Castello G, Calemma R, **Ascierto PA**, Palmieri G. Predictor of germline mutations in candidate genes among patients with malignant melanoma from South Italy. *The 6th International Conference on the Adjuvant Therapy of Malignant Melanoma*. Stockolm, Sweden: n. P26, 74, 2006
 74. Pisano M, Tilocca MG, Loi M, Mura ME, Manca A, Palmieri G, Cossu A, Tanda F, Castiglia D, **Ascierto PA**, Giuliano P, Fabbri D, Dettori MA, Delogu G and Rozzo C. Antiproliferative and pro-apoptotic activity of eugenol and isoeugenol related biphenyls on malignant melanoma tumour cell lines. 8th National Congress of Medical Oncology, Milano, Italy, n. C4 *Ann. Oncol.* 17, Suppl.11: 26-38, 2006.
 75. Pisano M, Tilocca MG, Loi M, Mura ME, Manca A, Palmieri G, Cossu A, Tanda F, Castiglia D, **Ascierto PA**, Giuliano P, Fabbri D, Dettori MA, Delogu G and Rozzo C. Antiproliferative and pro-apoptotic activity of eugenol and isoeugenol related biphenyls on malignant melanoma tumour cell lines. 8th National Congress of Medical Oncology, Milano, Italy, n. C4 *Ann. Oncol.* 17, Suppl.11: 26-38, 2006.
 76. Rozzo C, Tilocca MG, Demuro PP, Pisano M, Manca A, Sini MC, Castiglia D, D'Atri S, **Ascierto PA**, Giuliano P, Calemma R, Cossu A, Tanda F, Palmieri G. Analysis of the

- MAPK-ERK gene pathway in primary and metastatic melanoma cell lines. 8th National Congress Med. Oncology, Milano, n. C4. *Ann. Oncol.* 17, Suppl.11: 26-38, 2006.
77. Casula M, Colombino M, Satta MP, Cossu A, Budroni M, Caracò C, Daponte A, Calemma R, **Ascierto PA**, Palmieri G. Mutational analysis of candidate genes among patients with malignant melanoma from south Italy. 31th ESMO Scientific and Educational Conference, Istanbul, n. 820PD. *Ann. Oncol.* 17, Suppl. 9: 241-244, 2006.
 78. Casula M, Colombino M, Cossu A, Budroni M, Satta MP, Sini MC, Palomba G, Baldinu P, Tanda F, Caracò C, Daponte A, Simeone E, Calemma R, Loddo C, **Ascierto PA**, Palmieri G. Mutation prevalence for candidate genes varies in melanoma population from south Italy. 12th Annual Meeting IMI 2006, Bari, 2006
 79. Rozzo C, Tilocca MG, Demuro PP, Pisano M, Manca A, Sini MC, Castiglia D, D'Atri S, **Ascierto PA**, Cossu A, Tanda F, Palmieri G. Functional interactions of the MAPK-ERK gene pathway in melanoma patients. 12th Annual Meeting IMI 2006, Bari, 2006
 80. Palmieri G, Casula M, Sini MC, Cossu A, Lissia A, Tanda F, **Ascierto PA**, Biology of melanoma progression and its therapeutic implications. 12th Annual Meeting IMI 2006, Bari, 2006
 81. Sini MC, Manca A, Cossu A, Budroni M, **Ascierto PA**, Botti G, Mozzillo N, Comella G, Casula M, Satta MP, Palomba G, Baldinu P, Rozzo C, Lissia A, Tanda F, Palmieri G. Progressive alterations at chromosome 9p21 in melanomagenesis. 12th Annual Meeting IMI 2006, Bari, 2006.
 82. Simeone E, Napolitano M, Mauro F, Palmieri G, Ridolfi R, Riccobon A, M Petrini, De Rosa V, Satriano RA, Di Martino S, Nicoletti G, Gentilcore G, Capone M, Calemma R, Loddo C, Talamanca AR, Caracò C, Castello G, and **Ascierto P.A.** Blood reduction of circulating regulatory T cell (Treg) by intra venous High Dose Interferon treatment in melanoma matients: preliminary results. Presented at the Fourth Research Meeting on Melanoma; 2007 May 10-11; Milan, Italy.
 83. Di Martino S, Ialenti A, Napolitano M, Palmieri G, De Maio A, Tersigni MR, Gentilcore G, Capone M, Calemma R, Loddo C, Aiello, Talamanca AR, Ombra N, Simeone E, Caracò C, Castiglia D, Farina B, Faraone R, Castello G, and **Ascierto P.A.** NEMO (Nf-Kb Essential Modulator) Binding Domain (NDB) peptide induce apoptosis in A375 melanoma cell line. Presented at the Fourth Research Meeting on Melanoma; 2007 May 10-11; Milan, Italy.
 84. **P.A. Ascierto**, A. Testori, R. Ridolfi, M. Guida, I. Stanganelli, G. Bianchi-Scarrà, V. Chiarion-Sileni, F. Di Filippo, A. Romanini, R. Rossi, R. Bono, G. Palmieri. The role of Fund Rising to increase melanoma research. Presented at the Fourth Research Meeting on Melanoma; 2007 May 10-11; Milan, Italy.
 85. G Palmieri, MC Sini, M Casula, C Rozzo, **PA Ascierto**, F Cremona, M Budroni, A Lissia, F Tanda, A Cossu. Genetic alterations at chromosome 9p21 and melanoma progression. Presented at the Fourth Research Meeting on Melanoma; 2007 May 10-11; Milan, Italy.
 86. Casula M, Palmieri G, Bono R, Pizzichetta MA, **Ascierto PA**, Alaibac M. Polimorfismi genetici e melanoma. 13th Annual Meeting IMI 2007, Padova, 29-31 ottobre 2007.
 87. G Palmieri, MC Sini, M Casula, MP Satta, P Baldinu, G Palomba, **PA Ascierto**, R Calemma, G Botti, C Caracò, N Mozzillo, S Canzanella, M Budroni, F Tanda, A Cossu. Molecular Classification of melanoma for new therapeutic strategies. 13th Annual Meeting IMI 2007, Padova, 29-31 ottobre 2007.
 88. M Casula, MC Sini, M Colombino, P Baldinu, G Palomba, C Caracò, **PA Ascierto**, C Loddo, N Mozzillo, A Muggiano, M Budroni, F Galimi, A Lissia, A Cossu, G Palmieri. Role of the Fanconi gene pathway into the pathogenesis of melanoma. 13th Annual Meeting IMI 2007, Padova, 29-31 ottobre 2007.
 89. MC Sini, M Casula, A Manca, P Baldinu, G Palomba, G Botti, **PA Ascierto**, C Caracò, F Cremona, A Muggiano, M Budroni, A Lissia, F Tanda, A Cossu, G Palmieri. Sequential

accumulation of molecular alteration at the chromosome 9p21 during development and progression of melanoma. 13th *Annual Meeting IMI 2007*, Padova, 29-31 ottobre 2007.

90. G Palmieri, M Casula, MC Sini, M Colombino, A Cossu, A Lissia, M Budroni, **PA Ascierto**, G Botti, P Baldinu, G Palomba, F Galimi, F Tanda. Fanconi Genes may Contribute to Melanoma Pathogenesis. (abstr B-125). Annual Congress of the Society for Melanoma Research, New York, 1-4 November 2007. *Pigment Cell Res.* 2007; 20: 568.
91. C Ierano, C D'Alterio, V Mettievier, C Arra, R Franco, G Palmieri, P Giuliano, **P Ascierto**, G Castello and S Scala. An activating point mutation of CXCR4 occurred in human melanoma and colon cancer cell lines. Abstract #5321. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA
92. A. M. Eggermont, S. Suciu, W. Ruka, J. Marsden, A. Testori, P. Corrie, S. Aamdal, **P. A. Ascierto**, P. Patel, A. Spatz, EORTC Melanoma Group. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 9004).
93. G. Palmieri, M. C. Sini, M. Casula, P. Baldinu, G. Palomba, M. Colombino, **P. A. Ascierto**, G. Botti, C. Caracò, N. Mozzillo, A. Cossu, F. Tanda. Molecular classification for the management of melanoma patients. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 20028).
94. A. De Maio, E. Natale, C. Mistretta, S. Di Martino, G. Gentilcore, M. Capone, M.L. Ascierto, G. Palmieri, **P.A. Ascierto**, B. Farina, M.R. Faraone-Mennella. Poly-ADPribosylation reaction in melanoma cells treated with NEMO (NF-kB Essential Modulator) Binding Domain Peptide. 2nd *International meeting Cell stress and apoptosis to Arturo*: July 3rd-4th, 2008, Fisciano (SA), Italy
95. Colombino M, Casula M, Sini MC, Cossu A, Lissia A, Budroni M, **Ascierto PA**, Caraco` C, Botti G, Manca A, Baldinu P, Palomba G, Tanda F, Palmieri G. Role of Fanconi, MAPK, and p16CDKN2A Gene Pathways into the pathogenesis of Melanoma. 10th National Congress Med. Oncology, 11-14 October, 2008 Verona, Italy. *Ann. Oncol.* 19, Suppl.9: ix36, 2008 (abstr. D16).
96. Casula M, Satta MP, Palomba G, Sini MC, Mulas C, Capra D, Cossu A, Lissia A, Tanda F, Budroni M, Caraco` C, Calemma R, **Ascierto PA**, Calmieri G, Muggiano A. D17 Germline Mutations in Candidate Genes among Patients with Cutaneous Melanoma from Sardinia. 10th National Congress Med. Oncology, 11-14 October, 2008 Verona, Italy. *Ann. Oncol.* 19, Suppl.9: ix36-37, 2008 (abstr. D17).
97. **P. A. Ascierto**, S. Di Martino, M. Napolitano, G. Gentilcore, M. Capone, M. L. Ascierto, M. N. Ombra, A. De Maio, A. Ialenti, G. Palmieri. The role of NEMO (NF-kB essential modulator) binding domain (NDB) peptide in inducing apoptosis in A375 melanoma cell line (abstr. 22). ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer: October 29 - November 1, 2008, Hollywood, Florida.
98. De Maio A, Natale E, Mistretta C, Di Martino S, Napolitano M, Ianaro A, Gentilcore G, Capone M, Tersigni MR, Ascierto ML, Ciccariello L, Palmieri G, Ialenti A, **Ascierto PA**, Farina B, Faraone-Mennella MR. PARP1 as apoptosis marker in A375 melanoma cells treated with NF-kB Essential Modulator binding Domain peptide. *XXI Italian Meeting on ADP-Ribosylation Reaction*: 24-25 November 2008, Lanciano, Italy.
99. **P. A. Ascierto**, M. Napolitano, E. Celentano, E. Simeone, G. Gentilcore, M. Capone, L. Ciccarelli, G. Palmieri, G. Castello, N. Mozzillo. Reduction of circulating regulatory T cell (Treg) by intravenous high-dose interferon (HDI) treatment in melanoma patients. Forty-Fifth Annual Meeting of American Society Clinical Oncology, Orlando, *Proceedings of American Society Clinical Oncology* - May 20 Suppl. to *J. Clin. Oncol.* 27, No 15S: 9040, 2009.

100. E. Simeone, A. Daponte, G. De Feo, V. Montesarchio, V. Chiarion-Sileni, I. De Michele, C. Caracò, G. Palmieri, N. Mozzillo, **P. A. Ascierto**. Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Forthty-Fifth Annual Meeting of the American Society of Clinical Oncology, Orlando, *Proceedings of American Society Clinical Oncology* - May 20 Suppl. to J. Clin. Oncol. 27, No 15S: e20009, 2009.
101. Tersigni M, Belardo G, Napolitano M, **Ascierto PA**, Ialenti A, Ianaro A. NEMO-binding domain peptide induces apoptosis in human melanoma cells: an effect associated toinhibition of constitutive NF-kB activation. Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, Germany. *Eur. J. Cancer Supplements* 2009; 7 (2): 580, (abstr 9313).
102. **Ascierto PA**, Gentilcore G, Napolitano M, Simeone E, Capone M, Daponte A, Palmieri G, Castello G, Celentano E, and Mozzillo N. Treatment with intravenous High Dose Interferon (HDI) is able to reduce levels of circulating regulatory T (Treg) cells in melanoma patients. Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, Germany. *Eur. J. Cancer Supplements* 2009; 7 (2): 583, (abstr 9320).
103. Altomonte M, Queirolo P, Testori A, **Ascierto P**, Danielli R, Di Giacomo AM, Chiarion Sileni V, Bajetta E, Ridolfi R and Maio M. The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients. Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, Germany. *Eur. J. Cancer Supplements* 2009; 7 (2): 585, (abstr 9328).
104. **Ascierto PA**, Napolitano M, Celentano E, Simeone E, Daponte A, Gentilcore G, Capone M, Palmieri G, Castello G, and Mozzillo N. Decreased levels of regulatory T (Treg) cells in peripheral blood of melanoma patients after treatment with intravenous High Dose Interferon (HDI). 11th National Congress of Medical Oncology, Milan, Italy. *Ann. Oncol.* 2009; 20, Suppl. 8: viii75 (abstr E22).
105. De Maio A, Capone M, Natale E, Gentilcore G, Gravina C, Mistretta C, Di Martino S, Simeone E, Daponte A, Caracò C, Palmieri G, Faraone –Mennella M.R. and **Ascierto P.A.** NEMO (Nf-Kb Essential Modulator) Binding Domain (NDB) peptide could induce apoptosis in several melanoma cell lines. 11th National Congress of Medical Oncology, Milan, Italy. *Ann. Oncol.* 2009; 20, Suppl. 8: viii76 (abstr E26).
106. Gentilcore G, Ascierto ML, Napolitano M, Capone M, Simeone E, Daponte A, Corrado C, Wang E, Mozzillo N, Marincola FM and **Ascierto PA**. cTregs (Circulating Regulatory T Cells) reduction in Melanoma Patients treated with Intravenous High-dose IFNα2b. *iSBTC 24th Annual Meeting. October 29-31, 2009 Washington, DC (USA)*.
107. Ascierto ML, Gentilcore G, Gravina C, Worschesh A, Wang RY, Pos Z, Capone M, Natale E, De Maio A, Pirozzi G, De Martino S, Wang E, Marincola FM and **Ascierto PA**. In vitro anticancer property of NBD peptide through inhibition of NF-kB activation. *iSBTC 24th Annual Meeting. October 29-31, 2009 Washington, DC (USA)*.
108. Palmieri G, Casula M, Muggiano A, Cossu A, Budroni M, Caracò C, **Ascierto PA**, Pagani E, Stanganelli I, Canzanella S, Mulas C, Capra D, Satta MP, Sini MC, Palomba G. Analyses of key-regulator genes in melanoma susceptibility and pathogenesis among patients from south Italy. Congress Society for Melanoma Research Boston. *Pigment Cell & Melanoma* Vol. 22 n.6 December 2009.
109. Palmieri G, Alaibac M, Casula M, Pizzichetta MA, Bono R, **Ascierto PA**, Stanganelli I, Canzanella S, Zattra E, Satta MP, Palomba G, Sini MC, the Italian Melanoma Intergroup IMI. The EGF 61A>G polymorphism has no role in nevi formation and melanoma pathogenesis within italian population. Congress Society for Melanoma Research Boston. *Pigment Cell & Melanoma* Vol. 22 n.6 December 2009.
110. A. M. Eggermont, S. Suciù, P. Rutkowski, J. Marsden, A. Testori, P. Corrie, S. Aamdal, **P. A. Ascierto**, P. Patel, A. Spatz, EORTC Melanoma Group. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus

- observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 8505).
111. G. Palmieri, M. Casula, M. Budroni, A. Cossu, F. Tanda, **P. A. Ascierto**, S. Canzanella, G. Palomba, M. Colombino, A. Muggiano, Italian Melanoma Intergroup. Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 8543).
 112. L. Ridolfi, L. Fiammenghi, M. Petrini, A. Granato, V. Ancarani, E. Pancisi, M. Guidoboni, A. Riccobon, **P. A. Ascierto**, R. Ridolfi. Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study. *J Clin Oncol* 28:15s, 2010 (suppl; abstr TPS311).
 113. Chapman P.B, Hauschild A., Robert C., Larkin J. M. G., Haanen G., Ribas A., Hogg D., Day S. O' , **Ascierto P. A.** , Testori A. , Lorigan P., Dummer R., Sosman J. A., Garbe , C. Lee R. J. , Nolop K. B , Nelson B., Hou J., Flaherty K. T., McArthur G. A. "Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma". *J Clin Oncol* 29: 2011 (suppl; abstr LBA4).
 114. Di Giacomo M., **Ascierto P. A.**, Fonsatti E., Pittiglio E., Queirolo P., Pilla L., Ridolfi R., Santinami M. , Testori A. , Parmiani G., Maio M. "A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial". *J Clin Oncol* 29: 2011 (suppl; abstr TPS230).
 115. Colombino M. , Capone M. , Maio M. , De Giorgi V., Cossu A., Lissia A. , Rubino C., Massidda B. , Staibano S. , Nappi O., Botti G., Caraco C. , Mozzillo N. , Manca A, Sini M., **Ascierto P. A.** , Palmieri G. "Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients". *J Clin Oncol* 29: 2011 (suppl; abstr 8574).
 116. Queirolo P., Morabito A., Piccioli P., Lastraioli S. ,Callegari S., Camoriano M., **Ascierto P. A.**, Laurenti S., Dozin B. , Pistillo M. P ; "Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy". *J Clin Oncol* 29: 2011 (suppl; abstr 8588).
 117. **Ascierto P.A.**, Gentilcore G., Madonna G., Esposito A. , Pirozzi G. , De Maio E., Curvietto M ,Palmieri G., Mozzillo N. , Legos J."Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600E-BRAF mutations different from the common V600E-BRAF variant?". *Eur J Cancer*. 47:2011(suppl 4;abstr PP65).
 118. McArthur G. , Hauschild A., Robert C., Haanen J. B., **Ascierto P.A.**, Lee R.J., Nolop K., Nelson B., Flaherty K.T., Chapman P.B. "Vemurafenib Improves Overall Survival Compared to Dacarbazine in Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomized, Open Label, Multicentre Trial".*Melanoma and Skin Cancer. ESMO 2011*(abstr. 28LBA)
 119. Gentilcore G., Camerlingo R. ,Madonna G. Simeone E. ,De Maio E., Esposito A., Succio M., Mozzillo N., Pirozzi G., **Ascierto P.A.**"GSK2118436, Effective BRAF Inhibitor for Mutated Melanoma Cell Lines in BRAF V600-E". *Proceedings of the XXIX National Conference of Cytometry*. Salerno 2011.
 120. Gentilcore G., Simeone E., De Maio E., Esposito A., Curvietto M., Madonna M., Caracò C., Pirozzi C., Mozzillo N., **Ascierto.P.A.** "Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metstatic Melanoma Compassionate Use Programm". *J Immunother*. SICT 2011 (Vol 34, Number 9).
 121. Ascierto M.L., Idowu M., Zhao Y., Bedognetti D. **Ascierto P.A.**, Douglas Bear H., Wang E., Marincola F.,De Maria A., Manjili M.. Involvement of NK cell molecular signatures in favorable prognosis of breast cancer Patients. *J Clin Oncol* 2012;30: (suppl;abstr 10565);

122. Simeone E.,Gentilcore G.,Romano A.,Daponte A., Caraco C., Grimaldi A.M., Curvietto M., Esposito A., Queirolo P.,Mozzillo N. **Ascierto P.A.** Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. *J Clin Oncol* 2012;30: (suppl;abstr 8573);
123. Palmieri G.,Sini M.C.,De Giorgi V., Lissia A.,Massi D.,Rubino C.,Cossu A.,Stanganelli I., Palomba G., Botti G.,Caraco C.,Mozzillo N., **Ascierto P.A.**, Colombino M..Assessment of germ-line and somatic alterations in main candidate genes among patients with multiple primary melanoma. *J Clin Oncol* 2012;30: (suppl;abstr 8581);
124. Kirkwood J.M., Long G.V., Trefzer U., Davies M.A., **Ascierto P.A.** ,Chapman P.B., Puzanov I.,Hauschild A.,Robert C., Kefford R.,Goodman V.L., Switzky J.C.,Swann R.S.,Martin A.M., Guckert M.E., Streit M.R.W., Schadendorf D.. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR)to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positivemelanoma with brain metastases (mets). *J Clin Oncol* 2012;30: (suppl;abstr 8511);
125. Chapman P.B., Hauschild A., Robert C., Larkin J.M.G., John B. A. G., Ribas H.A., Hogg D., Hamid O., **Ascierto P.A.** ,Testori A., Lorigan P. ,Dummer R., Sosman J.A.,Garbe, Maio M. ,Nolop K.B., B.J. Nelson, Joe A.K., Flaherty K.T., McArthur G.A.. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. *J Clin Oncol* 2012;30: (suppl;abstr 8502);
126. **Ascierto P.A.**, Berking C., Agarwala S.S., Schadendorf D., Van Herpen C.,Queirolo P., Blank C.U., Hauschild A.,Beck J.T., Zubel A.,Niazi F.,Wandel S.,Dummer R. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. *J Clin Oncol* 2012;30: (suppl;abstr 8511);
127. Di Giacomo A.M., **Ascierto P.A.**,Pilla L., Ridolfi R.,Santinami M., Testori A.,Queirolo P., Giannarelli D., Parmiani G.,Maio M.. Phase II multicenter trial of ipilimumab combined with fotemustine in patients withmetastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. *J Clin Oncol* 2012;30: (suppl;abstr.8513);
128. Larkin J.M. G.,Queirolo P., Arance A.M., Brown M.P., Hauschild A., Del Vecchio M., McArthur G.A., Neyns B.,Becker J.C., Hansson J., Hogg D., **Ascierto P.A.**,Loquai C.,Espinosa E., Garbe C., Patel P.M.,Schachter J.,Mitchell L.,Veronese M.L.,Blank C.U. An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. *J Clin Oncol* 2012;30: (suppl;abstr 8517);
129. Long G.V., **Ascierto P.A.**, Grob J.J., Hamid O., Keffor R., Lebbe C., Minor D.R., Ribas A., Schadendorf D., Fecher L.A., TrefzerU., Arya N., Gagnon R.C., Goodman V.L., Siegfried A., Mazumdar J., Martin A.M.; Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (mut) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). *J Clin Oncol* 2012;30: (suppl;abstr 8518);
130. Maio M., Testori A., **Ascierto P.A.** ,Ruggero Ridolfi R., Santinami M., Pilla L., Queirolo P., Grosso M., Simeone E., Vittoria S., Nicoletti L, Rivoltini L., Ferrucci P.F., Parmiani G., Di Giacomo A.M.. The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. *J Clin Oncol* 2012;30: (suppl;abstr 8529);
131. Baurain J.F., Smylie M., **Ascierto P.A.** , Roman L., Houston S., Konto C., Chin K.M., Chen T.T., Francis S., Wolchok J.D. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. *J Clin Oncol* 2012;30: (suppl;abstr 8539)
132. Gutzmer R., Rivoltini L., Levchenko E., Testori A., Utikal J. **Ascierto P.A.**, Salaun B., Vanhoutte N., Gillet M., Brichard V. Immunogenicity and safety of the prame cancer

- immunotherapeutic in metastatic melanoma: Phase I/II dose escalation study. *Ann. Oncol.* 2012;23:(Supplement 9) ix361-ix375.
133. Maio M., Queirolo P., Testori A., Altomonte M., Maur M., Bajetta E., **Ascierto P.A.**, Chiarion Sileni V., Di Giacomo A.M., Ridolfi R. Safety and efficacy of ipilimumab 10mg/kg among patients with advanced melanoma from Italy enrolled in a European Compassionate use program. *Ann. Oncol.* 2012;23:(Supplement 9) ix369-ix375
 134. Colombino M., Sini M., De Giorgi V., Lissia A., Massi D., Rubino C., Cossu A., Ayala F., **Ascierto P.A.**, Palmieri G. Multiple primary melanomas from same patients present discrepant somatic alterations in main candidate genes. *Ann. Oncol.* 2012;23:(Supplement 9) ix364-ix375
 135. Blank C., Del Vecchio M., **Ascierto P.A.**, Queirolo P., Hauschild A., Arance A., Brown M., Mitchell L., Veronese L., Larkin J. An open-label, multicentre safety study of vemurafenib in patients with metastatic melanoma. *Ann. Oncol.* 2012;23:(Supplement 9) ix366-ix375
 136. Simeone E., Benedetto L., Gentilcore G., Caracò C., Grimaldi A.M., Mori S., Mozzillo N., **Ascierto P.A.** Ipilimumab treatment after electrochemiotherapy could be an effective sequential combination approach. *Ann. Oncol.* 2012;23:(Supplement 9) ix375-ix375
 137. **Ascierto P.A.**, Chiarion Sileni V., Del Vecchio M., Altomonte M., De Galitiis F., Ridolfi L., Cognetti F., Testori A., Bernengo M.G., Queirolo P. The European ipilimumab Expanded Access Programme (EAP): efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma. *Ann. Oncol.* 2012;23:(Supplement 9) ix367-ix375
 138. Pigozzo J., **Ascierto P.A.**, Calabrò L., De Galitiis F., Ferrucci P.F., Queirolo P., Bernengo M.G., Aglietta M., Mandalà M., Del Vecchio M. Efficacy and safety of ipilimumab reinduction therapy patients with pretreated advanced melanoma participating in an Expanded Access Programme (EAP) in Italy. *Ann. Oncol.* 2012;23:(Supplement 9) ix369-ix375.
 139. Maio M., Chiarion Sileni V., Pilla L., Nicoletti S.V.L., Di Guardo L., Queirolo P., De Galitiis F., Mandalà M., Guida M., **Ascierto P.A.** Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European Expanded Access Programme (EAP). *Ann. Oncol.* 2012;23:(Supplement 9) ix369-ix375
 140. Ascierto M.L., Idowuz M.O., Zhao Y., Bedognetti D., Tomei S., **Ascierto P.A.**, Wang E., Marincola F., De Maria A. NK Cell Molecular Signatures are Predictive of Relapse Free Survival of Favorable Prognosis of Breast Cancer Patients. *J. Immunother.* 2012;35:(number. 9) ix754-ix791;
 141. Hotson D., Conroy A., Evensen E., Gentilcore G., Simeone E., Esposito A., Curvietto M., Cesano A., Hawtin R., **Ascierto P.A.** CTLA-4 Defines Distinct T Cell Signaling Populations in Healthy Donors and Metastatic Melanoma Patients. *J. Immunother.* 2012;35:(number. 9) ix760-ix791;
 142. Hansson J., Grob J., Basset-Seguin N., Dreno B., Jouary T., Kunstfeld R., Hauschild A., Page D., Mitchell L., **Ascierto P.A.** Second interim analysis of STEVIE, a single-arm open-label study to evaluate the safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC). *Pigment Cell Res* 2012 ix861-ix903;
 143. McArthur G., Hauschild A., Robert C., Larkin J., Haanen J.B., Ribas A., Hogg D., Hamid O., **Ascierto P.A.**, A. Testori A., Lorigan P., Dummer R., Sosman J.A., Flaherty K., Yin M., Carol I., Shieh F., Schilling R., Trunzer K., Chapman P. Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease – results from the phase 3 clinical study BRIM3. *Pigment Cell Res* 2012 ix871-ix903.
 144. Maio M., Danielli R., Chiarion-Sileni V., Pigozzo J., Parmiani G., Ridolfi R., De Rosa F., Del Vecchio M., L. Di Guardo P., Queirolo V., Picasso P., Marchetti F., De Galitiis M., Mandalà M., Guida E., Simeone, **Ascierto P.A.**; Efficacy and safety of ipilimumab in patients

- with pre-treated, uveal melanoma; *Annals of Oncology*, Volume 24, Issue 11, 1 November 2013, Pages 2911–2915;
145. Robert C., Ascierto P.A., Maio M., Hernberg M., Schmidt H., Waxman I., Garbe C., Lebbé C., Hauschild H.; Institut Gustave Roussy, Villejuif; A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). *J Clin Oncol* 31, 2013 (suppl; abstr TPS9106);
 146. Grob J.J., Kunstfeld R., Dreno B., Jouary T., Mortier L., Basset-Seguin N., **Ascierto P.A.** Hansson J., Mitchell L., Starnawski M., Hauschild A.; Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. *J Clin Oncol* 31, 2013 (suppl; abstr 9036);
 147. Maio M., Hassel J.C., Del Vecchio M., Testori A., **Ascierto P.A.**, Marshall E., Glen H., Lorigan P., Meek E, Liou S., Hodge J.P., Bologna F., Dave H.P.; Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma. *J Clin Oncol* 31, 2013 (suppl; abstr 9027);
 148. James M. G. Larkin, Del Vecchio M., **Ascierto P.A.**, Schachter J., Garbe C., Neyns B., Mandala M., Lorigan P., Miller WH, Guminski A.D., Berking C., Rutkowski P., Queirolo P., Hauschild A., Arance A.M, Paul Brown M., Mitchell L., Veronese M.L., Blank C.U.; Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. *J Clin Oncol* 31, 2013 (suppl; abstr 9046);
 149. **Ascierto P.A.**, Simeone E., Chiarion-Sileni V., Queirolo P., Del Vecchio M., Di Guardo L., Guidoboni M., Marchetti P., Antonini Cappellini G.C., Ferrucci P.F., Cognetti F., Bernengo M.G., Guida M., Marconcini R., Mandala M., Parmiani G., Rinaldi G., Aglietta M, Calabro L., Maio M.; Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). *J Clin Oncol* 31, 2013 (suppl; abstr 9035);
 150. Simeone E., Benedetto L., Gentilcore G., Caracò C., Di Monta G., A.M.Grimaldi, Esposito A., Capone M, Marone U., Curvietto M., Madonna G., Di Cecilia M, Mori S., Mozzillo N., **Ascierto P.A.**; Combination therapy with ipilimumab and electrochemotherapy: Preliminary efficacy results and correlation with immunologic parameters. *J Clin Oncol* 31, 2013 (suppl; abstr e20031)
 151. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, **Ascierto PA.** Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. *Ann Oncol.* 2013 Nov;24(11):2911-5.
 152. P Bossi, S Cavalieri F Perrone R Miceli **Ascierto P.A.** L Locati C Bergamini R Granata S Alfieri C Resteghini D Galbiati A Busico N Paielli R Patuzzo A Maurichi G Gallino R Ruggeri L Mariani M Palla L Licitra; A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma *Annals of Oncology*, Volume 28, Issue suppl_6, 1 October 2017, mdx428;
 153. R. Rai O.M. Ezeoke J.L. McQuade L. Zimmer C. Koo J.J. Park L. Ardolino D. Yip S. Goldinger J.V. Cohen M. Millward V. Atkinson A.Y. Kane **Ascierto P.A.** C. Garbe R. Gutzmer D.B. Johnson M.D. Hellman G.V. Long A.M. Menz; *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017, mdx376.013;
 154. J-J. Grob D. Schadendorf J. Wagstaff I. Márquez-Rodas C. Lebbé **Ascierto P.A.** F.S. Hodi K. Grossmann J.C. Hassel D. Walker R. Bhore J. Larkin J.D. Wolchok Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial; *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017, mdx377.009;
 155. K. Lewis J. Larkin A. Ribas K.T. Flaherty G.A. McArthur **Ascierto P.A.** B. Dréno E. McKenna Q. Zhu Y. Mun A. Hauschild Impact of duration of response (DOR) on overall

- survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017;
156. K. Lewis M. Maio L. Demidov M. Mandala **Ascierto P.A.** C. Herbert A. Mackiewicz P. Rutkowski A. Guminski G. Goodman B. Simmons C. Ye Y. Yan D. Schadendorf BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017
 157. J. Weber M. Mandala M. Del Vecchio H. Gogas A.M. Arance L.C. Cowey S. Dalle M. Schenker V. Chiarion-Sileni I. Márquez-Rodas J-J. Grob M. Butler M.R. Middleton M. Maio V. Atkinson P. Queirolo V. de Pril A. Qureshi J. **Ascierto P.A.**, Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial; *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017
 158. James M. G. Larkin, Karl D. Lewis, Antoni Ribas, Keith Flaherty, **Ascierto P.A.**, Brigitte Dréno, Edward Francis Mckenna, Qian Zhu, Yong Mun, Axel Hauschild, Grant A. McArthur; Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). *J Clin Oncol* 35, 2017 (suppl; abstr 9556);
 159. **Ascierto P.A.**, Dummer R., Melero I., Palmieri G., Giannarelli D., Abrami E., Curvietto M., Simeone E, Grimaldi A.M.; SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation. *J Clin Oncol* 35, 2017 (suppl; abstr TPS9598);
 160. **Ascierto P.A.**, Bechter O., Wolter P., Lebbe C., Elez E., Miller WH., Georgina V. Long, Omlin A.G., Siena S., Calvo E., Pickard M., Gollerkeri A, Wollenberg L., Germa C., Dummer R.; A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. *J Clin Oncol* 35, 2017 (suppl; abstr 9518);
 161. **Ascierto P.A.**, Ignacio Melero, Shailender Bhatia, Petri Bono, Rachel E. Sanborn, Evan J. Lipson, Margaret K. Callahan, Thomas Gajewski, Carlos A. Gomez-Roca, F. Stephen Hodi, Giuseppe Curigliano, Marta Nyakas, Matthias Preusser, Yoshinobu Koguchi, Matthew Maurer, Raphael Clynes, Priyam Mitra, Satyendra Suryawanshi, Eva Muñoz-Couselo; Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. *J Clin Oncol* 35, 2017 (suppl; abstr 9520);
 162. Paul B. Chapman, **Ascierto P.A.**, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev V. Demidov, Celeste Lebbe, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, Yingjie Huang, Ying Zhang, Matthew Squires, Bijoyesh Mookerjee, Axel Hauschild; Memorial Sloan Kettering Cancer Center, New York, NY; Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma; *J Clin Oncol* 35, 2017 (suppl; abstr 9526);
 163. Reinhard Dummer, **Ascierto P.A.**, Helen Gogas, Ana M. Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem de Groot, Naoya Yamazaki, Carmen Loquai, Laure A. De Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith Flaherty; Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs

- vemurafenib (VEM) or enco in BRAF-mutant melanoma. J Clin Oncol 36, 2018 (suppl; abstr 9504)
164. Helen Gogas, Reinhard Dummer, **Ascierto P.A**, Ana M. Arance, Mario Mandalà, Gabriella Liskay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem de Groot, Naoya Yamazaki, Carmen Loquai, Laure A. De Parseval, Michael D Pickard, Ashwin Gollerkeri, Caroline Robert, Keith Flaherty; Adverse events of special interest in the phase 3 COLUMBUS study; J Clin Oncol 36, 2018 (suppl; abstr 9567)
 165. Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana M. Arance, Charles Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez Rodas, Jean-Jacques Grob, Marcus Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Reinhard Dummer, Veerle de Pril, Anila H. Qureshi, James M. G. Larkin, **Ascierto P.A**; Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238); J Clin Oncol 36, 2018 (suppl; abstr 9502);
 166. Brigitte Dreno, **Ascierto P.A**, Grant A. McArthur, Victoria Atkinson, Gabriella Liskay, Anna Maria Di Giacomo, Mario Mandalà, Lev V. Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis De la Cruz-Merino, Caroline Dutriaux, Claus Garbe, Isabelle Anne Rooney, Jessie J. Hsu, Erica Park, Antoni Ribas, James M. G. Larkin; Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study; J Clin Oncol 36, 2018 (suppl; abstr 9522);
 167. Helen Clare Dearden, Lewis Au, Daniel Ying Wang, Lisa Zimmer, Zeynep Eroglu, Jessica Louise Smith, Marcello Curvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Alexander Guminski, Georgina V. Long, Shahneen Kaur Sandhu, **Ascierto P.A**, Matteo S. Carlino, Douglas Buckner Johnson, James M. G. Larkin, Alexander M. Menzies; Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy; J Clin Oncol 36, 2018 (suppl; abstr 9545);
 168. Antonella Manca, Maria Colombino, Milena Casula, Amelia Lissia, Tiziana Scotto, Antonio Pazzola, Rosanna Satta, MariaCristina Sini, Grazia Palomba, Valentina Doneddu, Gerardo Botti, Corrado Caraco, **Ascierto P.A**, Antonio Cossu, Giuseppe Palmieri; Mutation frequencies in a gene panel among primary tumors and metastases in patients with melanoma; J Clin Oncol 36, 2018 (suppl; abstr e21554);
 169. Simone M. Goldinger, Serigne Lo, Jessica Cecile Hassel, Andrea Forschner, Meredith Ann McKean, Lisa Zimmer, Chloe Chia Hoey Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth Iannotti Buchbinder, **Ascierto P.A**, Ralf Gutzmer, Elisa A. Rozeman, Christoph Hoeller, Douglas Buckner Johnson, Anja Gesierich, Peter Kolblinger, Naima Benannoune, Justine Vanessa Cohen, Alexander M. Menzies; The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series; J Clin Oncol 36, 2018 (suppl; abstr e21588);
 170. Lori J. Wirth, Ekkehard Eigendorff, Jaume Capdevila, Luis G. Paz-Ares, Chia-Chi Lin, Matthew H. Taylor, Rodryg Ramlau, Marcus Butler, Jean-Pierre Delord, Zsolt Horvath, Hans Gelderblom, **Ascierto P.A**, Angelica Fasolo, Dagmar Führer, Hongqian Wu, Geraldine Bostel, Scott Cameron, Jason Edward Faris, Andrea I. Varga; Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer; J Clin Oncol 36, 2018 (suppl; abstr 6024)

EVENTI SCIENTIFICI ORGANIZZATI

- Workshop – videoconferenza: MELANOMA: surgical treatment and polyvalent melanoma cell vaccine. Napoli 8 febbraio 1997.
- 3rd International Conference Melanoma Day. Napoli 3 giugno 2000.
- MasterCourse “Management del paziente affetto da Melanoma”. 28 crediti formativi ECM. Napoli 19-21 novembre 2003.
- Annual Meeting IMI 2004 – MELANOMA – From Research to Treatment. Napoli 21-23 ottobre 2004.
- Evento ECM MasterCourse “Management del paziente con Melanoma” Napoli 21/09/2005- n. 19 crediti formativi ECM
- “Melanoma Open Issues” Grado (GO) 04/11/2005 – n. 8 crediti formativi ECM (MEDICI)
- “Infermiere e Melanoma: Problemi Aperti” Grado (GO) 04/11/2005 – n. 5 crediti formativi ECM
- “METTI IL MELANOMA IN FUORIGIOCO” 11-12 /02/2006 – iniziativa di raccolta fondi per la ricerca scientifica sul MELANOMA in collaborazione con LEGA CALCIO NAZIONALE, RAI, TRE, TIM, VODAFONE e WIND. Esito raccolta fondi - donazioni €35.000 – Segreteria Organizzativa 12 febbraio 2006.
- Evento ECM MasterCourse “Milano Marittima – 20-21 aprile 2006 - n. 7 crediti formativi ECM
- Congresso Internazionale “International Focus on Melanoma from Molecular Oncology a New Era for Melanoma Treatment” Napoli 27-28 aprile 2006 – n. 3 crediti formativi ECM
- Evento ECM MasterCourse “Management del paziente con Melanoma” Trani (BA) 21-22 giugno 2006 - n. 6 crediti formativi ECM
- Evento ECM MasterCourse “Management del paziente con Melanoma” Alghero (SS) 19-20 ottobre 2006 – n. 7 crediti formativi ECM
- Italian Melanoma Intergroup 12th Annual Meeting 2006” 30 novembre - 2 dicembre 2006 - Bari – n. 12 crediti formative ECM (MEDICI)
- 12th Annual Imi Meeting 2006 “Infermiere e Melanoma: Problemi Aperti.” Bari 30 novembre - 1 dicembre - n. 8 crediti formativi ECM (INFERMIERI)
- “METTI IL MELANOMA IN FUORIGIOCO – II EDIZIONE” 7/04/2007 – iniziativa di raccolta fondi per la ricerca scientifica sul MELANOMA in collaborazione con LEGA CALCIO NAZIONALE, RAI, TIM, TELECOM ITALIA, VODAFONE e WIND. Esito raccolta fondi - donazioni €40.000
- Evento ECM MasterCourse “Management del paziente con Melanoma: dalla Ricerca alla Terapia” Roma – 23-24 aprile 2007 - n. 9 crediti formativi ECM
- Evento ECM MasterCourse “Management del paziente con Melanoma: dalla Ricerca alla Terapia” Palermo – 27-28 settembre 2007 - n.8 crediti formativi ECM.
- “13th Annual Meeting of the Italian Melanoma Intergroup” Padova – 29-31 ottobre 2007 - n.9 crediti formativi ECM
- Tavola Rotonda “La Ricerca Sanitaria in Italia - il ruolo degli IRCSS pubblici” Roma -Senato della Repubblica - 17 dicembre 2007
- “Melanoma: The past, the present and the future”. Napoli, 7 maggio 2008.
- “Epatite B: Un’epidemia sconosciuta”. Napoli, 17 giugno 2008.
- “Razionale pre-clinico della bioterapia dei tumori”. Nell’ambito del Progetto di Alleanza Contro il Cancro "Rete nazionale per studi clinici e di strutture GMP per le bioterapie dei tumori”. Istituto Scientifico San Raffaele di Milano, 4 luglio 2008.
- Corso di aggiornamento sulle Bioterapie dei Tumori: aspetti scientifici e regolatori. Istituto Nazionale Tumori Fondazione Pascale di Napoli, 11-12 dicembre 2008
- Il ruolo degli IRCCS oncologici nella ricerca transazionale. Roma, 17 marzo 2009.

- Corso di Formazione Itinerante “Il Team di Cura nel governo clinico del paziente oncologico”. IRCCS Pascale, 27-28 marzo e AO Cotugno, 5-6 giugno 2009.
- Il Ruolo del farmaco in Oncologia. Napoli, 27 aprile 2009.
- Doping e Cancro. Roma, 21 settembre 2009.
- Melanoma: Nuove opzioni terapeutiche e prospettive future. Napoli, 3 dicembre 2009.
- Corso ECM “Immunoterapia e Melanoma”. Napoli, 28 giugno 2010.
- Corso di Formazione Itinerante NIBIT sulla Immunobioterapia dei Tumori Umani: basi teoriche, risultati clinici e tossicità delle più promettenti strategie terapeutiche in oncologia. Milano, 23 ottobre 2010, Siena 20 novembre 2010, Palermo 11 dicembre 2010 e Genova 18 dicembre 2010.
- Convegno: Nasce la Fondazione Melanoma. Roma, 18 novembre 2010.
- In collaborazione con il National Institute of Health di Bethesda “Melanoma Research: a bridge Naples-USA”. Napoli 6-7 dicembre 2010.
- Corso ECM, Nuove Strategie Terapeutiche nel Melanoma Avanzato. Napoli, 5 settembre 2011.
- Convegno: Ad 1 anno dalla nascita della Fondazione Melanoma. Roma, 26 ottobre 2011.
- Corso ECM. L’evoluzione nella diagnostica delle lesioni melanocitarie: il dermatologo e l’istopatologo. Napoli, 26 novembre 2011.
- Melanoma Research: a bridge Naples all the world. Napoli, 5-6 dicembre 2011.
- Corso ECM, International expert panel on new melanoma pathways: The Target Therapy approach. Napoli 11 febbraio 2012.
- Corso ECM, The Immunoscoring as a new possible approach in the classification of cancer. Napoli 13 febbraio 2012.
- MSD Oncology Melanoma Forum, Treating Melanoma Patients In The World Of Novel Agents: What Has Changed And What Remains The Same? Amsterdam 29-30 marzo 2012
- Melanoma Bridge, Napoli 2-4 dicembre 2012.
- World Immunoscoring, Napoli 5 dicembre 2012
- 38° Congresso ESMO Amsterdam 27 settembre 1 ottobre
- Relatore al XIX Congresso Nazionale IMI. Napoli 8-10 dicembre 2013
- “Melanoma Immunoscore Meeting outlining research efforts”- Portland 17-18 gennaio 2013.
- 28° Annual Meeting SITC. Nazional Harbor- 7-10 novembre 2013.
- XV Congresso nazionale AIOM. Milano 11-13 ottobre 2013
- Convegno Nazionale Aiom Incontra Nibit - "Presente E Futuro Dell'immuno-Oncologia" Roma 15-16 Aprile 2016.
- VI Corso Nazionale AIOM - Siapec-Iap - Napoli, 9 Giugno 2016 “Strategie Di Immunoterapia nel Melanoma.
- AIOM Posto Asco Review - Updates And News From The Annual Meeting In Chicago - Bologna Royal Carlton Hotel June 17-18, 2016;
- XVII Congresso Nazionale AIOM - Roma 28/30 Ottobre 2016 “Immuno-Oncology: Raise The Bar Overall Survival As A New Standard Of Efficacy Roma, 29 Ottobre 2016 (Simposio BMS).
- V Corso di aggiornamento in Oncologia 2013. Napoli-9 settembre 4 dicembre 2013.
- 8° World Congress of Melanoma. Hamburg 17-20 luglio 2013.
- European Training on Melanoma. Milano 25 ottobre 2013.
- Tumor Immunology meets oncology (TIMO IX). Halle 3-4 maggio 2013.
- 2013 ASCO Annual Meeting. Chicah 31 maggio 4 giugno 2013.
- Responsabile Scientifico dell’evento “Mame Management of Metastatic Melanoma”. Napoli 14 Settembre 2014.
- Tucson Symposium 2014. Tucson 25-26 febbraio 2014.

- International Melanoma Working Group (IMWG). Budapest 24-25 marzo 2014.
- International Symposium “Riuniting cancer Immunology and Immunotherapy from the lab to the clinic”. Pamplona 4-5 marzo 2014.
- 39° ESMO Congress. Madrid 26-30 settembre 2014.
- XXX Congresso Nazionale IMI- Treviso 5-7 ottobre 2014.
- XVI Congresso Nazionale AIOM. Roma 24-26 ottobre 2014.
- 11° International Congress of the Society for Melanoma Research. Zurigo 13-16 novembre 2014.
- Annual Meeting SITC. National Harbor. 6-9 novembre 2014.
- 20° Hong Kong Medical Forum. Hong Kong 16-17 maggio 2015.
- “Pathophysiology and management of cardiovascular complications in oncology. Napoli 1 ottobre 2015.
- 1° Mediterranean Conference “New therapies in the treatment of melanoma. Palermo 11-12 settembre 2015.
- Coordinatore Scientifico al “BCC Training Days: Basal Cancer Treatment and Management”. Napoli 17-18 dicembre 2015.
- 11° EADO Congress. Marseille. 28-31 ottobre 2015.
- Melanoma Bridge 2015. Napoli 1-4 dicembre 2015.
- 18° ECCO-ESMO Congress. Vienna 25-29 settembre 2015.
- Immunotherapy of Cancer Conference-ITOC 2. Monaco 25-27 marzo 2015.
- Tucson Symposium 2015. Tucson 16-19 marzo 2015.
- Current Trends in Immuno-Oncology: Melanoma. 24 giugno 2015.
- ADCC Data Advisory Board at ESMO in Copenhagen, Denmark – 7th October 2016.
- American Society Of Clinical Oncology (ASCO) Annual Meeting 2016 Jun 03 - 07, 2016 , [Illinois](#)
- “SMR 2016 Society for Melanoma Research” Boston, 06-09 Novembre 2016.
- “SMR 2016 Society for Melanoma Research” Australia, 18-21 ottobre 2017.
- 32° Annual Meeting SITC. National Harbor 8-12 novembre 2017.
- Responsabile Scientifico dell’evento “Landascale in Immunooncologia. Milano 12-13 ottobre 2017.
- 4° Immunotherapy of Cancer conference. Praga 20-22 marzo 2017.
- ITOC Education Workshop Immunotherapy. Monaco 6-7 ottobre 2017.
- 13° EADO Congress. Atene. 3-6 maggio 2017.
- Melanoma Bridge 2017. Napoli 30 novembre 2 dicembre 2017.
- International workshop in Cardioncology” Napoli 22-febbraio 2018.
- Docente all’evento “Nivolution Raising the bar in Oncology&Hematology”. Roma 23-24 febbraio 2018.
- Relatore al corso ECM “Melanoma.net. Napoli 15-16 marzo 2018.
- Docente all’evento “Milestone in Immuno Oncology”. Napoli 28-30 marzo 2018.
- Docente al Master di II Livello in Immunooncologia. Roma 18-20 aprile 2018.
- Relatore al corso “Therapeutic Route-map. Sassari 24 maggio 2018
- Relatore al corso “Therapeutic Route-map. Civitanova Marche. 22 giugno 2018
- Consulente all’AB “Avelumab nel carcinoma a cellule di Merkel”. Milano 4 luglio 2018.
- Docente Al Corso “Prometeo”- Napoli 6-7 Luglio 2018.
- Responsabile Scientifico Al Corso “Immersion”. Milano 12-13 Luglio 2018.
- Docente al corso “Educazionale immersivo in gestione multidisciplinare del paziente oncologico. Milano 12 luglio 2018
- Responsabile Scientifico All’evento “Grandangolo Focus In Immunooncologia. Roma 18-19 Settembre 2018.

- Docente all'evento "Milestones in Immuno Oncology". Milano 3-5 ottobre 2018.
- Consulente all'AB "Cemiplimab Cutaneous Squamous Cell Carcinoma. Roma 17 Ottobre 2018.
- Relatore all'XX Congresso AIOM. Roma 16-18 novembre 2018
- Relatore al corso "progetto prometeo". Roma 23-24 novembre 2018.
- Responsabile Scientifico dell'" Immunotherapy Bridge". Napoli 28-29 novembre 2018
- Responsabile Scientifico "Melanoma Bridge". Napoli 29 novembre 1 dicembre 2018.
- Relatore all'annals Of Oncology Associate Editor's Meeting. Londra 8 Febbraio 2019.
- Relatore al 1° Congresso Nazionale "Gipatec". Napoli 7-8 Marzo 2019.
- Corso Di Formazione Manageriale Per Direttori di Unità'. Napoli 6 Marzo-8 Maggio 2019.
- 1° Corso Di Formazione Per Case Manager E Coordinatori Gom. Napoli 11-18 Marzo 2019.
- Relatore "all'AACR Annual Meeting 2019". 29 Marzo -3 Aprile 2019.
- Relatore all'evento "Cracking cancer". Firenze 10 maggio 2019.
- Relatore all'evento "Equivalenza Trapeutica in Italia. Roma 10 giugno 2019.
- Relatore all'Meeting "INT Pascale-Karolinske Institute". Salerno 14 giugno 2019.
- Relatore al Corso ECM "Immersione". Napoli 1 luglio 2019
- Consulente all'AB "Il Setting Adiuvante del melanoma". Napoli 9 luglio 2019.
- Relatore all'" Investigator Meeting sullo studio clinico Secombit". Roma 13 settembre 2019.
- Relatore al Corso ECM "La scelta del trattamento in oncologia. Napoli 17 settembre 2019.
- Responsabile Scientifico evento "We in Action". Napoli 19-20 settembre 2019.
- Responsabile Scientifico all'Immunotherapy bridge- 1-2 dicembre 2021 napoli
- Responsabile Scientifico al Melanoma Bridge 2-4 dicembre napoli
- Relatore al cracking cancer forum- padova 18-19 novembre 2021
- Relatore a health on the table- napoli 18 ottobre 2021
- Relatore al convegno Nuove strategie in immunoncologia -1 ottobre 2021 bologna
- Relatore al leuropeas society for medical oncology- 16-21 settembre (web meeting)
- microbiota project -14 luglio 2021
- Relatore al congresso landscape in oncologia 21 giugno 2021- napoli
- Relatore al congresso l'accesso alle terapie per le malattie rare VI edizione- 10 maggio 2021 e 10 giugno 2021 (web meeting)
- Relatore al congresso health on the table- 27 maggio -18 ottobre 2021 (web meeting)
- Relatore al congresso campus in oncologia-- 8-11 aprile 2021 sorrento
- Relatore al congresso global melanoma congress- 15 aprile 2021 (web meeting)
- Relatore all'EADO congress 15-17 aprile 2021 (web meeting)
- Relatore al congresso 3 international workshop on tumor evolution- 30- 31 marzo 2021- Roma
- Responsabile Scientifico all'Immunotherapy bridge- 30 nov-1 dic 2022 napoli
- Responsabile Scientifico al melanoma bridge -1-3 dicembre 2022 napoli

- Relatore al congresso marcangolo -25-26 novembre porto sant'elpidio
- Relatore al congresso giornate d'oriche di dermatologia- 17-19 nov 2022 ancona
- Relatore al congresso eortc melanoam group meeting -27-28 ottobre 2022 assisi
- Relatore al congresso nuove opportunità terapeutiche nel melanoma in fase adiuvante e avanzata:l'esperienza della regione sicilia -messina, 7 ottobre 2022
- Relatore al congresso carcinoma basocellulare localmente avanzato – 21 maggio 2022 roma
- Responsabile Scientifico al capri campus- 8-10 aprile 2022
- Relatore al congresso grandangolo focus in immunoncologia- 25-26 gennaio 2022 roma
- Responsabile Scientifico all'immunotherapy bridge 29-30 novembre 2023 napoli
- Responsabile Scientifico al melanoma bridge 1-2 dicembre 2023 napoli
- Relatore al congresso ecm “diagnosi e gestione delle tossicità cutanee e sistemiche correlate al trattamento immunoterapico ed alle terapie a bersaglio molecolare nei pazienti affetti da melanoma e da tumori cutanei non melanoma” 11 dicembre 2023 Pascale Napoli
- Relatore al congresso no meeting terza edizione la rlt nella pratica clinica dei prossimi anni- 13 dicembre 2023 napoli
- Relatore al congresso corso ecm “la valutazione e gestione infermieristica del paziente con tossicità immunocorelata alla gestione chirurgica degli eventi avversi indotte da immunecheckpoint inhibitors e da target therapy nel melanoma e nei tumori cutanei non melanoma” 18 dicembre 2023 i.n.t. pascale napoli
- Relatore al congresso masterclass mito - il ruolo dell'immunoterapia nel trattamento delle neoplasie Ginecologiche. 27 novembre 2023 napoli
- Relatore al congresso non melanoma skin cancer congress --16 ottobre 2023 roma
- Relatore al congresso building bridges to interconnect people- -27 settembre 2023 milano
- Relatore al congresso new perspectives in metastatic uveal melanoma - 19-20 settembre napoli
- Relatore al congresso convegno cicon -20-23 settembre 2023 milano
- Relatore al congresso we in action 12-13 settembre 2023 napoli
- Relatore al congresso hotspot melanoma -14-15 settembre 2023 vienna
- Relatore al congresso novita' post asco 2022 nel carcinoma polmonare ed altre neoplasie -16 giugno 2023. Pascale di napoli
- Relatore al congresso cracking cancer forum - 4/5 maggio 2023 palermo
- Responsabile Scientifico al nivolution congress – 27 maggio 2023 roma
- Relatore al congresso 3th interventional oncology meeting- 13-14 aprile 2023 roma
- Relatore al congresso skin cancer campus- 14-16 aprile 2023 sorrento
- Relatore al congresso grandangolo focus in immunoncologia- 28-29 marzo 2023 roma

INCARICHI TECNICI

- Nominato nel FEBBRAIO 2007 membro del Coordinamento Tecnico Provinciale di Benevento per l'attuazione del Piano Ospedaliero Regionale 2007-2009.
- Nominato nell' OTTOBRE 2007 componente della Commissione Oncologica Nazionale per l'attuazione del Piano Oncologico Nazionale 2007-2009.

RICONOSCIMENTI

- Dicembre 1998: citazione nel resoconto del “XXIII Congresso dell’European Society for Medical Oncology – 6-10 novembre 1998, Atene, Grecia” in La Clinica Terapeutica Volume 149, n.6 novembre-dicembre 1998.
- DICEMBRE 2003: premio anno 2003 “NUMEROUNO” cat. Medici conferitogli dal Tribunale per i diritti del malato.
- 02 GIUGNO 2005: nomina a Cavaliere dell’Ordine al Merito della Repubblica Italiana per meriti scientifici.
- Gennaio 2008: Citazione biografica su Wikipedia – l’enciclopedia libera del web.
- Settembre 2008: Meet the Professor sul tema dell’immunosoppressione tumorale con particolare riguardo al ruolo dei T-reg, presso l’Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori di Meldola (FC).
- 19 Luglio 2010: Fondatore e Presidente della Fondazione Melanoma Onlus.
- 02 GIUGNO 2011: nomina a Commendatore dell’Ordine al Merito della Repubblica Italiana per meriti scientifici.
- Citazione biografica su “Who's Who in America 2011 -65th Edition”. 2010 Marquis Who's Who LLC editions, New Providence, NJ, USA.
- Citazione biografica su “Who's Who in Medicine and Healthcare 2011-2012 -8th Edition”. 2011 Marquis Who's Who LLC editions, New Providence, NJ, USA.
- Citazione biografica su “Who's Who in America 2012 -66th Edition”. 2011 Marquis Who's Who LLC editions, New Providence, NJ, USA.
- Co-Chair della sessione “Melanoma/Skin Cancer – Oral Abstract Session” al convegno ASCO 2011
- Speaker al Clinical Science Symposium “The Role of Mek Inhibitors” al congresso ASCO 2012.
- Ha partecipato, insieme al prof. Michael Atkins, nella faculty del PeerVoice Online Independent Medical Education Programme – Case Study Programme for Metastatic Melanoma: Incorporating Novel Immunotherapy Into Practice, con una lecture dal titolo “Optimising Sequential Therapy in the Patient With BRAF-Positive Metastatic Melanoma: What Are the Options?”.
- Citazione biografica su “Who's Who in the World -30th Edition” 2013 Marquis Who's Who LLC editions, New Providence, NJ, USA.
- Febbraio 2013: Lecture “Immunoscore in Malignant melanoma” presso l’Istituto di Patologia dell’Università di Berna.
- Premio Zanibelli 2018 - Premio personaggio dell'anno. Roma 2 ottobre 2018.
- Premio Medicina Italia. Pescara 11 novembre 2018.
- Premio “Carlo La Catena” 2019 - Medaglia d'argento al merito e all'impegno civico
- Premio Campania” as Science – Best Award of 2019.
- Premio memorial Michele Siani -Prendersi cura con il Sorriso 2020.
- Premio "Maranesi nel sociale".2020.
- Premio nazionale Don Diana. Luglio 2020.
- Premio Liburia 2020 Capri Event. luglio 2020
- Premio Il Normanno. Luglio 2020
- Premio Giffoni Film Festival. Luglio 2020
- Premio Acto per la vita Luglio 2020
- Premio Ambasciatore del Sorriso. Settembre 2020
- Premio San Gennaro Day . Settembre2020
- Premio Internazionale "Sebetia-Ter" per la Medicina-Chirurgia-Ricerca scientifica. Settembre 2020
- Premio "Telesia for peoples". Ottobre 2020

- Premio G. Moscati, medaglia del Senato della Repubblica. Novembre 2020
- Premio Terre di Campania . Dicembre 2020
- Premio "2020 Hero Awards"- Filitalia International & Foundation. Dicembre 2020
- Premio Maranesi nel sociale 1a Edizione. Febbraio 2021
- Premio al valore medico-scientifico in memoria Prof. Crisci. Marzo 2021
- Premio "Le eccellenze dell'informazione scientifica e la centralità del paziente". luglio 2021
- Premio al "Valore medico scientifico Crisci". Luglio 2021
- Premio Internazionale Scuola Medica Salernitana - “Lumen et Magister”. Novembre 2021
- International Excellence Awards. Novembre 2021.
- Premio nazionale Ferdinando Palasciano. Capua. Novembre 2021
- Premio Nazionale "Don Paolo Capobianco" per la questione meridionale. Dicembre 2021
- Premio Rete Mediterranea per l'impatto sociale 2021.
- International Excellence Awards 2021 5a Edizione. Dicembre 2021
- Primo al mondo, secondo la classifica Expertscape, tra gli esperti nella cura del melanoma nel periodo 2012-2022 e 2013-2023.

Napoli, 16 maggio 2024

Dr. Paolo A. Ascierto